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PATHOPHYSIOLOGY
Food allergy is an unintentional reaction of the immune system to an innocuous foreign 
substance (food allergen) with relevant clinical symptoms as a result. The patient has to 
be previously in contact with the allergen or a similar allergen from another source to 
become sensitised. This sensitisation may occur by consumption, however, also by skin 
contact, inhalation or in utero (1). Patients with an atopic constitution have a predis-
position to develop specific IgE (sIgE) to food or inhalation allergens and to becoming 
sensitised. The patient is allergic if the sensitisation results in typical allergic symptoms. 
This typical allergic reaction is called an immediate or anaphylactic type-I reaction (Gell 
and Coombs classification)(2).
During the first exposure to an allergen, activation of Th2-cells takes place, which in 
turn activates the B- cells to produce sIgE. This sIgE binds during re-exposure to the 
antigenic determinant (epitope) of the allergen and to the Fc-receptors, present on the 
surface of the effector cells (mast cells and basophils). Cross-linking between two sIgE 
molecules on the effector cell by the allergen causes activation of the basophils and 
mast cells, which results in signal transduction and receptor mediated exocytosis of the 
mediator vesicles (3).
The phenomenon of allergen cross-reactions occurs when antibodies responsible for 
the allergic reaction bind to the original allergen and to similar allergens e.g. in case of 
botanically related allergens (4). However, these allergens bind often with different af-
finity. The cross-reaction can occur between food allergens mutually and food allergens 
and inhalation allergens. Allergic reactions based on cross-reactivity are in general mild.
CLINICAL PRESENTATION
The clinical presentation of food allergy can encompass gastro-intestinal symptoms 
(oral allergy, nausea, vomiting, stomach pain and vomiting), cutaneous symptoms 
(urticaria, redness, itchiness and angioedema), eye symptoms, upper airway symptoms, 
lower airway symptoms, cardio-vascular symptoms and indefinite symptoms (change 
in behaviour and pallor/feeling weak). In particular in children, the allergic reaction can 
manifest with indefinite symptoms as tiredness, listless and crying (5). The symptoms 
can be divided into objective and subjective symptoms. Subjective symptoms are 
symptoms according to the patients and the physician could not objectify this. Objec-
tive symptoms can be measured or observed. The most severe immediate type-I allergic 
reaction is called anaphylaxis and is defined in the guidelines for food allergy and 
anaphylaxis (6).
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DIAGNOSTIC PROCEDURE
The first step in the diagnostic procedure of food allergy is taking the history. The reaction 
type and the time interval between exposure to the allergen and onset of symptoms are 
important in determining whether there may be an allergy. Allergy testing starts with 
demonstrating sensitisation by either a skin prick test (SPT) or specific IgE (sIgE). The 
oral food challenge (FC) test could determine the clinical relevance of sensitisation. The 
double-blind placebo-controlled (DBPCFC) test is considered as the gold standard. The 
DBPCFC is been carried out in two days. The placebo and active challenge material are 
randomly administered on these days with at least a one-week interval. The doctor and 
patient are not informed on which day the active challenge material (verum) or placebo 
is given. Blinding would be opened after the challenge test. The interpretation of the 
challenge test results is important to diagnosis food allergy or tolerance (7).
The diagnostics of food allergy has been improved recently with the use of compo-
nent resolved diagnosis (CRD). CRD measures sIgE against individual allergens utilising 
native or recombinant allergens (8). Native allergens are purified from allergen extracts 
and recombinant allergens are biotechnology produced by bacteria or yeasts.
CRD could distinguish between a genuine sensitisation and a sensitisation based on 
cross-sensitisation of food allergens mutually or food allergens and inhalation allergens 
(pollen- food syndrome). CRD gives insight in the sensitisation pattern and the risk of 
an allergic reaction (9). There are relatively harmless, unstable allergens e.g. profilines 
(10) and potential dangerous allergens that are extreme resistant to proteolysis, heat 
denaturation and pH changes as the allergens of the Prolamin superfamily e.g. Lipid 
Transfer Proteins (LTPs)(11) and 2S albumines (12). Pathogen related proteins, like PR-
10 proteins play an important role in pollen- food syndrome and cause usually mild to 
moderate symptoms as ‘oral allergy’ (13).
CRD is a relatively new in the diagnostic work-up of food allergy, but is rapidly incor-
porated into clinical use. Therefore, the clinician must have knowledge on the chemical, 
physical and immunological characteristics of the different allergenic families to under-
stand the CRD test results (9). Next to this single-plexed allergen assays, multi-plexed 
allergen assays are also available as ImmunoCAP ISAC. The ImmunoCAP ISAC provided 
sIgE results for 112 components from more than 51 allergens simultaneously, using only 
30 µl serum (14). This test method is useful if there is enquiry for many components and 
as consequence high costs or in patients with high complex sensitisation patterns of 
food and inhalation allergens (9).
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CASHEW NUT ALLERGY AND CASHEW NUT COMPONENTS
There are indications that the cashew nut is an upcoming important allergen (15–16). 
The cashew nut (Anacardium occidentale) belongs to the Ancardiaceae family and is 
botanically related to pistachio (Pistacia Vera) nut and the mango (Mangifera indica). The 
rapid increase in processing of cashew nuts in food product and the change in eating 
and cooking habits may be responsible for the increasing significance of cashew nut 
allergy (16). Previous studies demonstrated that a minimal amount of cashew nut can 
cause severe reaction in cashew sensitised patients (17). Therefore, research on cashew 
nut allergy is important to make clinician aware of this allergy.
The major allergen components of the cashew nut are Ana o 1, Ana o 2 and Ana o 
3 (18–21). Ana o 1 is a vicilin-like protein, resistant to heat and proteolysis. The other 
two allergens are Ana o 2, a legume-like protein and Ana o 3, a 2S albumin. All three 
allergens are classified as seed storage proteins. A previous already demonstrated that 
sensitisation to Ana o 3 is highly predictive of clinical reactivity in cashew nut sensitised 
patients (22).
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It is important for the patient to diagnose cashew nut allergy in a safe and efficient way 
with less false negative and false positive test results. The SPT, sIgE determination and 
the open and DBPCFC challenge test fall short of this. The DBPCFC as gold standard 
is costly, time-consuming and a potentially stressful test for the patient. Therefore, the 
study Improvement of Diagnostic mEthods for ALlergy assessment (IDEAL) was devel-
oped with cashew nut allergy as a show-case.
The aim of this study is:
1) To investigate the clinical presentation of cashew nut allergy i.e the clinical relevance 
of cashew nut sensitisation and the clinical reaction patterns during the DBPCFC 
tests with cashew nut.
2) To optimise the diagnostic procedures of cashew nut allergy by improvement of the 
measurement and interpretation of the SPT and to improve the diagnostic procedure 
of food allergy by combining different diagnostic tools: history, standard diagnostics 
(SPT and sIgE) and component resolved diagnosis (CRD) i.e. IgE-levels to Ana o 1, Ana 
o 2 and Ana o 3, to finally predict the outcome of the DBPCFC with a model.
3) To address the clinical consequences of cashew nut allergy as the clinically relevance of 
co-sensitisation between cashew nuts, pistachio nut and mango, the effect of DBP-
CFC test on health-related quality of life in children participating in a study of cashew 
nut allergy and the rate of cashew nut introduction after a negative challenge test.
The content of the thesis is more comprehensive and contributes also to the knowledge 
of the cashew nut and cashew nut allergy.
The first paper ‘Systematic review on cashew nut allergy’ gives an overview of the rel-
evant literature on the cashew nut and cashew nut allergy.
The second paper ‘Multicentre double-blind placebo-controlled food challenge study in 
children sensitised to cashew nut’ shows the clinical results of the IDEAL- study. This article 
demonstrates the clinical relevance of cashew nut sensitisation and the clinical reaction 
patterns during the DBPCFC tests with cashew nut.
The third paper ‘Threshold dose distribution and eliciting dose of cashew nut allergy’, 
shows the threshold distribution curve of the IDEAL-study and the LOAELs in a subgroup 
of children who reacted to the lowest dose of cashew nut protein (1 mg).
The objectives of the fourth paper ‘Measurement and interpretation of skin prick test 
results’ are to compare different techniques of quantifying SPT results, to determine a 
cut-off value for a positive SPT for histamine equivalent prick -index (HEP) area, and to 
study the accuracy of predicting cashew nut reactions in DBPCFC tests with the different 
SPT methods.
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We investigate in the fifth paper ‘sIgE Ana o 1, 2 and 3 accurately distinguish tolerant 
from allergic children sensitised to cashew nuts’ the performance of component sIgE 
determinations in diagnosing cashew nut allergy.
We describe in the sixth paper ‘Prediction of cashew nut allergy in sensitised children’ a 
multivariate model to predict the outcome of the DBPCFC test with cashew nut.
The seventh paper: ‘Low percentage of clinically relevant pistachio nut and mango co-
sensitisation in cashew nut sensitised children’ assess the clinical relevance of pistachio 
nut and mango co-sensitisation in cashew nut sensitised children.
The eight paper ‘No difference in health-related quality of life, after a food challenge with 
cashew nut in children participating in a clinical trial’ demonstrates the effect on quality 
of life in positive and negative challenged children using the food allergy quality of life 
questionnaires (FAQLQ’s) before and after the DBPCFC test.
The last paper ‘Failure of introduction of cashew nuts after a negative food challenge test’ 
is a letter to the editor on the rate of introduction of cashew nuts after a negative food 
challenge test.

Chapter 2
Literature overview

Chapter 2.1
Systematic review on cashew nut 
allergy
This paper gives an overview of the relevant literature on cashew nut and cashew 
nut allergy. This article is published in Allergy in 2014.
Van der Valk JP, Dubois AE, Gerth van Wijk R, Wichers HJ, de Jong NW. Systematic review on 
cashew nut allergy. Allergy 2014;69:692-8.
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ABSTRACT
Recent studies on cashew nut allergy suggest that the prevalence of cashew nut allergy 
is increasing. Cashew nut consumption by allergic patients can cause severe reactions, 
including anaphylaxis. This review summarises current knowledge on cashew nut al-
lergy to facilitate timely clinical recognition and to promote awareness of this emerging 
food allergy amongst clinicians. The goal of this study is to present a systematic review 
focused on the clinical aspects of allergy to cashew nut including the characteristics 
of cashew nut, the prevalence, allergenic components, cross-reactivity, diagnosis and 
management of cashew nut allergy.
The literature search yielded 255 articles of which 40 met our selection criteria and 
were considered to be relevant for this review. The 40 articles included one prospective 
study, six retrospective studies and seven case reports. The remaining 26 papers were 
not directly related to cashew nut allergy. The literature suggests that the prevalence of 
cashew nut allergy is increasing, although the level of evidence for this is low. A minimal 
amount of cashew nut allergen may cause a severe allergic reaction, suggesting high 
potency comparable with other tree nuts and peanuts. Cashew allergy is clearly an 
underestimated important healthcare problem, especially in children.
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INTRODUCTION
Although peanut allergy has been on the increase for two decades or more, studies 
indicate that cashew nut is also becoming an important food allergen (1, 2). The rapid in-
crease in consumption of cashew nuts and the change in eating and cooking habits may 
be responsible for the increasing significance of cashew nut allergy (2). In this paper, we 
summarise the relevant information available on epidemiology, allergen components, 
clinical features, diagnosis, clinical and in vitro cross-sensitisation and management of 
cashew nut allergy.
DATA SOURCES AND LITERATURE SEARCH
In our search, we adhered to the methods and procedures of the Preferred Reporting 
Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for reporting this 
systematic review, excluding irrelevant items. Registration number in PROSPERO is 
CRD42013004047. We used Ovid MEDLINE and EMBASE databases to identify relevant 
articles using the string: (Anacardi*(tw) OR cashew*(tiab)) AND (Hypersensitiv*(tw) OR 
hyper sensitiv* (tw) OR allerg*(tw)) for Ovid MEDLINE and (Anacardi* OR cashew*): de, 
ab, ti AND (Hypersensitiv* OR (hyper NEXT/1 sensitiv*) OR allerg*): de, ab, ti for EMBASE. 
We also checked references to relevant articles (‘snowballing’). We aimed to include 
studies focused on the clinical aspects of cashew nut allergy. We considered only stud-
ies in English. There was no restriction on publication date. Mouse model studies were 
excluded. Initially, all articles on cashew nut allergy or on cashew nuts were included. 
Thereafter articles on contact dermatitis, genetics, product labelling, poisoning, detec-
tion methods and possible medicinal effects of cashew plants were excluded. Forty 
of 255 articles found with the literature search (244 articles) and by ‘snowballing (11 
articles) were considered relevant for the review. Of these 40 articles, one article was a 
prospective study and six articles were retrospective studies. Five of these seven articles 
focused on clinical symptoms and constitute a major source for this review. In addition, 
seven case reports about cashew nut were located. The remaining 26 articles are mainly 
descriptive and not directly related to cashew nuts or cashew nut allergy. This literature 
selection procedure is shown schematically in Figure 2.1. Apart from this selection, we 
added literature to describe the characteristics of the cashew nut, the prevalence, al-
lergenic components, cross-reactivity and diagnosis of cashew nut allergy.
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RELEVANT PAPERS
The fi ve relevant studies on clinical symptoms of cashew nut allergy are presented in Table 
2.1. The prospective study by Rance et al. (2) analysed the clinical features and results of 
skin prick tests (SPT), specifi c IgE (sIgE) assays and food challenge tests of 42 children 
with cashew nut allergy without an associated peanut allergy. The study by Davoren et 
al. (3) described the clinical features, including anaphylactic reactions, to tree nuts and 
peanuts. Clark et al. performed a retrospective case-matching study in children referred 
Figure 2.1:  Summary of  the search and selection.
Figure 2.1: Summary of the search and selection.
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for either cashew nut (47 children) or peanut (94 children) allergy. The severities of the 
most severe reactions were compared (4). The paper by Hourihane et al. (1) reported the 
clinical features of cashew nut allergy in 26 paediatric and three adult subjects, whose 
history of reaction was supported by positive SPT or raised cashew-specifi c IgE. Grigg et 
al. (5) performed a retrospective chart review and phone survey to identify the clinical 
characteristics of cashew nut allergic patients in comparison with peanut allergic patients. 
The paper by Corderoy et al. was a retrospective chart review. This study evaluated the 
mean SPT wheal diameter, cashew sIgE, age at challenge and previous clinical history 
to determine whether any of these variables predicted the risk of a subsequent reaction 
during oral food challenges (6). The retrospective study by York et al. (7) investigated the 
ethnicity of 100 children with a clinical history of cashew nut allergy.
Table 2.1: Relevant studies on clinical symptoms of cashew nut allergy
Author Year Type of study
Number 
of cases
Children/
adults Symptoms (% and n =)
Rance (2) 2003 Prospective 
study
42 Children Respiratory 25 % (28/112)*
Cutaneous 56 % (63/112)
Gastro-intestinal 17 % (19/112)
Davoren (3) 2011 Retrospective 
chart review
27 Children Anaphylaxis: 74.1 % (20/27)†
Respiratory: 15 % (3/20)
Respiratory, cardiovascular system,
skin: 5 % (1/20)
Respiratory, skin,
gastro-intestinal 25 % (5/20)
Respiratory and skin: 40 % (8/20)
Respiratory and
gastro-intestinal 15 % (3/20)
Non- anaphylaxis: 25.9 % (7/27)
Skin 100 % (7/7
Hourihane (1) 2000 Retrospective 
study
29 Children 
and adults
Wheeze: 48 % (14/29)
Collapse/feeling faint: 38 % (11/29)
Grigg (5) 2009 Retrospective 
chart review
16 Children Anaphylaxis: 50 % (8/16)‡
Respiratory: 50 % (8/16)
Cutaneous: 72.4 % (11/16)
Gastro-intestinal: 18.8 % (3/16)
Eye symptoms: 18.8 % (3/16)
Clark (4) 2007 Case-
matching 
study
47 Children Cutaneous: 98 % (46/47)
Gastro-intestinal: 32 % (15/47)
Rhino-conjunctivitis: 6 % (3/47)
Wheeze: 40 % (19/47)
Laryngeal oedema: 9 % (4/47)
Cardiovascular: 13 % (6/47)
Lightheaded: 13 % (6/47)
 *42 cases, 112 events.
†Defi ned as a rapidly evolving generalized multisystem allergic reaction characterised by cardiovascular 
involvement and involvement of other systems (skin and/or gastro-intestinal (5).
‡As defi ned by the Second Symposium on the defi nition and management of anaphylaxis (36).
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CASHEW NUT AND CASHEW NUT ALLERGY
The cashew nut
The Portuguese discovered the cashew nut in northeastern Brazil in the sixteenth century 
and exported the cashew nut tree to other continents (8). The cashew nut (Anacardium 
occidentale) belongs to the Ancardiaceae family. Botanically the cashew nut is actually 
a seed and not a nut, but historically it has been referred as to a nut. The cashew nut is 
kidney-shaped and grows on the bottom of the cashew apple. It is surrounded by a shell 
as well as a layer of toxic oil. Because of this toxic oil, the cashew nut must be roasted 
before it is safe to eat. Sixty per cent of cashew nuts are consumed as a snack, and the 
remaining 40 per cent is processed in products such as butters, pestos, bakery – and 
confectionary items, sweets, ice creams and chocolates (1, 5, 9). The cashew nut is used 
especially in the Indian, Thai and Chinese cuisines. In the world production of edible 
nuts, the cashew nut ranks as third with Vietnam, Nigeria, India and Brazil as the major 
cashew nut exporters. Cashew nut cultivation is not organized on a plantation scale 
in most producing countries. The price of the cashew nuts is much higher than that of 
peanuts and other nuts because of the labour-intensive manner of processing required 
to turn the raw nut into the edible cashew nut (9). The world production of cashew nuts 
has experienced a rapid growth. A tenfold increase has been observed during the last 
50 years. The world production of cashew nuts was approximately 1.24 million tonnes in 
2000 and increased to approximately 3.58 million tonnes in 2010 (9).
EPIDEMIOLOGY
Many published reports deal with the prevalence of tree nut allergy in general. Although 
cashew nut allergy is reported as a common tree nut allergy, we found only a few studies 
on the prevalence of cashew nut allergy (10). The search yielded studies suggesting an 
increase in cashew nut allergy in children and an increased recognition of cashew nut 
allergy in clinical practice (2, 3, 5). In a study by Tariq et al. (11), 0.08 % of children under 4 
in the United Kingdom were found to be sensitised to cashew nuts. Moneret-Vautrin et 
al. (12) reported that 41 % of the nut allergic patients in France were sensitised to cashew 
nut. Hasegawa et al. (13) observed relatively more cashew nut allergy in female adults. 
The study of York et al. (7) indicates that cashew nut allergy may be more prevalent in 
the Asian population. Forty-one of 100 patients derived from a multicultural paediatric 
allergy clinic in Leicester (UK) with a clinical history suggestive of cashew nut allergy 
were from Asian/ Asian British background compared with only 21 % with a history 
suggestive of allergy to other nuts. A possible explanation for this ﬁnding is that Asian 
children have earlier exposure to cashew nuts because of dietary practices leading to 
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more cashew nut allergy compared with other populations (7). Despite the impression 
that sensitisation and clinical allergy to cashew nut are increasing, methodologically 
rigorous studies documenting this have not yet been performed.
ALLERGENS
The major cashew allergens are Ana o 1, Ana o 2 and Ana o 3. Ana o 1 is a 50 kDa vicilin-
like protein resistant to heat and proteolysis. The other two known allergens are Ana 
o 2, a 33 kDa legume-like protein, and Ana o 3, a 13 kDa 2S albumin (14–16). All three 
allergens are classiﬁed as seed storage proteins. Of patients allergic to cashew nut, 50 % 
(10 of 20 sera) are sensitised to recombinant Ana o 1, 62 % (13 of 21 sera) to recombinant 
Ana o 2 and 81 % (21 of 26 sera) to recombinant Ana o 3 determined by Western im-
munoblotting (14, 15, 17). Allergens from these families of seed storage proteins are 
known to be allergenic in other tree nuts, legumes and seeds.
CLINICAL CROSS-REACTIVITY, CROSS-REACTIVITY IN VITRO AND CO-
SENSITISATION
The cashew nut as well as the pistachio (Pistacia vera) nut and the mango (Mangifera indica) 
belong to the Anacardiaceae family and are thus botanically related. A high degree of se-
rological cross-reactivity has been established between cashew nut and pistachio (Pis v 1, 
Pis v 2 and Pis v 3) by sIgE- inhibition tests. This may be explained by the highly conserved 
primary and three-dimensional structure of these allergen homologue pairs, present in 
both cashew nut and pistachio (18–22). Clinical cross-reactivity between cashew nut and 
pistachio was suggested in the study by Noorbakhsh et al. and the study by Willison et al. 
(20, 23). Garcia et al. and Quercia et al. (19, 24) also reported clinical cross-reactivity between 
cashew and pistachio, although sIgE inhibition tests were not performed. Cross-reactivity 
between pistachio nut and mango seed has also been established by sIgE- inhibition 
tests. Information on the molecular basis of serological or clinical cross-reactivity between 
cashew and mango fruit, and on which proteins could be involved, is not available (25). 
Allergens with a high degree of homology with cashew nut in their allergenic proteins 
include hazelnut, mustard seed, peanut, pistachio, sesame, soybean and walnut (15–18, 
23). Co-sensitisation is seen between the cashew nut and almond, hazelnut, orange seed, 
pistachio, peanut, pectin and walnut (2, 3, 19, 22, 25–27). Sensitisation against cashew nut 
allergy seems to be a primary sensitisation rather than a cross-reaction between cashew 
nuts and pollens. An overview of the homology, clinical cross-reactivity, cross-reactivity in 
vitro and co-sensitisation between cashew nut and other allergens is shown in Table 2.2.
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CLINICAL FEATURES
The age of onset of cashew nut allergic symptoms varies between 2 months and 27 
years with a mean of approximately 3 years (1, 2, 4, 5). Most allergic reactions to cashew 
nut, such as other food allergies, manifest with skin lesions followed by respiratory and 
gastro-intestinal symptoms (Table 2.1). The study of Davoren et al. showed cutaneous 
involvement as the initial symptom in 100 % of the non-anaphylactic cases. The initial 
symptoms in most anaphylactic patients are respiratory, often combined with skin 
symptoms. On the other hand, 30 % of the anaphylactic cases had no cutaneous reac-
tion, which might make it difficult to recognize anaphylaxis (3). Compared with peanut 
allergy, cashew nut allergy causes more gastro-intestinal symptoms (5). Cashew nut 
causes severe allergic reactions similar to responses to other tree nuts and peanut (2, 3, 
28) and can be lethal in both adults and children (29). However, some studies reported 
anaphylactic reactions even more frequently to cashew nut than to peanut (50 % and 
30 %, respectively) (5). This was also found in the study by Davoren et al. of 214 children 
with peanut or tree nut allergy. Thirty per cent of the peanut and 74 % of the cashew 
Table 2.2: Overview of allergen homology, co- and cross-sensitisation and co- and cross-reactivity between 
cashew nut and other food allergens
Allergen
Allergen 
homology
Co-sensitisation
(n/total)
Serological 
cross-reactivity
Clinical dual 
reactivity (n/total)
Probable clinical 
cross-reactivity
Pistachio Wilison (23) Rance (2) (28/42)
Garcia (19) (3/3)
Sansosti (22) (1/1)
Fernandez (2) (4/42)
Willison (23)
Noorbakshs (20)
Hasegawa (13)
Parra (21)
Garcia (19) (1/3)
Ferdman (26) (1/1)
Noorbakhsh (20)
Willison (23)
Mango - - - - -
Walnut Barre (18)
Wang (17)
Robotham (15)
Rance (2) (4/42) - - -
Almond - Rance (2)
(10/42)
- - -
Hazelnut Barre (18) Rance (2)
(6/42)
- - -
Peanut Barre (18)
Wang (16)
Clark (3) (13/47) - - -
Soybean Wang (16)
Wang (17)
- - - -
Orange seed - O ‘Sullivan (27) 
(35/100)
- - -
Pectin - Ferdman (26) (1/1) Rasanen (35) - -
Sesame Wang (17)
Robotham (15)
- - - -
Mustard seed Robotham (15) - - - -
- Literature not found
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nut sensitised patients developed an anaphylactic reaction after ingestion (3). Although 
being suggestive, this analysis did not correct for other possible factors, which might 
bias these results, such the eliciting doses or a history of asthma. Clark et al. performed a 
case-matching study of children with a history of a reaction after cashew nut or peanut 
ingestion and evidence of sensitisation (positive skin prick test). Children with the most 
severe reaction to peanut ingestion were matched 2: 1 to children with the most severe 
reaction to cashew nut ingestion. This study showed no significant differences in clinical 
features between the cashew nut and peanut group, except asthma (more prevalent 
in the peanut group). This study reported that allergic reactions to cashew nuts are 
often more severe than reactions to peanuts, with more frequent bronchoconstriction 
and cardiovascular symptoms in the cashew group despite the fact that asthma was a 
more frequent co-morbidity in the peanut group (4). At the Royal Children’s Hospital in 
Melbourne, 117 anaphylactic reactions occurred over a 5-year period, more frequently 
to cashew nut than to peanut (18 % and 13 %, respectively). However, it is not described 
whether this difference is statistically significant and the percentages are not adjusted 
for other risk factors (28). The study by Davoren et al. showed that five of 27 patients 
with cashew nut allergy had an allergic reaction after only skin or mucosal contact. One 
of these five patients developed anaphylaxis (3). This suggests significant reactions 
even to minimal levels of exposure. Blom et al. determined the eliciting doses in 31 
patients with a positive double-blind placebo-controlled food challenge test (DBPCFC) 
and found that the protein dose, at which 50 % of the allergic population was likely to 
respond (ED50), was 25.4 mg (any type of symptoms) which is comparable to peanut 
(17.2 mg) and hazelnut (13.5 mg) and clearly lower than that of egg or milk (82.0 and 
82.6 mg, respectively) (30). The severity of accidental reactions to cashew reactions 
could be increased further by the fact that compared with peanut and hazelnut, cashew 
is more often in particulate form resulting in higher doses. However, further research is 
necessary. These data collectively suggest that cashew nut allergy may be considered an 
exceptionally potent allergen that is a relatively frequent cause of anaphylaxis.
DIAGNOSIS
Corderoy et al. showed that patients with positive or negative cashew nut challenge 
tests do not differ in median cashew nut sIgE. In contrast, however, the SPT was signifi-
cantly larger in patients with positive challenge tests. Skin prick tests seem to be supe-
rior to sIgE in predicting challenge outcome (6). The reliability of SPT depends on several 
factors such as age, method of skin prick testing and quality of the extract. A cut-off 
value of ≥ 8 mm (SPT) gave a 95 % positive predictive value for a positive challenge test 
outcome (31). However, the size of the study and the population characteristics limit, 
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however, the generalizability of the data. There are currently no studies reporting the 
relative importance of sensitisation to major allergens of cashew in predicting clinical 
reactivity to cashew nut or the severity of such reactions. A relatively new approach is 
component-resolved diagnosis, which might be useful to determine sIgE to cashew nut 
allergens.
ALGORITHM FOR THE DIAGNOSIS OF CASHEW NUT ALLERGY
Cashew nut allergy is often diagnosed by history, combined with measuring sensitisa-
tion by skin prick test and in vitro specific IgE tests. As with other foods, the latter tests 
do not distinguish very well between clinical allergy and asymptomatic sensitisation. For 
the diagnosis, the gold standard remains DBPCFC, according to international guidelines 
DBPCFC should not be used in case of a clear-cut history of anaphylaxis after consump-
tion of cashew nuts (32). The fact that this test is time-consuming, labour-intensive, 
expensive and not entirely without risk has prompted research into the development 
of models predictive of clinical reactivity based on other parameters. DunnGalvin et al. 
developed a prediction model for peanut allergy, which might replace DBPCFC. When 
validated in the same centre, the model showed an AUC of 0.97 to predict peanut allergy 
(33). However, this prediction model was not able to predict peanut allergy in a Dutch 
study (34). A prediction model has not yet been developed for cashew nut allergy.
MANAGEMENT
The mainstay of therapy in food allergic patients is avoidance of the allergic food. This is 
increasingly difficult to achieve in cashew nut allergic patients because of the increase
in cashew nuts in many food products. Causal treatment for food allergy in form of 
oral immunotherapy (OIT) is in development. Oral immunotherapy for food such as egg, 
milk and peanut seems to be a promising way to induce desensitisation or tolerance 
despite the difficulties, such as the side effects and doses schedule. Possibly OIT can 
play a role in the treatment for cashew nut allergy in the future. Furthermore, avoidance 
of botanically related foods such as pistachio must be advised in case of established 
cashew nut allergy. More research is needed to better underpin an advice on avoidance 
of botanically related foods with allergenic homology to cashew nut.
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SUMMARY AND CONCLUSION
Recent studies on cashew nut allergy suggest that the prevalence of cashew nut allergy 
has increased. Whilst this may be a real increase, increased cashew nut consumption 
may be revealing more cases, and more cases may be noticed because of increased 
awareness of patients and doctors. The latter seem less likely given the often severe 
nature of reactions to cashew nut. The major allergenic proteins described in cashew 
nuts to date are legume-like proteins and 2S albumins. The DBPCFC test is currently 
the gold standard to establish cashew nut allergy. Cashew nuts allergens are apparently 
highly potent and can cause relatively severe reactions. They are a relatively common 
cause of anaphylaxis and can cause death. Avoidance of pistachio nuts must currently 
be advised in case of a cashew nut allergy, but advice of avoidance of other related al-
lergens needs further investigation. In comparison with literature and research focussed 
on peanut, cashew allergy is clearly an underestimated but important healthcare prob-
lem, especially in children. Further research is urgently needed on this relatively new 
food allergen, including allergenic content, diagnostic tools and dietary advice for the 
patients required to prevent severe anaphylactic reactions.
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Multicentre double-blind placebo-
controlled food challenge study in 
children sensitised to cashew nut
This article demonstrates the clinical relevance of cashew nut sensitisation and the clini-
cal reaction patterns during the DBPCFC tests with cashew nut. This article is published 
in PloS One in 2016.
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ABSTRACT
Background
Few studies with a limited number of patients have provided indications that cashew-
allergic patients may experience severe allergic reactions to minimal amounts of cashew 
nut. The objectives of this multicentre study were to assess the clinical relevance of 
cashew nut sensitisation, to study the clinical reaction patterns in double-blind placebo-
controlled food challenge tests and to establish the amount of cashew nuts that can 
elicit an allergic reaction.
Methods and Findings
A total of 179 children were included (median age 9.0 years; range 2–17 years) with 
cashew nut sensitisation and a clinical history of reactions to cashew nuts or unknown 
exposure. Sensitised children who could tolerate cashew nuts were excluded. The study 
included three clinical visits and a telephone consultation. During the first visit, the 
medical history was evaluated, physical examinations were conducted, blood samples 
were drawn and skin prick tests were performed. The children underwent a double-
blind placebo-controlled food challenge test with cashew nut during the second and 
third visits.
The study showed that 137 (76.5 %) of the sensitised children suspected of allergy to 
cashew nut had a positive double-blind placebo-controlled food challenge test, with 
46 % (63) manifesting subjective symptoms to the lowest dose of 1 mg cashew nut 
protein and 11 % (15) developing objective symptoms to the lowest dose. Children most 
frequently had gastro-intestinal symptoms, followed by oral allergy and skin symptoms. 
A total of 36 % (49/137) of the children experienced an anaphylactic reaction and 6 % 
(8/137) of the children were treated with epinephrine.
Conclusion
This prospective study demonstrated a strikingly high percentage of clinical reactions to 
cashew nut in this third line population. Severe allergic reactions, including anaphylaxis 
requiring epinephrine, were observed. These reactions were to minimal amounts of ca-
shew nut, demonstrated the high potency of this allergens.
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INTRODUCTION
Only a limited number of clinical studies have been published on cashew nut allergy. 
Five relevant studies have been performed examining clinical symptoms (1). All of these 
studies were based on a limited number of patients, varying between 16 and 47 par-
ticipants. Cashew-allergic patients most frequently show skin symptoms, followed by 
respiratory and gastro-intestinal symptoms. Studies have shown that a small amount of 
cashew nut allergen may cause severe clinical reactions, suggesting a high potency of 
this nut, comparable to that of other tree nuts and peanuts (2). The study by Davoren et 
al. reported that 30 % of the peanut and 74 % of the cashew nut sensitised patients with 
peanut and tree nut allergy developed an anaphylactic reaction after allergen inges-
tion. Moreover, in this study, 5 of 27 patients with cashew nut allergy experienced an 
allergic reaction after only skin or mucosal contact. One of these five patients developed 
anaphylaxis (3).
Clinical history, combined with the outcome of a skin prick test (SPT) and/or specific IgE 
(sIgE) test, is often used to establish the diagnosis of cashew nut allergy. The gold standard, 
however, is the double-blind placebo-controlled food challenge (DBPCFC) test.
The objectives of this study were to assess the clinical relevance of cashew nut sensi-
tisation, to study the clinical reaction patterns and the severity of symptoms during the 
DBPCFC tests with cashew nut and to establish the amount of cashew nut that can elicit 
an allergic reaction.
MATERIAL AND METHODS
Study design and patient selection
This study was a collaboration of three tertiary care centres for food allergy and the 
Research Centre Wageningen, the Netherlands. Consecutive new children and children 
known to have a sensitisation to cashew nut (sIgE and/or SPT) and a history of previous 
reaction(s) to cashew nut or unknown exposure were asked to participate in this study. 
More than 1000 children from this tertiary care population between 2 and 17 years of 
age were asked to participate. Approximately 1 in 3 parents of children who responded 
to the invitation (40 %), agreed. Children with high sIgE (≥ 100 kU/l) to cashew nut and/
or anaphylactic reactions after cashew nut ingestion in the past were also included. 
Sensitised children who could tolerate cashew nuts were excluded. All
children were included in the study between May 2012 and March 2015. The last 
enrolled child finished the study in May 2015. The inclusion and exclusion criteria of the 
study are shown in Table 3.1 and a flowchart of the patient inclusion is shown in Figure 
3.1.
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Study procedure
The study program consisted of three clinical visits and a telephone consultation, as 
shown in Table 3.2. During the first visit, written informed consent was obtained (from 
parents of children (2–12 years old) and from parents and children (≥ 12 years old) and 
two medical history questionnaires were completed. Blood samples were drawn, SPT 
and physical examinations were conducted by a nurse and a physician. All children 
underwent a DBPCFC test with cashew nut in the second and third visits. The results of 
the challenge tests were discussed with the parents of the children by phone within a 
week after the DBPCFC test.
Figure 3.1: Flowchart of patient inclusion
Table 3.1: Inclusion and exclusion criteria
Inclusion criteria
Age between 2 and 17 years.
Positive skin prick test (mean wheal diameter ≥ 3 mm Ø and HEP-index area ≥ 0.4 and/ or detectible sIgE (> 
0.35 kU/L) to cashew nut.
History of previous positive reaction to cashew nut or unknown exposure.
Written informed consent from parents (2-12 years old), or parents and child (≥ 12 years old).
Exclusion criteria
History of severe or uncontrolled asthma (according to the physician’s assessment).
Autoimmune diseases, cardiovascular diseases or cancers.
Severe psychosocial problems.
The patient is allergic to one or more of the ingredients of the test food, unless a suitable substitute for the 
ingredient in question can be found.
Unable to stop taking antihistamine medication for a short period.
Use of beta-blockers.
Unable to speak and understand the Dutch language.
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Medical ethical approval for this study was obtained on 19 April 2012 and the study 
was registered in the Dutch trial register on 10 August 2012 (registered with administra-
tive delay).
Questionnaires
We used two questionnaires, which were specifically designed for this study. The medical 
history questionnaire contained 54 questions about general health, asthma and eczema. 
Also food allergies other than cashew nut allergy were evaluated by questions about the 
symptoms, the time between exposure and reaction, and the amount of allergenic food 
that caused the reaction. The dietary history questionnaire (12 questions) was used to 
identify allergic reactions in the past caused by cashew nut consumption. The type and 
severity of reaction was extensively evaluated and the amount of cashew nut causing 
the reaction was determined. The time between the reaction in history and the intake 
was also checked.
METHODS
Skin prick test
The children underwent a SPT with cashew nut, pistachio nut, hazelnut, peanut, mango 
and birch pollen extracts, a positive control (histamine 10 mg/ml ALK-Abello, Nieu-
wegein, the Netherlands) in duplicate and a negative control. All the extracts, except 
birch pollen (ALK 10.000 BU), were made according to a previously described method 
(3). Cashew nuts (roasted, unsalted) and pistachio nuts, hazelnuts and peanuts (fresh, 
not roasted, unsalted nuts) were homogenised mechanically, ground with a mortar and 
pestle, defatted by ether extraction, and subsequently the extracts were air-dried. A 10 % 
Table 3.2: Study program
Visit 1 Visit 2 Visit 3
Telephone 
consultation Final visit (optional)
Week 1 Week 4 Week 6 Week 7 Week 8
Written informed 
consent
DBPCFC test
Session 1
DBPCFC test
Session 2
Result DBPCFC test Dietary advice
Medical history
(2 questionnaires)
Physical 
examination
Blood samples
(19 ml)
Skin prick test
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w/v extract in PBS (phosphate-buffered saline) with the pre-treated material was made 
and stored at -20°C in small aliquots. Before testing the aliquots were defrosted and 
mixed. Mango juice was prepared from small pieces of ripe mango fruit pulp, without 
skin or kernel.
SPTs were performed by applying a drop of the allergen extract on the skin of the 
volar part of the forearm. The extract was pierced through the skin barrier with a lancet. 
Twenty minutes after the skin tests, the contours of the wheal were encircled with a 
fine-tip pen and transferred to a record sheet by translucent tape. The area of the wheals 
was determined by using a scanner device (Hewlett Packard 2400c) in combination with 
software previously developed in our centre: Precise Automated Area Measurement of 
Skin Test (PAAMOST). The area of the allergen-induced wheal was divided by the mean 
area of the two positive histamine-induced wheal controls. This ratio was defined as the 
Histamine Equivalent Prick (HEP)-index area. The average wheal diameter was measured 
as well. An average wheal diameter ≥ 3 mm and a HEP-index area ≥ 0.4 was considered 
positive (4).
In vitro tests
Serum samples were analysed for sIgE using the Siemens IMMULITE 2000 XPi Immuno-
assay System (Med. Imm. Laboratory; Reinier de Graaf Groep (RdGG). Levels above 0.35 
kU/L were considered positive. sIgE against cashew nut, pistachio nut, hazelnut, peanut, 
mango and tree pollen were determined.
Food challenge test
Procedure and recipe challenge test
Each patient underwent a DBPCFC test with cashew nut. The test food was administered 
in increasing amounts of 8 doses at time intervals of 30 minutes. Placebo and cashew 
nut challenges were randomly administered on separate days with at least a one-week 
interval. Validated and standardised food challenge material was used in the DBPCFC 
tests (5). Roasted cashew nuts were provided by Intersnack, Doetinchem, the Neth-
erlands. NIZO Food Research, Ede, the Netherlands prepared the low-fat food matrix 
(muffin dough). The food matrix predominantly consisted of wheat, sugar, gingerbread 
spice mix and coconut. The total volume/weight of the cashew nut gingerbread was 
120 grams. The starting dose consisted of 1 mg cashew protein, followed by increasing 
doses of 3, 10, 30, 100, 300, 1000, 1736 mg cashew protein. Dose 8 consisted of the 
remainder of the 120 grams cashew nut gingerbread recipe. In children below the age 
of 4 years the challenge was stopped at step 7 (1000 mg cashew protein), because of the 
large amount of challenge material. The challenged doses are shown in Table 3.3.
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Assessment and DBPCFC tests
The DBPCFC test was discontinued and considered positive when objective symptoms 
occurred, or when subjective symptoms re-occurred twice after the same dose of chal-
lenge material had been administered, three times consecutively (6), or when severe 
subjective symptoms persisted for more than one hour. If the child presented with the 
same symptoms on the placebo as on the verum day, the DBPCFC test was considered as 
undetermined. Anaphylaxis was defined as described in the EAACI Guidelines for Food 
Allergy and Anaphylaxis (7).
Procedure after the outcome of the DBPCFC test
In negative challenge test results, the child was advised to introduce cashew nuts at 
home. If the parents or child expected to experience problems with the introduction, a 
home introduction schedule developed by Vlieg-Boerstra et al. (8) and made available 
online (9) with increasing amounts of cashew nuts was recommended. These introduc-
tion schedules comprise instructions for parents and photographs with information on 
the required amounts of specific food for home introduction. The schedules were advised 
to improve the safety of the cashew nut introduction at home. Children with a positive 
DBPCFC test were advised to strictly avoid cashew nuts. If necessary, the participant was 
referred to a dietician after the DBPCFC test for extensive information and advice.
Statistical analysis
In this descriptive study, the patient and the study characteristics were reported in me-
dian, ranges and proportions. All analyses were done using SPSS software, 20th edition.
Table 3.3: Challenge dosage DBPCFC test with cashew nut (5)
Dose steps Cashew nut protein (mg)
Cashew nut protein cumulative 
(mg)
Cashew nut 
cumulative 
(number)*
1 1 1 0.01
2 3 4 0.03
3 10 14 0.10
4 30 44 0.30
5 100 144 1
6 300 444 3
7 1000 1444 10
8 1736 3180 22
* 1 cashew nut = approximately 700 milligrams.
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RESULTS
Study population
The study included a total of 179 children. The most commonly cited reason for not 
participating was that it was time consuming, burdensome for the child to undergo 
allergy testing (SPT and sIgE), and the fear of a reaction during the challenge test. The 
median age was 9.0 years (range 2–17 years), with 106 boys (59 %) and 73 girls (41 %). 
The children came from all over the Netherlands because the three participating medical 
research centres were spread across the country. All patients’ demographic and clinical 
characteristics are summarised in Table 3.4.
Questionnaires
Symptoms consistent with eczema were reported by 70 children (39 %) and those for 
asthma by 55 children (31 %). 94 children (53 %) had symptoms consistent with hay fever. 
In 112 children (63 %) consumption of, or contact with cashew nuts had elicited an al-
lergic reaction before study entrance. These symptoms consisted mostly skin symptoms 
after cashew nut consumption in their history, followed by gastro-intestinal symptoms, 
respiratory symptoms, oral allergy symptoms and eye symptoms. The majority of the 
children reacted to cashew nuts as a single food ingested and not incorporated in other 
foods and to an amount of approximately one cashew nut.
Table 3.4: Demographic and clinical characteristics
Total 179
Gender
Male 106 (59 %)
Female 73 (41 %)
Median age (years) 9.0 (range 2-17)
Atopic disease symptoms
Asthma 55 (31 %)
Eczema 70 (39 %)
Hay fever 94 (53 %)
Diagnostics
Median sIgE cashew nut (kU/l) 3.72 (range 0-100)
Median SPT (HEP-index area) 3.02 (range 0-15.16)
Diagnosis DBPCFC test
Positive 137 (76.5 %)
Negative 36 (20.1 %)
Undecided 6 (3.4 %)
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Twenty-three percent (42 of 179 children) reported pistachio nut consumption. 21 
of 42 children (50 %) reported allergic symptoms to pistachio nut. of these children. 
Mango was consumed by 116 of 179 children (65 %) and allergy was reported in 8 of 116 
children (7 %). Hazelnuts were consumed by 143 of 179 children (80 %) and 32 of these 
143 children (22 %) reported a hazelnut allergy. Peanuts were consumed by 151 of 179 
children (84 %) and peanut allergy was reported in 52 of these 151 children (34 %) (Figure 
3.2).
Sensitisation to cashew nut
173 children had a positive sIgE cashew value (> 0.35 kU/l) and 164 had a positive SPT 
(diameter ≥  3 mm and HEP-index area ≥  0.4). The median sIgE cashew was 3.72 kU/l 
(range 0-≥ 100 kU/l). The median HEP-index area of cashew SPT was 3.02 (range 0–15.16).
Food challenge
A total of 179 children were challenged with cashew nuts and 137 of the challenges were 
considered positive (76.5 %), 36 negative (20.1 %) and 6 undecided (3.4 %). Most children 
experienced gastro-intestinal symptoms (nausea, vomiting, stomach pain and diarrhea), 
followed by oral allergy symptoms, skin symptoms (redness and itchiness), urticaria 
and angioedema (Table 3.5). A total of 49 (36 %) of the children had an anaphylactic 
reaction as defined by the EAACI Guidelines for Food Allergy and Anaphylaxis (7). The 
most commonly observed type of anaphylactic reaction was a combination of skin and 
gastro-intestinal symptoms (Table 3.6). A total of 8 children (6 %) with a positive reaction 
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Figure 3.2: History and sensitisation to tested allergens
This figure shows the history and sensitisation to cashew nut and the history and co-sensitisation to pista-
chio nut, mango, hazelnut and peanut.
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were treated with epinephrine. A single dose (0.15ml < 25 kg and 0.30ml > 25 kg) of 
epinephrine was sufficient to treat the child. None of the children had a life-threatening 
reaction.
Only objective symptoms were seen in 16 children (12 %), 47 children reported only 
subjective symptoms (34 %) and 74 (54 %) of the children showed both. After the first 
dose (1 mg cashew protein) 63 (46 %) children experienced subjective symptoms and 
objective symptoms were observed after the first dose in 15 children (11 %). Figure 3.3 
shows the threshold distribution curve for objective and subjective symptoms. Anaphy-
laxis was observed in 23 (17 %) children with the start of the reaction to the first dose. 
Table 3.5: Clinical symptoms during positive DBPCFC tests
Symptoms
Gastro-intestinal
Number of children with positive DBPCFC 
test
Total N = 137 (76.5 %)
Number %
Oral allergy 87 64
Nausea, stomach pain, vomiting, diarrhea 98 72
Skin
Urticaria 29 21
Redness, itchiness 38 28
Angioedema 37 27
Eye symptoms 26 19
Upper airway symptoms 20 15
Lower airway symptoms 9 7
Cardio-vascular symptoms 0 0
Indefinite symptoms
Change in behavior 18 13
Pallor/ feeling weak 9 7
Table 3.6: Anaphylactic reactions during positive DBPCFC tests
Anaphylaxis Total N = 49/137 (36 %)
S kin and respiratory 3 (2 %)
Skin and decrease of blood pressure* 0
Skin and gastro-intestinal 40 (30 %)
Respiratory and decrease of blood pressure* 0
Respiratory and gastro-intestinal 6 (4 %) **
Decrease of blood pressure and gastro-intestinal 0
Decrease of blood pressure > 30 % SB 0
*Or associated symptoms such as syncope, incontinence and collapse
** Children had also skin symptoms.
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Cashew nut allergy could not be confirmed with the DBPCFC test in almost 20 % of the 
children with a positive history.
Co-sensitisation
In cashew nut sIgE-sensitised children, sIgE co-sensitisation to pistachio nuts was 
observed in 98 % of the cases (169/173), to hazelnut in 69 % of the cases (119/173), to 
peanut in 62 % of the cases (107/173), to mango in 21 % of the cases (37/173) and in 
77 % of the cases (134/173) to tree pollen. SPT cashew co-sensitisation to pistachio nut 
was seen in 92 % (151/164). Lower percentages of SPT co-sensitisations were seen for 
hazelnut 71/163 (44 %), to peanut 97/164 (59 %) to mango 31/164 (19 %), and to birch 
pollen 99/163 (61 %).
DISCUSSION
Here, we present a diagnostic study in children sensitised to cashew nuts, carried out 
in three pediatric food allergy expertise centres in the Netherlands. We performed a 
DBPCFC test with cashew nut in this group, to measure the clinical relevance of sensiti-
sation, to investigate the severity of the allergic reaction to cashew nut and the dosage 
of cashew nut to which they react.
More than 75 % of the children sensitised to cashew nuts showed a clinical response 
in the DBPCFC test. This percentage is much higher than that observed in a previous 
other cashew nut study that analysed the clinical features of 42 children with a clinical 
history suggestive of cashew nut allergy, and a positive skin prick test (SPT) and/or a 
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Figure 3.3: Threshold distribution curve for objective and 
subjective symptoms in cashew nut allergic children
Figure 3.3: Threshold distribution curve for objective and subjective symptoms in cashew nut allergic chil-
dren
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positive specific sIgE and/or a previous positive food challenge test (10). Only in 8 (19 %) 
of these children a cashew nut allergy could be confirmed with a positive challenge test. 
The percentage of a clinically relevant sensitisation to cashew nut in our study was also 
higher compared to the results of studies with other food allergens such as hazelnut. 
A study by Flinterman et al. showed that of the 28 children sensitised to hazelnut, a 
DBPCFC test could only confirm a hazelnut allergy in half of the patients (11). During 
the challenge test in our study, most patients experienced gastro-intestinal symptoms, 
with skin manifestations as the second most prevalent symptom. This is in contrast to 
other studies on cashew-allergic patients in which skin symptoms were observed more 
frequently than respiratory and gastro-intestinal symptoms (10). Sixty-three percent of 
the children tested reported a history of allergic reactions to cashew nuts in our study. 
However, a cashew nut allergy could not be confirmed with the DBPCFC test in almost 
20 % of the children with a positive history. Half of these children experienced the last al-
lergic symptoms to cashew nut between one month and two years ago. A negative oral 
food challenge test after positive testing and/or positive history is reported between 
9 % and 38 % for peanut allergy (12–16). Children with a positive history and negative 
testing may have outgrown their allergy or may have an unreliable history. In addition 
personal co-factors or differences in exposure may account for this discrepancy. Acci-
dental ingestion of cashew nut is not very likely as they are incorporated in products in 
an unrecognisable form less often than peanut or hazelnut.
With the first dosage of only 1 mg of cashew protein, 46 % of the children experienced 
subjective and 11 % objective symptoms. The food allergy threshold study by Blom et al. 
with 363 DBPCFC tests showed that the number of patients with any type of symptoms 
caused by 1 mg cashew nut-, hazelnut-, egg-, milk- and peanut protein varied between 5 
and 20 % (17). The number of patients with objective symptoms to 1 mg hazelnut protein 
was reported in 10 % of the patients and was comparable with our results for cashew 
nut. The number of patients reported with objective symptoms to 1 mg egg-, milk- and 
peanut protein was lower compared with cashew nut in our study. This confirms the 
potency and thus the potentially dangerous nature of cashew nut compared to other 
allergens.
Almost 40 % of the children in our study showed anaphylactic reactions and 6 % of 
these children was treated with epinephrine. Anaphylaxis was observed in 17 % of the 
children with the start of the allergic reaction to the first dose (1 mg cashew nut protein). 
A previous threshold study demonstrated that approximately 5 % of 257 peanut allergic 
patients reacted to 1 mg peanut protein with severe symptoms (18). Therefore, our 
study supports previous observations, showing that minimal amounts of cashew nut 
are sufficient to cause these severe allergic reactions.
Cashew nut, pistachio nut and mango belong to the Anacardiaceae family and are 
thus botanically related. In line with previous reports, this study shows a high rate of 
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co-sensitisation between cashew nuts and pistachio nuts in SPT and sIgE (respectively 
92 % and 98 %) (19–22). Almost 50 % (21/42) of our pistachio nut sensitised and exposed 
children reported allergic reactions to pistachio nuts.
Many cashew nut and pistachio nut sensitised children reported no consumption of 
cashew nut and/or pistachio nut. In most cases, these children were previously advised 
to eliminate cashew nuts and also pistachio nuts from the diet because of the possibility 
of cross-reactions. We advise, however, in these cases to perform a DBPCFC test to avoid 
unnecessary eliminations.
Mango is also botanically related to cashew nut, but our study shows only 19 % 
co-sensitisation with mango in cashew positive SPT children and 21 % in sIgE positive 
children. In this study, almost all children have consumed mango and only 7 % reported 
a history of reactions due to the consumption of mango. Cross-reactivity has not been 
reported between cashew nut and mango (1) and oral challenges with mango are nec-
essary to confirm the histories we obtained.
Strengths and weaknesses of this study
The strength of this study was the prospective multicentre study design and its size 
compared to previous studies on cashew nut allergy (1). This relatively large number of 
children enabled us to estimate the rate of clinical reactions in sensitised children and 
to determine the severity of cashew nut allergy. All children underwent a DBPCFC test 
with cashew nut and thus, the diagnosis was based on this gold standard to establish 
food allergy, and consequently the clinical relevance of sensitisation and potency of the 
cashew nut allergen could be accurately examined. A limitation of this study was that 
we were unable to use the well-accepted scoring system to assess DBPCFC tests as pro-
posed by a PRACTALL consensus group, as this was published after the start of the study 
(23). Furthermore, there might be a selection bias in this study because a lot of children 
or parents of children refused to participate in this study because of e.g. fear for severe 
allergic reactions during the DBPCFC test. However, there was also a large group of 
children with an unknown history of cashew nut ingestion and among this group were 
children with a severe cashew nut allergy. Furthermore, many children experienced an 
anaphylactic reaction in this study. Therefore, the selection bias seems to be small.
CONCLUSION
This is the largest prospective clinical study reported in children, sensitised to cashew 
nut so far. The study demonstrates a high percentage of clinical reactivity to cashew 
nut in sensitised children. Cashew nuts may cause severe allergic reactions, including 
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anaphylaxis. A minimal amount of cashew nut (1 mg comparable with 1/100 part of a 
cashew nut) may be sufficient to cause clinical symptoms. `
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Chapter 3.2
Threshold dose distribution and 
eliciting dose of cashew nut allergy
This letter shows the threshold distribution curve of the IDEAL-study and the lowest 
observed adverse effect levels in cashew nut allergic children. This letter is accepted by 
Annals of Allergy, Asthma & Immunology in 2016.
Van der Valk JP, Gerth van Wijk R, Baumert JL, Nordlee JA, Vlieg-Boerstra B, de Groot 
H, Dubois AE, de Jong NW. Threshold distribution and lowest observed adverse effect 
levels in cashew nut allergic children. Ann. of Allergy, Asthma & Immunology. Annals of 
Allergy, Asthma & Immunology in 2016. Accepted.
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A previous study by our group demonstrated that 137/179 (76.5 %) of the cashew 
nut sensitised children suspected of cashew nut allergy had a positive double-blind, 
placebo-controlled food challenge (DBPCFC), with 63/137 (46 %) children manifesting 
subjective and/or objective symptoms to the lowest dose (1 mg cashew nut protein) 
(1). The primary aim of this study was to determine the distribution of threshold doses 
and the eliciting doses (EDs) in this population. The secondary aim was to investigate 
whether children that reacted to 1 mg cashew nut (n = 63) could react to even lower 
doses than 1 mg: the Low-dose follow-up study.
The children participated in the ‘Improvement of Diagnostic mEthods for ALlergy 
assessment’ (IDEAL-study, trial number NTR3572). The inclusion and exclusion criteria 
and detailed study protocol with stop criteria for the DBPCFC were previously described 
(1). Briefly, we measured sensitisation (specific IgE [sIgE] and skin prick test [SPT]) with 
cashew nut extract and performed DBPCFC tests with eight-step incremental doses 
regime (1, 3, 10, 30, 100, 300, 1000, 1736 mg of cashew nut proteins) (2). All children who 
reacted to 1 mg cashew nut in the IDEAL-study were asked to participate in a Low-dose 
follow-up study, that consisted in DBPCFC with six-step incremental dose regime, start-
ing with 0.01 mg, followed by increasing doses of 0.03, 0.10, 0.30, 1, and 3 mg cashew 
protein, performed between 4 and 30 months after the initial IDEAL- challenges. The 
low-dose challenges were considered positive if objective or subjective symptoms oc-
curred. There were no stop criteria, all patients completed the low-dose DBPCFC test to 
step 6, unless not medically justified/ unethical or if the patient refused to continue the 
test. To facilitate the weighing of these small doses, ground cashew nuts were diluted 
1:10 with granulated sugar, according to the technical method of Taylor et al. (3).
The Interval-Censoring Survival Analysis (ICSA) approach was utilized to analyse the 
NOAEL and LOAEL intervals for each allergic individual as described previously (4). The 
SAS LIFEREG procedure (v.9.2) was used to fit the Log-Normal, Log-Logistic and Weibull 
parametric distributions based upon cumulative doses for this cashew-allergic popula-
tion and confidence intervals were calculated. The eliciting doses (EDs) were determined 
(4).
The patient characteristics and diagnostic results of the 179 participating children 
of the IDEAL-study were previously described (1). The median age of the children was 
9.0 years (range 2–17 years), with 106 boys (59 %) and 73 girls (41 %). The median sIgE 
cashew was 3.72 kU/l (range 0-≥ 100 kU/l). The median HEP-index area of cashew SPT 
was 3.02 (range 0–15.16) (5). Most children experienced gastro-intestinal symptoms 
(nausea, vomiting, stomach pain and diarrhea) (72 %), followed by oral allergy symptoms 
(64 %), skin symptoms (redness and itchiness) (28 %), angioedema (27 %) and urticarial 
symptoms (21 %).
The Low- dose follow-up study included 12/63 children (10 girls [83 %] median age 
13.0 yrs.).
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Cumulative distribution curves for (%) of objective eliciting threshold in the 137 ca-
shew nut allergic children was measured (Figure 3.4). It was not possible to calculate the 
threshold distribution curve for subjective symptoms, because of the high percentage 
of children (46 %) reacting to dose 1 with subjective symptoms. The doses at which 5, 10 
or 50 % of the cashew-allergic population (ED05, ED10 and ED50, respectively) would be 
expected to experience objective symptoms ranged from 0.8 to 1.6 mg, 3.5 to 4.3 mg 
and 108.4 to 149.1 mg of cashew nut protein for the ED05, ED10 and ED50, respectively, 
based upon the Log-Normal, Log-Logistic and Weibull models.
Of the 12 Low-dose challenge tests, 8 were positive, 3 were negative and 1 was unde-
termined. As only 12 children participated and 51 did not, we compared the groups to 
exclude selection bias (Fisher’s exact test, Mann Whitney u test). There was no significant 
difference in terms of age (p = 0.83), sIgE to cashew (p = 0.46), SPT to cashew (p = 0.21) 
and severity of reaction during the DBPCFC with cashew nut (p  =  0.75). Only gender 
differed significantly (p = 0.004). The lowest dose of cashew nut protein to which subjec-
tive symptoms occurred was 0.01 mg, while for transient objective symptoms (red skin), 
this was 0.30 mg. Placebo reactions during the low-dose challenge test were reported 
in a higher percentage (4/12 children, 33 %) than in the original challenge test (20/179 
children, 11 %). These 4 placebo reactions during the Low-dose follow-up study, were 
most likely caused by increased anxiety. One challenge was therefore undetermined, 
and the other 3 placebo reactions consisted mainly of mild oral allergy symptoms, in 
contrast to more severe symptoms as stomachache, nausea, tiredness, feeling of swollen 
Figure 3.4: Cumulative distribution (%) of  objective threshold in 137 cashew nut allergic children. 
Distribution curves are based on LOAEL and NOAELs for objective symptoms. Data were fitted with 
the use of  different statistical models (Log- Normal, Log- Logistic and the Weibull).
Figure 3.4: Cumulative distribution (%) of objective threshold in 137 cashew nut allergic children. Distri-
bution curves are based on LOAEL and NOAELs for objective symptoms. Data were fitted with the use of 
different statistical models (Log- Normal, Log- Logistic and the Weibull).
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throat and erythema during the verum day. Consequently, there was no doubt about 
the positive outcome of these challenges.
Three children reacted to a higher dose of cashew nut protein and four patients did 
not react at all in the low-dose challenge test. We could not find a relation in time inter-
val between the IDEAL-study and the Low-dose follow-up study, (higher or lower doses 
reactions) as being a cause of the difference in reaction doses in both studies. Previously, 
Glaumann et al. observed in 29 peanut-allergic patients that only two of these children 
reacting to the same threshold dose and with the same severity score in two successive 
food challenge test with peanut (6).
Concerning ED studies, the study by Blom et al. showed a much higher ED05 in 31 
cashew nut allergic children at 7.4 mg cashew nut protein compared to the ED05 in 
our study (7). The authors indicate in the discussion that this is an unexpectedly high 
quantity taking into account that cashew nut allergy is considered to be as severe as 
a peanut allergy. The study by Taylor et al. showed in 286 peanut allergic patients an 
ED05 for objective symptoms of 7.3 mg whole peanut (equivalent to 1.8 mg of peanut 
protein based on 25 % protein in a peanut kernel) (8). Our study demonstrated a lower 
cashew nut ED05 for objective symptoms than EDs for other allergens as reported in the 
above-mentioned study.
Minimal eliciting doses for different allergenic foods were previously investigated by 
an expert panel in a study on threshold dose by Taylor et al. (9). This study demonstrated 
that the eliciting dose on which 1 % (ED01) of the population reacted with objective 
symptoms were 0.1 mg (Log-Logistic) and 0.22 mg (Log-Normal) for peanut. The ED01 
ranges between 0.02 mg and 0.25 mg protein for hazelnut based upon the Log-Normal, 
Log-Logistic and Weibull models. The 0.30 mg cashew nut protein as lowest eliciting 
dose of mild objective symptoms in our Low-dose follow-up study is in the same order 
of magnitude.
In conclusion, the statistically determined eliciting dose on which 5 % of this cashew 
nut population reacted with objective symptoms was very low (0.8 to 1.6 mg cashew 
nut protein). Individual patients may react to as little as 0.3 mg and 0.01 mg cashew 
nut protein with mild objective symptoms and subjective symptoms, respectively. 
However, the low-dose challenge tests were only performed in 12 children, they were 
not reproducible, and the children reported mainly subjective symptoms, which makes 
interpreting the low-dose data with caution.
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Chapter 4
Improvement of diagnostic methods

Chapter 4.1
Measurement and interpretation of 
skin prick tests results
In this paper, the different techniques of quantifying SPT results are compared, a cut-off 
value for a positive SPT for histamine equivalent prick -index (HEP) area is determined, 
and the accuracy of predicting cashew nut reactions in double-blind placebo-controlled 
food challenge (DBPCFC) tests with the different SPT methods are studied. This article is 
published in Clinical and Translational Allergy in 2016.
Van der Valk JPM, Gerth van Wijk R, Hoorn E, Groenendijk L, Groenendijk IM, de Jong NW. 
Measurement and interpretation of skin prick test results. Clin. Transl. Allergy. 2016.6:8.
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ABSTRACT
Background
There are several methods to read skin prick test results in type-I allergy testing. A 
commonly used method is to characterise the wheal size by its ‘average diameter’. A 
more accurate method is to scan the area of the wheal to calculate the actual size. In 
both methods, skin prick test (SPT) results can be corrected for histamine-sensitivity 
of the skin by dividing the results of the allergic reaction by the histamine control. The 
objectives of this study are to compare different techniques of quantifying SPT results, 
to determine a cut-off value for a positive SPT for histamine equivalent prick -index 
(HEP) area, and to study the accuracy of predicting cashew nut reactions in double-blind 
placebo-controlled food challenge (DBPCFC) tests with the different SPT methods.
Methods
Data of 172 children with cashew nut sensitisation were used for the analysis. All patients 
underwent a DBPCFC with cashew nut. Per patient, the average diameter and scanned 
area of the wheal size were recorded. In addition, the same data for the histamine-
induced wheal were collected for each patient. The accuracy in predicting the outcome 
of the DBPCFC using four different SPT readings (i.e. average diameter, area, HEP-index 
diameter, HEP-index area) were compared in a Receiver-Operating Characteristic (ROC) 
plot.
Results
The ‘scanned area method’ is more accurate, as expected, in measuring wheal area size 
than the ‘average diameter method’. A wheal average diameter of 3 mm is generally con-
sidered as a positive SPT cut-off value and an equivalent HEP-index area cut-off value of 
0.4 was calculated. The four SPT methods yielded a comparable Area under the Curve 
(AUC) of 0.84, 0.85, 0.83 and 0.83, respectively. The four methods showed comparable 
accuracy in predicting cashew nut reactions in a DBPCFC.
Conclusions
The ‘scanned area method’ is theoretically more accurate in determining the wheal area 
than the ‘average diameter method’ and is recommended in academic research. A HEP-
index area of 0.4 is determined as cut-off value for a positive SPT. However, in clinical 
practice, the ‘average diameter method’ is also useful, because this method provides 
similar accuracy in predicting cashew nut allergic reactions in the DBPCFC.
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INTRODUCTION
Standard diagnostics for Type-I acute allergic reactions to foods are based on the pa-
tient’s history combined with sensitisation tests and, optionally, a food challenge test. 
Tests to measure sensitisation comprise in vitro specific IgE (sIgE) determination and 
skin prick testing (SPT). The outcome of the SPT can result in a variety of wheal shapes, 
and there are several methods to measure these outcomes. In clinical practice and in 
most academic research, it is common to characterise the wheal shape by the ‘average 
diameter’ (1). However, with this method, it is implicitly assumed that the wheal may be 
described reasonably well by an ellipse or circle, which is not always the case in practice 
and this method is prone to errors. For this reason, a more advanced scanning method 
for SPT measurement has been applied for more than a decade in the Erasmus Medical 
Centre in Rotterdam. To even further increase the accuracy of SPT results, the histamine-
induced wheal size of the positive control might be considered as well to correct for 
skin histamine sensitivity. Furthermore, differences in technique of performing SPTs 
(inter-observer variability) contribute to the variation in wheal size. We divided the area 
(or diameter) of the allergen-induced wheal by the area (or diameter) of the positive 
histamine-induced wheal controls to correct for these factors. This ratio is defined as 
the Histamine Equivalent Prick (HEP)-index area (or diameter) or histamine-equivalent 
wheal sizes (HEWS)(2). The first objective of this study is to compare different techniques 
of quantifying SPT results. The second objective is to determine a cut-off value for area, 
HEP-diameter and HEP-index area equivalent to the standard used average diameter 
cut-off value of 3 mm, whereby the HEP-index area is considered as the most important, 
because of the accuracy of this method (area measurement) and the correction for skin 
sensitivity (HEP-index measurement). The last objective is to study the accuracy of diag-
nosing cashew nut allergic reactions in the double-blind placebo-controlled (DBPCFC) 
tests with the 4 SPT methods.
METHODS
Study design
In this parallel study, data of 172 children (2–17 years of age) with a cashew nut sensitisa-
tion (sIgE and/or SPT) were used for the analysis (trial number NTR3572). All patients 
underwent a SPT with cashew nut extract and a DBPCFC test with cashew nut. Medical 
ethical approval was obtained and all patients signed informed consent.
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Skin prick tests
The children underwent a SPT with homemade cashew nut extracts, a positive control 
(Histamine 10 mg/ml ALK-Abello, Nieuwegein, the Netherlands) in duplicate and a nega-
tive control. The SPT was performed by applying a drop of the allergen extract on the 
skin of the volar aspect of the forearm. Twenty minutes after the skin tests, the contours 
of the wheal were encircled with a fi ne-tip pen and transferred to a record sheet by 
translucent tape (3).
Diff erent techniques quantifying skin prick test results
The outcome of the SPT can result in a variety of wheal shapes, as shown in Figure 4.1. 
To determine the average diameter, the mean value of the longest and the midpoint 
orthogonal diameter (mm) of the wheal were measured (Figure 4.2). The area of the 
wheal was determined by using a fl atbed scanner (Hewlett Packard) in combination 
with software earlier developed by Erasmus MC: Precise Automated Area Measurement 
of Skin Test (PAAMOST). Mean values of two histamine-induced wheal sizes of the posi-
tive control were collected as well. Based on the measured data the HEP-indices were 
calculated for both the average diameter and area.
Consequently the four readings were defi ned as:
1. Average diameter (allergen-induced average wheal diameter)
2. Area (allergen-induced area measured by scanning device)
3. HEP-index diameter (allergen-induced average diameter divided by histamine-
induced average diameter)
4. HEP-index area (allergen-induced area divided by the histamine-induced average 
area)
Figure 4.1: Typical observed wheal forms in SPT’s
Figure 4.1: Typical observed wheal forms in SPT’sFigure 4.2: Definition of  D1 and D2
Figure 4.2: Defi nition of D1 and D2
Measurement and interpretation of skin prick tests results 73
Food challenge test
The children underwent a DBPCFC test with cashew nut. The validated and standardised 
food challenge material used in the DBPCFC was prepared according to the recipe 
developed by Berber-Vlieg et al (4). The DBPCFC was considered as positive when 1) 
objective symptoms occurred, 2) when subjective symptoms occurred twice on three 
successive administration of the challenge material, or 3) when subjective symptoms 
persisted for more than one hour. In total, 137 children had a positive challenge test.
Analysis
Receiver operating characteristics (ROC) curves and Area under the Curve (AUC) were 
calculated to evaluate the diff erent SPT methods. An area under the curve of 0.9–1 is 
considered as excellent, 0.8–0.9 as good and 0.7–0.8 as fair. All analyses were done with 
SPSS software, 20th edition.
RESULTS
Skin prick test
In total 172 SPT results with cashew, positive (in duplicate) -and negative control were 
evaluated. Median histamine wheal diameter was 5.38 mm (range 2.75–10.75 mm). All 
negative controls were negative. Mean variability between the duplicate measurements 
of histamine was 14 % (range 0–100 %). Median average diameter, area, HEP-diameter 
and HEP-index area of the SPT with cashew were 10.50 mm (range 0–26 mm), 71.8 
mm2 (range 0–324.1 mm2), 1.83 (range 0–5.13) and 2.97 (range 0–15.16), respectively.
Figure 4.3: Average diameter (method 1) versus scanned area (method 2)
Figure 4.3: Average diameter (method 1) versus scanned area (method 2)
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Different techniques of interpreting skin prick test results
As a first step of assessing the different techniques of interpreting the STP results, a 
comparison is made between the common-used average diameter method (‘1’) and 
the scanned area method (PAAMOST) (‘2’). These two methods are compared in a scat-
terplot in Figure 4.3. Every dot represents one patient. The dotted line shows the trend 
line of the data.
The average diameter on the horizontal axis in Figure 4.3 is defined as the mean value 
of the longest (D1) and the midpoint orthogonal diameter (D2) of the wheal, as shown 
in Figure 4.3:
 Eq. 1
We introduce the parameter α as the ratio between D1 and D2:
 Eq. 2
In our study population of 172 patients, the parameter α varies between 1.0 and 6.67. 
Assuming that we can reasonably well estimate the wheal size by an ellipse, the area of 
the wheal (A) is defined as:
 Eq. 3
In Eq.3 the wheal area is defined as a function of D1 and D2, while the wheal size is com-
monly characterised by the average diameter, in particular in method ‘1’. Combining 
Eqs.1 to 3, the wheal area can be rewritten as a function of the average diameter D and 
the ratio α:
 Eq. 4
The lower bound value for α is 1.0 (D1=D2). In this case, the wheal shape is circular and Eq. 
4 simplifies to the well-known formula describing the area of circle, A=π/4·D2. In Figure 
4.3, this lower bound case (area as a circle) is shown by the red line. Based on our set 
of 172 patients, the upper bound value of α is 6.67. Substituting α = 6.67 into Eq. 4, the 
upper bound (area as an ellipse) is obtained. This is shown by the grey line in Figure 4.3. 
Nearly all 172 dots are lying in between these two lines, with only a few exceptions. The 
reason for these outliers is that an ellipse could not sufficiently well represent the shape 
of these wheals. From Figure 4.3 it can be concluded that characterizing the wheal size 
by the average diameter method could be rather inaccurate. For a given average wheal 
diameter, the actual wheal area could vary between 50 % under and 50 % above the 
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trend line, visually in between the red and grey line. For example, if the mean wheal 
diameter is 15 mm, the real wheal area could lie between 80 mm2 (α = 6.67) and 176 
mm2 (α = 1.0), which is a rather large variation. Figure 4.3 shows also that the absolute 
error grows with wheal size. This inaccuracy, of up to 50 %, is completely eliminated if 
one applies the scanning method, i.e. method ‘2’.
If for practical reasons, one would like to use the average diameter method, the ‘best’ 
relationship between the average diameter D and the wheal area A may be obtained out 
of dotted trend line in Figure 4.3. This line can be estimated by the following equation:
 Eq. 5
It is interesting to note that this expression is rather diff erent than the commonly used 
expression A=π/4·D2, which implicitly assumes a circular wheal shape.
To determine the cut-off  value for HEP-index area equivalent to the standard used 
3 mm average diameter cut-off  value (5), comparison is made between the average 
diameter method (‘1’) and the scanned HEP- area method (‘4’). These two methods are 
compared in a scatterplot in Figure 4.4. The dotted line shows the trend line of the data. 
This trend line can be estimated by the following equation:
 Eq.6
Substituting D = 3 mm into Eq. 6, the HEP-index area is obtained and results in 0.4. There-
fore, a HEP-index area value of 0.4 is considered as the cut-off  value for a positive SPT.
The cut-off  values for area and HEP-index diameter were measured on the same 
method. This results in an area and HEP-index diameter cut-off  values of 4.71 mm2 and 
0.6, respectively.
Figure 4.4: Average diameter (method ‘1’) versus HEP-index area (method ‘4’)
Figure 4.4: Average diameter (method ‘1’) versus HEP-index area (method ‘4’)
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Accuracy of diagnosing cashew nut allergy
To study the accuracy of diagnosing cashew nut allergy with the four SPT methods, a 
ROC plot was generated. The four SPT methods, i.e. the average diameter, area, HEP-
index diameter and HEP-index area, yielded a comparable area under the curve of 0.84, 
0.85, 0.83 and 0.83, respectively. All four SPT methods were considered as good and 
equally accurate in diagnosing cashew nut allergy (Figure 4.5).
DISCUSSION
To determine the outcome of the SPT, it is common to characterise the wheal shape by 
the ‘average diameter’. However, this method is prone to errors, because it is assumed 
that the wheal size varies between a circle and an ellipse. In fact, the wheals have 
pseudopodia and interpretation based on two orthogonal diameters is not accurate. 
This study showed that for a given average wheal diameter, the actual wheal area could 
vary quite significantly and this inaccuracy grows with wheal size. This inaccuracy is 
completely eliminated if one applies the scanning method. This more precise method 
for measuring the wheal size area is previously described by Pijnenborg et. al. (6). The 
scanning method is also fast, easy in use, has a high reproducibility and is very useful in 
scientific research (1,3,6,7).
To even further increase the accuracy of SPT results, the HEP-index can be calculated, 
to rule out differences in skin reactivity. There are several factors that contribute to 
this difference e.g. poly-sensitised patients and patients with mould sensitisation have 
Figure 4.5: Receiver-operating characteristic curves for the 4 SPT methods
Figure 4.5: Receiver-operating characteristic curves for the 4 SPT methods
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significantly higher skin reactions (8) and the skin response varies in different ethnicities 
(9). Furthermore, differences in technique of performing SPTs (inter-observer variability) 
contribute to the variation in wheal size (10). To correct for these factors, the calculation 
of the HEP-index is useful and also easy to determine with the scanning method.
Notwithstanding all advances of the scanning method inclusive the HEP-index calcu-
lation, the ‘average diameter’ method is as accurate in diagnosing cashew nut allergy as 
the ‘HEP-index area’ method. Therefore, the ‘average diameter’ method can be used if 
there is no scanning device available. However, the ‘best’ relationship between the aver-
age diameter and the wheal area can be better estimated by the equation  
instead of the equation . Therefore, if one wishes to calculate the area out 
of the average diameter for e.g. research purposes, the equation should be 
used to approximate the area most accurate.
CONCLUSION
This study demonstrates that the scanning method for SPT measurement is more ac-
curate to measure the wheal area in a Type-I allergy than the average diameter. The aver-
age wheal diameter gives an overestimation or underestimation of the actual area up to 
maximal 50 %. It is possible to correct for skin sensitivity and inter-observer variability 
by using the ‘HEP-index area’ method. The HEP-index area value 0.4 can be considered 
as an equal cut-off value of 3 mm wheal average diameter. However, in clinical practice, 
the ‘average diameter method’ is also useful, because this method is equally accurate in 
predicting cashew nut allergic reactions in the DBPCFC tests.
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sIgE Ana o 1, 2 and 3 accurately 
distinguish tolerant from allergic 
children sensitised to cashew nuts
In this paper, we describe the performance of component sIgE determinations in diag-
nosing cashew nut allergy. This article is published in Clinical and Experimental Allergy 
in 2016.
Van der Valk JP, Gerth van Wijk R, Vergouwe Y, Steyerberg EW, Reitsma M, Wichers HJ, 
Savelkoul HFJ, Vlieg-Boerstra B, de Groot H, Dubois AEJ, de Jong NW. sIgE Ana o 1, 2 and 
3 accurately distinguish tolerant from allergic children sensitised to cashew nuts. Clin 
Exp Allergy. Aug 11 2016.
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ABSTRACT
Background
The double-blind, placebo-controlled food challenge test (DBPCFC) is the gold standard 
in cashew nut allergy. This test is costly, time-consuming and not without side effects. 
Analysis of IgE-reactivity to cashew nut components may reduce the need for food chal-
lenge tests.
Methods
In a prospective and multicentre study, children with suspected cashew nut allergy un-
derwent a DBPCFC with cashew nut. Specific IgE to cashew nut and to the components 
Ana o 1, 2 and 3 were determined. A skin prick test (SPT) with cashew nut extract was 
performed.
The association between the outcome of the food challenge test and specific IgE to 
Ana o 1, 2 and 3 was assessed with logistic regression analyses, unadjusted and adjusted 
for other diagnostic variables. Discriminative ability was quantified with a concordance 
index (c-index).
Results
173 children (103 boys, 60 %) with a median age of 9 years were included. 79 % had a posi-
tive challenge test outcome. A steep rise in the risk of a positive challenge was observed 
for specific IgE to each individual component Ana o 1, 2 and 3 with estimated risks up to 
approximately 100 %. Median values of Ana o 1, 2, 3 were 1.29 kU/l (range 0–100 kU/l), 
4.77 kU/l (range 0–100 kU/l) and 8.33 kU/l (range 0–100 kU/l) respectively and varied 
significantly (p < 0.001). Specific IgE to Ana o 1, 2 and 3 better distinguished between 
cashew-allergic and tolerant children (c-index = 0.87, 0.85 and 0.89 respectively), than 
specific IgE to cashew nut or SPT (c-index = 0.76 and 0.83 respectively).
Conclusion
The major cashew nut allergens Ana o 1, 2 and 3 are each individually predictive for the 
outcome of food challenge tests in cashew-allergic children.
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INTRODUCTION
Clinicians are seeing a growing number of cashew nut sensitised patients (1, 2). The 
clinical relevance of cashew nut sensitisation is high as consumption of this nut can 
cause severe allergic reactions (3). The double- blind, placebo-controlled food challenge 
(DBPCFC) test is the gold standard to determine the clinical relevance of sensitisation 
measured by skin prick test (SPT) or specific IgE (sIgE). However, the DBPCFC test is 
costly and time-consuming for the patients, which warrants the search for cheaper and 
simpler alternatives. The performance of in vitro diagnosis of food allergy has recently 
improved with the use of component resolved diagnosis (CRD) (4). CRD measures sIgE 
against individual allergens utilising purified or recombinant allergens.
The major allergens of the cashew nut (Anacardium occidentale) are Ana o 1, Ana o 
2 and Ana o 3. Ana o 1 is a vicilin-like protein, resistant to heat and proteolysis (5). The 
other two allergens are Ana o 2, a legume-like protein (6, 7) and Ana o 3, a 2S albumin 
(8). All three allergens are classified as seed storage proteins.
A case-control study by Savvatianos et al. suggested that sensitisation to Ana o 3 is 
highly predictive of clinical reactivity in cashew nut sensitised patients (9). To our knowl-
edge, association between the food challenge test with cashew nut and the two other 
components (Ana o 1 and Ana o 2) has never been investigated.
The primary objective of this multicentre study is to investigate the added value of 
component analysis (Ana o 1, 2 and 3) to the standard diagnostics (history, gender, sIgE 
to cashew nut and the SPT) for predicting the outcome of the DBPCFC test with cashew 
nut.
METHODS
Study design and standard diagnostics
This study was designed as a diagnostic study and registered in the Dutch Trial Register 
as ‘Improvement of Diagnostic mEthods for ALlergy assessment (IDEAL study)’ with 
cashew nut allergy in children as a showcase (trial number NTR3572). Consecutive new 
children and children known to have a sensitisation to cashew nut (sIgE and/or SPT) 
and a history of previous reaction(s) to cashew nut or unknown exposure were asked to 
participate in this study. 179 children were included from three tertiary care centres in 
the Netherlands (Erasmus MC Rotterdam, University MC Groningen and Reinier de Graaf 
Groep Delft) in the period May 2012 to March 2015. A flowchart of the patient inclusion 
is shown in Figure 4.6. Medical history was obtained and blood samples were drawn to 
determine sIgE to cashew nut and to Ana o 1, 2 and 3 using the Siemens IMMULITE 2000 
XPi Immunoassay System (Med. Imm. Laboratory; Reinier de Graaf Groep (RdGG). SPT 
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with cashew nut extract was performed and all patients underwent a DBPCFC test with 
cashew nut.
Participating children underwent a SPT with cashew nut extract, a positive control 
(histamine 10 mg/ml ALK-Abelló, Nieuwegein, the Netherlands) in duplicate and a nega-
tive control. For the cashew nut extract, cashew nuts (blanched, unsalted; Intersnack 
Doetinchem, the Netherlands) were homogenised mechanically, ground with a mortar 
and pestle, defatted by ether extraction, and subsequently air-dried. A 10 % w/v extract 
in phosphate-buffered saline (PBS) with this material was made. The SPT was performed 
by applying a drop of the allergen extract on the skin of the volar aspect of the forearm. 
Subsequently the dermis was punctured with a 1 mm sharp tip standard sterile lancet 
with horizontal shoulders (ALK-Abelló, Nieuwegein, the Netherlands) Twenty minutes 
after application, the contours of the wheal were encircled with a fine-tip pen and trans-
ferred to a record sheet with translucent tape (3). A scanner device (Hewlett Packard 
2400c) and software (Precise Automated Area Measurement of Skin Test (PAAMOST)) 
was used to determine the area of the wheals [10]. The area of the allergen-induced 
wheal was divided by the mean area of the two positive histamine-induced wheal 
controls (Histamine Equivalent Prick (HEP)-index area). A HEP-index area ≥  0.4 (corre-
sponding with a 3 mm wheal diameter) and an average wheal diameter ≥ 3 mm was 
considered positive (10). The HEP-index area method is used because scanning methods 
are more accurate in measuring the wheal area than estimating the wheal area by the 
mean diameter. Furthermore, the HEP-index area method corrects for skin-reactivity 
by considering the histamine-induced wheal size of the positive controls as well (10). 
Figure 4.6: Flowchart of patient inclusion
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The DBPCFC test consisted of an eight-step incremental dose regime of validated and 
standardised challenge material (11). The cumulative dose was 3180 mg cashew nut 
protein (approximately 22 cashew nuts based on 144 mg cashew nut protein per cashew 
nut with an average weight of 700 milligram; (Intersnack, the Netherlands B.V.)) when all 
8-dose steps were consumed. The DBPCFC was considered positive if, on the active chal-
lenge (verum) day: 1) objective symptoms occurred, or 2) subjective symptoms recurred 
twice on three successive administrations of the challenge material, or 3) subjective 
symptoms persisted for more than one hour (12). Anaphylaxis was defined as described 
in the EAACI Guidelines for Food Allergy and Anaphylaxis (13). The inclusion and exclu-
sion criteria and detailed study protocols were previously described (3). Medical ethical 
approval was obtained in April 2012. Parents of children (2–12 years old) and parents 
and children (≥ 12 years old) signed an informed consent form.
Cashew nut allergens Ana o 1, 2 and 3
Cashew nut allergens Ana o 1, 2 and 3 are not commercially available, so these were pu-
rified specifically for this study (14). In short, a total protein extract (in 0.1M ammonium 
bicarbonate, 0.5M NaCl) was obtained from defatted cashew nut. Stepwise precipitation 
of this total protein extract using 15 %, 30 %, 45 % and finally 52.5 % w/v ammonium sul-
phate yielded a supernatant containing only Ana o 1 (50kDa) and Ana o 3 (12.6kDa). The 
two allergens from this supernatant were separated by ultrafiltration ultracentrifugation 
using a 30kDa Amicon centrifugal filter, collecting Ana o 1 in the retentate and Ana o 3 
in the filtrate. Purified Ana o 2 was obtained by gel filtration chromatography (Superdex 
200) of a non-defatted cashew protein extract. The purified allergens were conjugated 
to biotin at a pre-determined protein to biotin ratio to achieve approximately 4–6 biotin 
groups per antibody molecule, generally requiring a 20 molar excess of biotin to anti-
body. The quality of the biotinylated cashew allergens was analysed by inhibition test-
ing with unlabelled allergens to verify that the biotinylation procedure had not altered 
IgE epitopes. Subsequently, the biotinylated allergen concentration required to saturate 
cashew-specific IgE binding in the Immulite assay was determined by titration experi-
ments using a pooled serum from patients with a history of cashew nut allergy. Quality 
control for specificity was assessed using in-house control samples with known cashew 
nut specific IgE values (Siemens IMMULITE 2000Xpi). The IgE values in kU/L for the 
individual cashew allergens reported here are thus based on the IgE readings obtained 
with the cashew extract in the commercial IMMULITE assay. The cashew allergen specific 
IgE assay on the IMMULITE 2000 Xpi system was performed according to standardized 
procedures (Siemens IMMULITE® 2000/2500 Operators Manual, 2007). Serum samples 
were used to measure sIgE levels to Ana o 1, 2 and 3 using the Siemens IMMULITE 2000 
XPi Immunoassay System (Med. Imm. Laboratory; Reinier de Graaf Groep (RdGG).
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Statistical analysis
The patient characteristics were reported in median, ranges and proportions. sIgE values 
above the upper detection limit of 100 kU/l were set to 100 kU/l (15). The association be-
tween the outcome of the DBPCFC with cashew nut (allergic yes/no) and the diagnostic 
variables were analysed with logistic regression analyses. The form of the association 
between the outcome of the DBPCFC and the continuous variables sIgE to Ana o 1, 2 and 
3, sIgE to cashew nut and the SPT were assessed with restricted cubic spline functions 
with 2 degrees of freedom. Restricted cubic spline functions are ﬂexible in modelling 
non-linear associations, but use few extra regression coefﬁcients. The strength of the 
association was evaluated with the concordance index (c-index). The c-index is equal 
to the Area Under the Receiver Operating Characteristic Curve (AUC) for a dichotomous 
outcome. The difference in -2 log likelihood (likelihood ratio, LR) was assessed for nested 
models including and excluding the variable of interest. The analyses were done with 
SPSS software, 20th edition and R programming language(16).
RESULTS
Patient characteristics and diagnostic results
Six patients had an uncertain DBPCFC test outcome with cashew nut and were consid-
ered as undetermined (e.g. children who did not completed the test). These children 
were excluded from the analysis. A total of 173 patients were included in the analysis 
(Table 4.1). The study included 137 (79 %) patients with a positive DBPCFC test and 36 
(21 %) patients with a negative DBPCFC test. In the group of children with a positive test, 
64 % (88/137) experienced a mild reaction and 36 % (49/137) had an anaphylactic reac-
tion during the DBPCFC test (3). The most commonly reported or observed symptoms 
during the DBPCFC in the non-anaphylactic group, were oral allergy symptoms (68 %), 
followed by gastro-intestinal symptoms such as nausea, stomach pain, vomiting and 
diarrhea (59 %) and redness of the skin (17 %). The children with an anaphylactic reaction 
most commonly experienced a combination of skin and gastro-intestinal symptoms (40 
children) followed by respiratory and gastro-intestinal symptoms (6 children) and skin 
and respiratory symptoms (3 children). All of the patient characteristics and diagnostic 
test results are summarised in Table 4.1.
Diagnostic variables in patients with no, mild and severe DBPCFC test reactions
Median values of Ana o 1, 2, 3 were 1.29 kU/l (range 0–100 kU/l), 4.77 kU/l (range 0–100 
kU/l) and 8.33 kU/l (range 0–100 kU/l) respectively and varied significantly (Wilcoxon 
signed rank test, p < 0.001). The median sIgE values to Ana o 1, 2 and 3 were significantly 
lower in the patient group with a negative DBPCFC test compared to the patients with a 
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positive DBPCFC test (Figure 4.7, (Mann-Whitney U test, p< 0.001)). However, the median 
sIgE values to Ana o 1, 2 and 3 were similar in the anaphylaxis group compared to the 
patient group with mild reactions (p = 0.831, 0.840 and 0.916, respectively).
The same applies for sIgE to cashew nut and the SPT. The correlation between Ana o 
1, 2 and 3 was strong (Pearson correlation coefficients between 0.80 and 0.90), with the 
highest correlation between Ana o 2 and 3.
Only 6 children had sIgE to cashew nut ≥ 100 kU/l, 1 child had sIgE to Ana o 1 ≥ 100 
kU/l, 5 children had sIgE to Ana o 2 ≥ 100 kU/l and 7 children sIgE to Ana o 3 ≥ 100 kU/l. 
We read the values above 100 kU/L from an extended Master curve, and the comparison 
between the anaphylaxis group and the group with mild reactions gave similar results.
Performance of the diagnostic variables
Specificity of each cashew allergen was verified through competitive inhibition testing 
using a cashew specific IgE positive patient serum pool, the cashew allergens and the 
raw extract. The inhibition plots demonstrated that the allergens tested were nearly 
completely inhibited by the relevant inhibitor extract in a concentration dependent 
manner. Additional inhibition studies were conducted to show that the specific allergens 
Table 4.1: Patient characteristics and diagnostic results of the 173 children sensitised to cashew nut with a 
positive and negative DBPCFC test
Positive DBPCFC test
N (%)
137 (79)
Negative DBPCFC test
N (%)
36 (21)
Male participants 77 (56) 26 (72)
Age, years* 9.0 (2 -17) 9.5 (2 -17)
Atopic disease symptoms
Asthma 43 (31) 9 (25)
Eczema 53 (39) 13 (36)
Hay fever 71 (52) 18 (50)
Total IgE, kIU/L* 509 (23-15431) 751 (31-7709)
sIgE to Ana o 1, kU/l* 2.0 (0- ≥ 100) 0.2 (0- 6.7)
sIgE to Ana o 2, kU/l* 6.3 (0- ≥ 100) 1.2 (0- 8.4)
sIgE to Ana o 3, kU/l* 13.0 (0- ≥ 100) 0.6 (0- 30.9)
sIgE to cashew nut, kU/l* 5.8 (0- ≥ 100) 1.2 (0- ≥ 17.1)
SPT with cashew nut extract, HEP 
index area*
3.4 (0.4-15.2) 0.5 (0-14.3)
Severity of reaction during 
DBPCFC
Mild reaction 88 (64) NA 
Anaphylaxis 49 (36) 
* median (range: min- max)
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were not cross-reacting to the unrelated allergens. Testing was performed using one 
positive sample with several unrelated allergen extracts. A negative sample was used to 
measure the background response. The analytical sensitivity of the assay was increased 
by using the appropriate biotin-labelled allergen concentration to allow detection of 
all specific IgE antibodies present in the sera with the highest cashew specific IgE titers.
Restricted cubic spline functions were used to visualize the form of association be-
tween the diagnostic parameters (sIgE to Ana o 1, 2 and 3, sIgE to cashew nut and the 
SPT) and the risk of a positive DBPCFC test (Figure 4.8). The curves of sIgE to Ana o 1, 2 
and 3 with the risk of a positive DBPCFC test increase sharply incline and reach a risk of 
approximately 100 % of cashew nut allergy at the highest levels of sIgE to all three Ana o 
components. The associations were strong with c-indices of 0.87 (95 % CI 0.80–0.93), 0.85 
(95 % CI 0.79–0.91) and 0.89 (CI 0.83–0.95) for sIgE to Ana o 1, 2 and 3, respectively (Table 
4.2). The standard diagnosis by means of sIgE to cashew nut showed a weaker associa-
tion (c-index = 0.76, 95 % CI 0.67–0.84). The association of the SPT and DBPCFC outcome 
was nearly as strong as the associations of sIgE to the Ana o allergens (c-index = 0.83, 
95 % CI 0.74–0.91).
Figure 4.7: Boxplots of  Ana o 1, 2 and 3, sIgE
The median values of sIgE to Ana o 1, Ana o 2, Ana o 3, cashew nut and HEP-
and those with an anaphylactic reaction during the DBPCFC test with cashew nut.
Figure 4.7: Boxpl t  of Ana o 2 nd 3, sIgE and SPT to cashew nut; compared are groups of patients 
without a reaction during the DBPCFC test with cashew nut, to those with a mild reaction and to those with 
anaphylaxis
The median values of sIgE to Ana o 1, Ana o 2, Ana o 3, cashew nut and HEP-index areas are given above the 
respective boxplots, divided in 3 groups of patients: without a reaction, with a mild reaction and those with 
an anaphylactic reaction during the DBPCFC test with cashew nut.
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Added value of components Ana o 1, 2 and 3 in multivariable models
We assessed the added diagnostic value of Ana o 1, 2 and 3 to that of easily available 
patient characteristics and the diagnostic variables. A model with only gender and 
history of cashew nut allergy showed a c-index of 0.67. With inclusion of Ana o the c 
index increased to 0.89 maximally for Ana o 3 (Table 4.3). When sIgE to cashew nut was 
additionally included, Ana o 1, 2 and 3 showed increases up to 0.92, and 0.93 when the 
Figure 4.8: Association between the levels of  sIgE
The line represents the percentage of allergic responders with different sIgE titres to Ana o 1, 2 and 3 and different SPT HEP-
nut allergy of approximately 100% can be obtained at the highest levels of sIgE to all three Ana o components.  
Figure 4.8: Association between the levels of sIgE Ana o 1, 2 and 3 (A) and the levels of sIgE to cashew nut 
and SPT with cashew extract (B) with the risk of a positive DBPCFC. Curves are modelled with restricted 
cubic spline functions with 2 degrees of freedom. Spikes at the bottom indicate the distribution of the 
diagnostic variable.
The line represents the percentage of allergic responders with different sIgE titres to Ana o 1, 2 and 3 and 
different SPT HEP-index areas. Predictive values of cashew nut allergy of approximately 100 % can be ob-
tained at the highest levels of sIgE to all three Ana o components.
Table 4.2: Strength of association between diagnostic variable and outcome of the DBPCFC test
C- index LR0
sIgE Ana o 1 0.866 45.6
sIgE Ana o 2 0.847 47.4
sIgE Ana o 3 0.890 56.0
sIgE cashew nut 0.755 24.8
SPT cashew nut 0.828 49.2
Variables are modeled with a restricted cubic spline function with 2 degrees of freedom.
sIgE= specific IgE, SPT= skin prick test, C-index= concordance index, LR0=likelihood ratio with the null 
model
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SPT was included. Concordance with sIgE Ana o 2 was slightly better than with sIgE Ana 
o 1 and 3. The estimates of the LRs showed similar results (Table 4.4).
DISCUSSION
We investigated the predictive value of CRD in cashew nut allergy in a multicentre study 
of 173 children. This study not only examines the diagnostic capacity of CRD with Ana o 
3, but also with Ana o 1 and 2.
The measured levels of sIgE to Ana o 1, 2 and 3 varied significantly, however the as-
sociations with the DBPCFC were comparable and strong for all components. This is in 
agreement with the results from studies with other allergens (17), where median values 
of Ara h 1, 2, 3, and 8, ranged widely from 0.9 kU/l, to 6.5 kU/l in children with a positive 
Table 4.3: Concordance index for multivariable models including Ana o 1, 2 or 3
History of cashew nut 
allergy + gender A + sIgE to cashew nut A + B + SPT
C-index (delta) C-index (delta) C-index (delta) 
(A) (B) (C) 
0.665 0.819 0.880
sIgE Ana o 1 0.880 (0.215) 0.884 (0.065) 0.905 (0.025)
sIgE Ana o 2 0.881 (0.216) 0.915 (0.096) 0.928 (0.048)
sIgE Ana o 3 0.894 (0.229) 0.899 (0.080) 0.914 (0.034)
sIgE= specific IgE, C-index= concordance index, delta: difference in c-index compared to the model without 
Ana o.
Table 4.4: Likelihood ratio for the added value of the five diagnostic variables
Diagnostic variable
History of cashew nut 
allergy + gender A + sIgE to cashew nut A + B + SPT
(A) (B) (C) 
LRadded LR0 LRadded LR0 LRadded LR0
10 38 67
sIgE Ana o 1 43 53 18 56 7.3 74
sIgE Ana o 2 48 58 39 77 18 85
sIgE Ana o 3 51 61 29 67 12 79
SPT cashew nut 44 54 29 67 - -
sIgE cashew nut 27 37 - - - -
SPT= skin prick test, sIgE= specific IgE, LR0= likelihood ratio of the model compared with a null model, LRad-
ded = likelihood ratio of nested models with and without the diagnostic variable
The diagnostic variables are modelled with a restricted cubic spline function with 2 degrees of freedom.
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peanut challenge. Consequently, these differences have to be taken into account when 
one of the cashew nut components is being used in clinical practice or research.
A markedly greater risk of cashew nut allergy as ascertained by DBPCFC was observed 
for higher values of sIgE to Ana o 1, 2 and 3. At higher levels of sIgE to Ana o 1, 2 and 
3 total risks of approximately 100 % were observed. The associations were strong with 
c-indices of 0.87, 0.85 and 0.89 for sIgE to Ana o 1, 2 and 3, respectively. Added value 
of sIgE to Ana o 1, 2 and 3 remained after considering standard diagnostic variables 
(gender, history of cashew nut allergy, sIgE to cashew nut and the SPT). However, the 
cashew nut component analysis could not distinguish between a mild and a severe 
cashew nut allergy.
In some serum samples, higher sIgE binding was seen to Ana o 1, 2, and 3 than to 
whole cashew nut extract. This phenomenon was also described in peanut by Aalberse 
et al. [18]. They found that IgE reactivity to peanut specific components was higher than 
to the crude peanut extract in 11 plasma samples, and speculated that conventional 
extracts may have lower concentrations of certain specific allergens in comparison with 
purified specific allergen components
The association between sIgE to Ana o 3 and a positive challenge test, was previously 
demonstrated by Savvatianos et al (9). This research group investigated sensitisation to 
Ana o 3 in 63 children in whom clinical reactivity to cashew nut was documented. Their 
study demonstrated a near-optimal AUC of 0.97 in the Receiver Operator Characteristics 
(ROC) curve. However, the clinical diagnosis of cashew nut allergy was based on clinical 
history in 95 % of the cases and only in 5 % of the cases on food challenge tests, therefore, 
the association observed with Ana o 3 levels may have been with sensitisation rather 
than with clinical allergy to cashew nut with as consequence a stronger association. 
However, the gold standard is the DBPCFC test that all children underwent in our study.
For other allergies such as that to peanut and hazelnut, the added value of CDR in 
the diagnosis of clinical allergy to these foods has been proved. Peanut allergen Ara h 2 
and hazelnut allergen Cor a 14, which are both 2S Albumins (as is Ana o 3), are of great 
importance to estimate the risk of a positive challenge test outcome with peanut and 
hazelnut, respectively (15,19,20). 2S Albumins are resistant to proteolysis, heat denatur-
ation and pH changes and are therefore considered to be clinically relevant allergens 
(21).
Our data show that sIgE to cashew nut and, to an even greater extent, SPT with ca-
shew nut extract, are associated with a positive DBPCFC test (c-index of 0.76 and 0.83, 
respectively). The associations with SPT and sIgE were previously shown for other food 
allergens, e.g. egg, milk, and peanut, and it has been suggested that SPT is superior to 
sIgE in predicting clinical allergy (22–26). A previous retrospective study on 983 children 
who underwent food challenge test with egg, milk and peanut also demonstrated that 
SPT results were more strongly associated with a positive food challenge test than 
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sIgE (LR 1.23 and 1.04) (27). The study by DunnGalvin et al., which aimed to predict the 
challenge outcome for 429 patients with suspected peanut, milk and egg allergy also 
showed a greater predictive capacity of SPT than sIgE (28). Here we show that this is ob-
viously the case for cashew nut allergy. One may speculate that a positive SPT indicates 
not only the presence of sIgE in the sensitised individual, but also reflects the biological 
activity of that sIgE.
This is the first study using all currently known cashew nut components to investigate 
the value of CRD in cashew nut sensitised children. Moreover, we address the predictive 
value of the SPT with cashew nut extract and sIgE, which has - to our knowledge - not 
been reported previously. We emphasize that this study comprises a relatively large 
number of children and that all of them underwent DBPCFC. However, there might 
have been a selection bias in this study. Approximately 7 % of the children or parents of 
children refused to participate in this study because of fear of severe allergic reactions 
during the DBPCFC test. As many children reported an unknown history of cashew nut 
ingestion (66/173 children) and as we observed many anaphylactic reactions (49/173) 
during the cashew nut DBPCFCs, this form of selection bias is probably limited.
Our sample included only 36 children without cashew nut allergy. Nevertheless, the 
strong associations of Ana o 1, 2 and 3 are statistically significant. The 95 % confidence 
intervals for the c-indices were wide, which made it not possible to determine which of 
the three had the strongest association with cashew nut allergy.
In conclusion, sIgE-levels to Ana o 1, 2 and 3 are each individually predictive for the 
outcome of food challenge tests in cashew-allergic children. The SPT is the second best 
alternative. Therefore, component analysis in combination with other diagnostic tools 
needs to be considered in the diagnostic work-up of cashew nut allergy. The diagnostic 
values of sIgE of the three Ana o components were very similar, as was to be expected 
because of the high correlation between these components. Therefore, measurement of 
one of the components Ana o 1, 2 or 3 is probably sufficient.
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Chapter 4.3
Prediction of cashew nut allergy in 
sensitised children
We describe in this clinical communication a multivariate model to predict the outcome 
of the DBPCFC test with cashew nut. Submitted.
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To the Editor,
As an alternative to the costly, time-consuming and possibly stressful double-blind, 
placebo-controlled challenge (DBPCFC) test, a model to predict the risk of cashew nut 
allergy was studied incorporating patient characteristics, standard diagnostic param-
eters (specific IgE (sIgE) and Skin Prick Test (SPT)) as well as component resolved diag-
nosis (CRD) . We previously demonstrated that sIgE to the components Ana o 1, 2 and 
3 discriminated better between cashew nut- allergic and tolerant children sensitised to 
cashew nut than the current testing methods (SPT and sIgE to cashew nut) (1). The aim 
of this study was to develop a prediction model for cashew nut allergy.
Results of children who participated in the IDEAL-study (trial number NTR3572) were 
analysed. The study protocol and inclusion criteria were previously described (2). Briefly, 
sIgE to cashew nut and to Ana o 1, 2 and 3 was measured, a SPT with cashew nut extract 
was performed and all patients underwent a DBPCFC test. For the SPT, a scanner device 
(Hewlett Packard 2400c) and software (Precise Automated Area Measurement of Skin 
Test (PAAMOST)) was used to determine the area of the wheals. The area of the allergen-
induced wheal was divided by the mean area of the two positive histamine-induced 
wheal controls (Histamine Equivalent Prick (HEP)-index area). A HEP-index area ≥  0.4 
(corresponding with a 3 mm wheal diameter) was considered positive (3). Cashew nut 
allergens Ana o 1, 2 and 3 were purified specifically for this study (4), and sIgE to these 
purified allergens was measured by the standardized Siemens IMMULITE procedure.
The DBPCFC test consisted of an eight-step incremental dose regime of validated and 
standardised food challenge material (5). The cumulative dose was 3180 mg cashew nut 
protein (approximately 22 cashew nuts) when all 8-dose steps were consumed.
Univariate and multivariable logistic regression analysis was used to assess the con-
tribution of potential predictors to cashew allergy. The odds ratios (ORs) for continuous 
variables were scaled in a way that they corresponded to a change in one standard 
deviation of the predictor distribution. The model building process followed the usual 
order in a diagnostic work-up. We used a relatively high p-value (p < 0.5) in the back-
ward selection procedure, because of the limited number of non-events (6). We also 
applied the ‘sign OK’ rule (7). Discriminative ability of the models was assessed with 
the concordance index (c-index). Internal validity was assessed with bootstrapping (8). 
The regression coefficients in the final model were multiplied with a shrinkage factor. 
Without shrinkage, predictions are generally too extreme. The prediction models were 
transformed into score charts for use the use in clinical practice.
The study included 137 (79 %) patients with a positive and 36 (21 %) patients with a 
negative DBPCFC test. The predictors: gender (girl), history of cashew nut allergy and 
atopic features were associated with a positive challenge test with the highest OR for 
history of cashew nut allergy (OR 2.9, 95 % CI 1.4–6.0). sIgE to the cashew nut and the 
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components Ana o 1, 2 and 3 were strongly associated with a positive challenge test 
(ORs of 8.6 (95 % CI 5.4–13.8), 5.4 (95 % CI 3.6–8.1) and 8.6 (95 % CI 5.8–12.7), respectively) 
(Table 4.5).
The discriminative ability of the model including gender, history of cashew nut allergy 
and atopic features was relatively low after correction for optimism (c-index  =  0.66). 
Adding sIgE to cashew nut increased the c-index to 0.80 and further increased when 
SPT was also included (c-index = 0.86). When CRD was included, only gender and SPT 
remained in the models after backward selection. Using the CRD in the work-up resulted 
in the highest discriminative ability with a c-index of 0.89 for Ana o 3 plus gender and a 
c-index of 0.90, when SPT is also considered (Table 4.6). As a result of the liberal p-value, 
95 % confidence limits for OR’s can include the value 1. Internal validity was satisfactory 
with shrinkage factors of 0.82 0.88, 0.88, 0.89 and 0.89 for the 5 models.
 An easy to use format of the prediction model is based on gender, sIgE to Ana o 3 
and the SPT (Figure 4.9) and facilitates calculation of the predictive risk of a positive 
challenge test in cashew nut sensitised children. Based on this score chart, 58 of the 173 
(34 %) children in our study had a score of ≥ 8 corresponding to a ≥ 95 % chance of a 
positive challenge test outcome. In 57 of these 58 (98 %) children, the cashew nut allergy 
was established with the DBPCFC test. Of the 115 children with a probability score of 
Table 4.5: Univariate logistic regression of patient characteristics for a positive challenge test with cashew 
nut, n (%) unless stated otherwise.
Variables Positive DBPCFC Negative DBPCFC
Anamnestic N = 137 (79 %) N = 36 (21 %) OR (95 % CI)
Gender (girl) 60 (86 %) 10 (14 %) 2.0 (0.9-4.5)
Age, years * 9.0 (range 2-17) 9.5 (range 2-17) 1.0 (0.9-1.0)
History of cashew nut allergy 92 (86 %) 15 (14 %) 2.9 (1.4-6.0)
Atopic features** 102 (81 %) 24 (19 %) 1.5 (0.7-3.2)
Standard diagnostics
sIgE to total cashew nut, kU/l* 5.8 (range 0- ≥ 100) 1.2 (range 0-17.1) 2.9 (2.1-4.0)
SPT with cashew nut extract (HEP-index 
area)
3.4 (range 0.4-15.2) 0.5 (range 0-14.3) 4.9 (2.9-8.5)
Components
Median sIgE to Ana o 1, kU/l* 2.0 (range 0- ≥ 100) 0.2 (range 0-6.7) 8.6 (5.4-13.8)
Median sIgE to Ana o 2, kU/l* 6.3 (range 0- ≥ 100) 1.2 (range 0-8.4) 5.4 (3.6-8.1)
Median sIgE to Ana o 3, kU/l* 13.0 (range 0- ≥ 100) 0.6 (range 0-30.9) 8.6 (5.8-12.7)
OR= odds ratio, SPT= skin prick test, sIgE= specific IgE
*For continous variables, OR is given for a change in standard deviation of the predictor distribution
**Symptoms reported of hay fever, eczema or asthma
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< 8 corresponding to a < 95 % chance of a positive challenge test outcome, 80 children 
(70 %) had a positive and 35 (30 %) had a negative DBPCFC test outcome.
We developed and internally validated a diagnostic model for cashew nut allergy in 
sensitised children. In situations where there is limited availability of double-blind test-
ing, the use of the model and scoring system presented here may be useful for identify-
ing children who have ≥ 95 % chance of having a positive challenge test result and in 
whom such testing is thus less likely to influence management. In our present series, this 
pertains to a substantial number of patients (34 %).
The specificity of the scoring system may be negatively influenced by several factors, 
including cross-reacting allergens. Currently there is no data on allergens cross-reacting 
with cashew nut e.g. PR-10 allergens. More research in this area is needed.
Gender was included in the model, with a higher risk of a positive challenge test for 
girls. Why sensitisation to cashew nut is more often clinically relevant in girls than boys 
is currently unknown.
Not all medical settings have the opportunity to perform the SPT (8). Therefore, we 
developed a model with and without the SPT. If there is no scanner device available to 
measure the HEP-index area, this can be calculated from the diameter of the wheal with 
Table 4.6: Multivariate models with demographics and history, standard diagnostics (sIgE to cashew nut 
and SPT) and component Ana o 3
Variables
Demographics
and History
Model A
+ Standard diagnostics
Model B
+ Component Ana o 3
Model C
Without SPT With SPT Without SPT With SPT
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
Gender (girl) 1.8 (0.8-4.2) 2.4 (1.0-6.0) 2.9 (1.0-8.6) 2.1 (0.7-6.3) 2.6 (0.8-8.2)
History of cashew nut 
allergy
2.9 (1.4-6.4) 3.5 (1.5-8.1) 1.8 (0.6-4.9)
Atopic features* 1.8 (0.8-4.1) 1.6 (0.6-3.9) 2.0 (0.7-5.8)
sIgE to total cashew 
nut(kU/l)**
3.2 (2.3-4.4) 2.2 (1.5-3.1)
SPT with cashew nut 
extract(HEP-index 
area)**
4.1 (2.2-7.7) 2.4 (1.3-4.6)
sIgE to Ana o 3 (kU/l)** 8.7 (5.9-
12.8)
5.1 (3.4-7.7)
C-index
(optimism corrected)
0.66 0.80 0.86 0.89 0.90
OR= odds ratio, SPT= skin prick test, sIgE= specific IgE
*Symptoms reported of hay fever, eczema, or asthma
**For continous variables, OR is given for a change in standard deviation of the predictor distribution
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the following equation: HEP-index area  =  0.0096D2+ 0.2674D – 0.5033 (D= diameter) 
(3). If sIgE results to Ana o components are not available, the SPT is second best in the 
diagnostic model for cashew nut allergy (likelihood ratio test statistic χ2: Ana o 13.75 
and SPT 6).
A prediction model for cashew nut allergy has never been developed previously 
and the final model in this article has higher discriminability (c-index of 0.90) than the 
individual Ana o 1, 2 and 3 components in our previous report (c-index of 0.87, 0.85 and 
0.89, respectively)(10). Our prediction model is very useful in clinical practice, however, 
the generalizability of this method needs to be established through external validation.
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Figure 4.9: Score chart for the predictive risk f a ositive DBPCFC with cashew nut including SPT for ca-
shew nut sensitised patients
The score chart facilitates calculation of the predictive risk of a positive challenge outcome and is devel-
oped for clinical practice. The score chart is based on the variables gender, sIgE to Ana o 3 and the SPT. The 
continuous scales of sIgE to Ana o 3 and SPT are divided in small steps. The scores are derived from the 
prediction model an updated intercept:
Lp = -0.487 + 0.847 * Girl + 0.792 * log(AnaO3 + 0.1) + 0.784 * log(SPT + 0.1)
Hypothetical example: a sensitised girl (1 point) with a sIgE to Ana o 3 value of 21 kU/l (5 points) and a SPT 
of 2.9 (3 points) scores 9 points and has 98 % risk on a positive challenge test.
Prediction of cashew nut allergy in sensitised children 103
 2. van der Valk JP, Gerth van Wijk R, Dubois AE, de Groot H, Reitsma M, Vlieg-Boerstra B, Savelkoul 
HF, Wichers HJ, de Jong NW. Multicentre double-blind placebo-controlled food challenge study 
in children sensitised to cashew nut. PLoS One. 2016 Mar 11;11(3).
 3. van der Valk JP, Gerth van Wijk R, Hoorn E, Groenendijk L, Groenendijk IM, de Jong NW. Measure-
ment and interpretation of skin prick test results. Clin Transl Allergy.2016.6:8.
 4. Reitsma M, Bastiaan-Net S, Sforza S, van der Valk JP, van Gerth van Wijk R, Savelkoul HF, de Jong 
NW, Wichers HJ. Purification and Characterization of Anacardium occidentale (Cashew) Allergens 
Ana o 1, Ana o 2, and Ana o 3. J Agric Food Chem. 2016 Feb 10;64(5):1191-201.
 5. Vlieg-Boerstra BJ, Herpertz I, Pasker L, van der Heide S, Kukler J, Jansink C, et al. Validation of novel 
recipes for double-blind, placebo-controlled food challenges in children and adults. Allergy. 2011 
Jul;66(7):948-54.
 6. Niggemann B, Beyer K. Diagnosis of food allergy in children: toward a standardization of food 
challenge. Journal of pediatric gastroenterology and nutrition. 2007 Oct;45(4):399-404.
 7. Steyerberg EW, Eijkemans MJ, Habbema JD Stepwise selection in small data sets: a simulation 
study of bias in logistic regression analysis. J Clin Epidemiol 1999 52:935–942.
 8. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, 
evaluating assumptions. 1996 Stat Med 15:361–387.

Chapter 5
Clinical consequences of cashew nut 
allergy

Chapter 5.1
Low percentage of clinically relevant 
pistachio nut and mango co-
sensitisation in cashew nut sensitised 
children
This short communication assess the clinical relevance of pistachio nut and mango co-
sensitisation in cashew nut sensitised children. Submitted
Van der Valk JP, el Bouch R, Gerth van Wijk R, de Groot H, Wichers HJ, Dubois AE, de Jong 
NW. Low percentage of clinically relevant pistachio nut and mango co-sensitisation in 
cashew nut sensitised children Submitted.
108 Chapter 5.1
ABSTRACT
Cashew nut, pistachio nut and mango belong to the Anacardiaceae family and are bo-
tanically related. The aim of this study is to assess the clinical relevance of co-sensitisation 
to pistachio nut and mango in cashew nut sensitised children. Children were recruited 
from the study: ‘Improvement of Diagnostic mEthods for ALlergy assessment (IDEAL) 
(trial number NTR3572). The IDEAL-study showed that children sensitised to cashew nut, 
were co-sensitised to pistachio nut in 98 % of cases and to mango in 21 % of cases. All chil-
dren had undergone a double-blind placebo-controlled food challenge (DBPCFC) with 
cashew nut in the IDEAL-study, and in this follow-up study a DBPCFC with pistachio nut 
and an open food challenge with mango was performed. Twenty-nine children (mean 
age of 11.6 years, 62 % male) were included. Pistachio nut sensitisation was clinically 
relevant in only 34 % of cashew sensitised children and only 31 % of cashew challenge 
positive children. None of the children was challenge positive to mango. An oral food 
challenge is recommended in children co-sensitised to cashew nut and pistachio nut.
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INTRODUCTION
Cashew nut, pistachio nut and mango belong to the Anacardiaceae family and are 
botanically related. Cashew nut allergic children are frequently advised to eliminate not 
only cashew nuts, but also pistachio nuts from their diet. This advice is based on the 
sensitisation pattern and possible cross-reactivity (1, 2). Cross-sensitisation between 
cashew nut and pistachio nut has been previously established by specific IgE (sIgE) inhi-
bition tests (3–6). However, studies that confirm clinical cross-reactivity by performing a 
challenge are rare (7).
The aim of this follow-up study of the ‘Improvement of Diagnostic mEthods for AL-
lergy assessment (IDEAL) study’ (trial number NTR3572) is to assess the clinical relevance 
of pistachio nut -and mango sensitisation in cashew nut sensitised children. The IDEAL-
study showed that children sensitised to cashew nut were co-sensitised to pistachio nut 
in 98 % (169/173) and to mango in 21 % (37/173).
METHODS
Patient selection and study design
Children were recruited from the multi-centre IDEAL-study and were included between 
January 2015 and June 2015. The inclusion/exclusion criteria and detailed study proto-
col of the IDEAL-study were previously described (8). For practical reasons only two of 
the three centres were invited to participate in this pistachio nut and mango follow-up 
study. Medical history, sensitisation results (sIgE and SPT) and results from the double-
blind placebo-controlled food challenge (DBPCFC) with cashew nut were obtained from 
the IDEAL-study. The children underwent a DBPCFC with pistachio nut and an open food 
challenge with mango in this follow-up study. Medical ethical approval was obtained in 
January 2015. Parents of children (2–12 years old) and parents and children (≥ 12 years 
old) signed the informed consent.
Skin prick test
All children underwent a SPT with cashew nut and pistachio nut extract and mango 
juice, a positive control (histamine 10 mg/ml ALK-Abello, Nieuwegein, the Netherlands) 
in duplicate and a negative control. Cashew nuts (roasted, unsalted) and pistachio nuts 
(fresh, not roasted, unsalted nuts) were homogenized mechanically, ground with a 
mortar and pestle, defatted by ether extraction, and subsequently air-dried. A 10 % w/v 
extract in phosphate-buffered saline with the pre-treated material was made. Mango 
juice was prepared from pieces of ripe mango fruit pulp, without skin or kernel (8). The 
SPT was performed by applying a drop of the allergen extract on the skin of the volar 
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aspect of the forearm; subsequently the epidermis was punctured with a standardised 
1 mm sharp tip sterile lancet.
We used a precise scanning method to ascertain the SPT results. We divided the area 
of the allergen-induced wheal by the mean area of two positive histamine-induced 
wheals. This ratio is defined as HEP-index area. A HEP-index area of ≥ 0.4 corresponding 
with a wheal diameter of ≥ 3 mm was considered positive (9).
Specific IgE
Serum samples were analysed for sIgE to cashew nut, pistachio nut and mango using 
the Siemens IMMULITE 2000 XPi Immunoassay System (Med. Imm. Laboratory; Reinier 
de Graaf Groep (RdGG). Levels above 0.35 kU/L were considered positive.
Challenge test with pistachio nut
All children underwent a DBPCFC with pistachio nut. The food challenge consisted of 
an eight-step incremental dose regime. The time interval between each step was 30 
minutes. The challenge recipe and dosages used for the DBPCFC with pistachio nut were 
based on validated and standardised cashew nut recipes (10). Roasted unsalted pista-
chio nuts were provided by Intersnack, Doetinchem, the Netherlands. The food matrix 
(muffin dough) mainly consisted of wheat, sugar, gingerbread spice mix and coconut. 
The challenge dose schedule is shown in Table 5.1 Children under the age of 4 years 
were not required to complete step 8.
Table 5.1: Challenge doses DBPCFC with pistachio nut and mango
Pistachio 
protein (mg)
Pistachio 
protein cum 
(mg)
Average 
amount of
Pistachio nut Mango 
protein (mg)
Mango 
protein cum 
(mg)
Mango 
volume (gr)
Dose 1 1 1  0.007* 3 3 0.3**
Dose 2 3 4 0.02 10 13 1
Dose 3 10 14 0.07 30 43 3
Dose 4 30 44 0.20 100 143 10
Dose 5 100 144 0.67 300 443 30
Dose 6 300 444 2.08 1000 1443 100
Dose 7 1000 1444 6.94 ———— ———— ————
Dose 8 1736 3180 12.06 ———— ———— ————
*The average weight of one pistachio nut was approximately 700 mg, with 23.8 g pistachio protein per 100 
g pistachio nuts. (Intersnack the Netherlands B.V.)
** 100 gram mango (with kernel and peel) contains approximately 1.0 gram mango protein
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Challenge test with mango
Children with no history of symptoms after the consumption of mango were considered 
non-allergic. The remaining children underwent the open challenge (OFC) with mango. 
The food challenge with mango (pieces of fruit without skin or kernel) consisted of a 
six-step incremental dose regime. The challenge dose schedule is shown in Table 5.1.
Statistical analysis
Statistical analyses were done with the Fisher exact test, Mann Whitney U test and chi 
square test. All analyses were performed with IBM SPSS Statistics, version 21.
RESULTS
Patient selection
Eighty-five children sensitised to cashew nut and pistachio nut, from two of the three 
participating centres of the IDEAL-study were asked to participate in the pistachio nut 
and mango follow-up study. A total of 29 children (34 %) participated, 38 (45 %) did not 
respond to the invitation, 16 (19 %) refused to participate citing reasons such as that the 
food challenge was time-consuming and burdensome for the child or there was fear for 
a reaction during the challenge. Two children were ultimately excluded because they 
did not receive all interventions.
Patient characteristics and diagnostic results
Twenty-nine children, 18 boys (62 %), mean age of 11.6 years (range 4–20 years) were 
included. Symptoms, consistent with eczema, asthma or hay fever were reported by 
15/29 (52 %), 7/29 (24 %) and 14/29 (48 %) of the children, respectively.
The median cashew nut sIgE was 5.28 kU/l (range 0.4–100 kU/l) and the median 
pistachio nut sIgE was 7.25 kU/l (range 0.6–82 kU/l). The median SPT HEP-index area of 
cashew nut and pistachio nut was 2.50 (range 0–8.8) and 2.02 (range 0–9.4), respectively. 
Twelve of the 29 children were co-sensitised to mango with a median sIgE to mango of 
0.71 kU/l (range 0–3.76) and a median SPT HEP-index area of 0.46 (range 0–1.45).
In order to exclude selection bias, we compared the patient characteristics and diag-
nostic results of the participating children (N = 29) with the non-participating children. 
There was no significant difference in gender (p = 0.80), age (p = 0.08), asthma (p = 0.10), 
eczema (p = 0.52), hay fever (p = 0.57), sIgE to cashew nut (p = 0.85), sIgE to pistachio nut 
(p = 0.71), SPT cashew nut (p = 0.50) and SPT pistachio nut (p = 0.13).
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Food challenge with cashew nut versus pistachio nut
The pistachio nut DBPCFC was positive in 10/29 (34 %) and negative in 19/29 (66 %) chil-
dren (Table 5.2). Most children with a positive DBPCFC with pistachio nut experienced 
‘oral allergy’ symptoms followed by gastro-intestinal symptoms, skin symptoms and 
upper airway symptoms. Eight of ten children experienced both objective and subjec-
tive symptoms and an anaphylactic reaction according to the EAACI Guidelines for Food 
Allergy and Anaphylaxis (11) occurred in one child.
Of the 29 children, 22 children (76 %) had a positive challenge with cashew nut and 
7 children (24 %) had a negative challenge with cashew nut. Only 9 of the 29 children 
(31 %) had positive challenge with cashew nut as well as a positive challenge with pis-
tachio nut (Table 5.2). In 6 of the 22 (27 %) children, an anaphylactic reaction occurred 
during the cashew nut challenge. These 6 children had in all cases a negative pistachio 
nut food challenge outcome.
Food challenge with mango
Seventeen children already consumed mango without problems, therefore a challenge 
was not indicated. One declined to undergo the OFC because it was time-consuming. 
In total, 11 children participated in the OFC with mango and in all cases the challenge 
was negative.
Food challenge results versus sIgE levels
In patients with a positive challenge to both, cashew nut and pistachio nut (n  =  9), 
the median sIgE amounted 10.90 kU/l and 17.10 kU/l, respectively. Significantly lower 
median sIgE values were found in children reacting to either cashew nut (2.48 Ku/L) or 
pistachio nut (3.77 kU/l), with p-values of 0.014 and 0.024, respectively.
Table: 5.2: Outcome of the DBPCFC with cashew nut, pistachio nut and OFC with/or home consumption 
of mango
Outcome DBPCFC
pistachio nut
Outcome OFC or home
consumption mango
Positive Negative
Total
Positive
Negative or home 
consumption
Outcome 
DBPCFC 
cashew
Positive 9/29
(31 %)
13/29
(45 %)
22/29
(76 %)
0 10/11 (91 %)
Negative 1/29
(3 %)
6/29
(21 %)
7/29
(24 %)
0 1/11 (9 %)
Total 10/29
(34 %)
19/29
(66 %)
29
(100 %)
11/29
(38 %)
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DISCUSSION
In this study we demonstrated that approximately one third of the children with ca-
shew nut sensitisation and co-sensitisation to pistachio nut reacted to pistachio nut. 
Co-sensitisation to mango was not clinically relevant in any children. Previous studies 
reported high percentages of co-sensitisation and cross-sensitisation between cashew 
nut and pistachio nut (1, 3–6, 12–14). The clinically relevance of these co-sensitisations 
has only been reported in two studies (4, 5). Children with an allergy to cashew nut and 
co-sensitisation to pistachio nut are often advised to eliminate both nuts from the diet. 
Based on our results this might not be the best approach. Although higher levels of (co-) 
sensitisation to cashew nut and pistachio nut are associated with a higher risk of clinical 
allergy to these nuts, a DBPCFC is clearly indispensable for making a definitive diagnosis 
in individual patients.
Apart from the need for a well-established diagnosis, unnecessary avoidance of pista-
chio nuts or mango may have other disadvantages. Unnecessary lengthy elimination of 
allergenic foods in sensitised patients can increase the risk of a severe allergic reaction 
after accidental intake of the allergen (15).
In conclusion, this is the first multi-centre study in patients sensitised and clinically 
allergic to cashew nut investigating the clinical relevance of co-sensitisation to pistachio 
nut and mango with food challenges. The percentage of clinical relevant co-sensitisation 
was low (34 %) for pistachio nut and absent for mango in this study population. Oral 
food challenges are recommended in order to avoid unnecessary avoidance of pistachio 
nut in cashew nut allergic patients.
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No difference in health-related quality 
of life, after a food challenge with 
cashew nut in children participating in 
a clinical trial.
This paper demonstrates the effect on quality of life in positive and negative challenged 
children using the food allergy quality of life questionnaires (FAQLQ’s) before and after 
the DBPCFC test. This article is published in Pediatric Allergy and Immunology in 2016.
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ABSTRACT
Background
Previous studies showed that Health-Related Quality of Life (HRQL) significantly im-
proved after the food challenge, with greater improvements in HRQL after a negative 
outcome than a positive outcome. It is currently unknown whether this also occurs in 
patients undergoing DBPCFCs with cashew nut in the context of a clinical trial.
Methods
Quality of life was studied in children enrolled in a cashew nut study using food allergy 
quality of life questionnaires (FAQLQs). Children, teenagers and parents of the children 
completed the questionnaires before the challenge test and 6 months after the DBPCFC 
with cashew nut. The difference in the change in HRQL between the children with a 
positive and negative DBPCFC outcome was studied by Mann-Whitney U test.
Results
In total 112 children (67 boys, median age 9 yrs.) were included. The children, teenagers 
and parents of the children completed in total 143 sets of questionnaires. There were no 
significant differences in baseline total and domain scores compared to the follow-up 
scores in the FAQLQ-CF, -TF and -PF. In children, the delta FAIM score in the negative 
DBPCFC tested group was significantly better than the delta FAIM score in the positive 
challenged group (p = 0.026). There were no significant differences in the changes in 
the scores of the FAQLQ-CF and FAQLQ-PF in the children with a positive challenge out-
come, compared to the children with a negative challenge result. However, there was 
a significant difference in the change in score between the latter groups in the domain 
‘accidental exposure’ of the FAQLQ-TF (p = 0.049).
Conclusion
This study showed no difference in change of HRQL scores after a DBPCFC with cashew 
nut in children participating in a clinical trial. The utility of HRQL as an outcome for clinical 
trials in food allergy may be limited if participant baseline HRQL is relatively unimpaired.
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INTRODUCTION
Food allergy is a growing problem in the Western world, especially in children (1). A food 
allergy may have an impact on the quality of life in children and their parents (2). The fear 
of severe reactions and the need of strict avoidance of allergenic foods may contribute 
to this impact on quality of life. Previous studies, with different allergenic foods, dem-
onstrated that Health-Related Quality of Life (HRQL) for patients with a suspected food 
allergy significantly improved after a double-blind placebo-controlled food challenge 
(DBPCFC). Greater improvements in HRQL scores were demonstrated in children with a 
suspected allergy for peanut, nut, milk, egg, wheat, soy and sesame after a negative DB-
PCFC test outcome (i.e. allergy refuted/passed test) than a positive DBPCFC test outcome 
(i.e. allergy confirmed/failed test) (3). This study included only patients who had sought 
medical care for their food allergy. In another study, HRQL of patients seeking medical 
care was compared to food allergic individuals from the general population (4). HRQL 
was found to be significantly more impaired in patients seeking medical attention for 
their food allergy than food allergic individuals in the general population, because this 
last patient group is probably less afraid of an allergic reaction and have fewer problems 
with dietary restrictions. Currently, there is little information on the utility of HRQL as an 
outcome in the setting of diagnostic clinical trials on specific food allergies. The primary 
aim of this study was to assess the difference in the effect on HRQL before and 6 months 
after a DBPCFC in children participating in a clinical trial on cashew nut allergy.
METHODS
Participants and procedure
Children (2–17 years of age) participating in the study ‘Improvement of Diagnostic 
mEthods for ALlergy assessment’ with cashew nut allergy in children as a show case (trial 
number NTR3572) were asked to participate in the evaluation of quality of life (5). Con-
secutive patients were invited. All patients underwent DBPCFC with cashew nut with an 
eight-step incremental dose regime of validated and standardised food challenge ma-
terials (6). The DBPCFC test was discontinued and considered positive when 1) objective 
symptoms occurred, or 2) when subjective symptoms re-occurred twice after the same 
dose of challenge material had been administered, three times consecutively (7), or 3) 
when subjective symptoms persisted for more than one hour. If the child developed the 
same symptoms with the same severity on the placebo as on the verum day, the DBPCFC 
test was considered as undetermined and the child was not included in the analysis.
120 Chapter 5.2
The children were divided into two groups, patients with a positive and patients with a 
negative DBPCFC outcome. Anaphylaxis was defined according to the EAACI Guidelines 
for Food Allergy and Anaphylaxis (8).
The validated Food Allergy Quality of Life Questionnaires (FAQLQ) and Food Allergy 
Independent Measure (FAIM) questionnaire were used and completed by the patient 
(8–17 years) and/or parents (0–12 years) before the challenge test and 6 months after 
the DBPCFC [9]. The FAIM questionnaire was used in this study to measure the longi-
tudinal and cross-sectional validity of the FAQLQs. Only patients who completed both 
questionnaires in the study period from April 2012 to August 2015 and filled out more 
than 80 % of the questions were included.
Medical ethical approval for this study was obtained (ethics committee Erasmus MC, 
Rotterdam, 2012–125). All participants signed informed consent (parents of children 
(2–12 years old) and parents and children (≥ 12 years old). The study is registered in the 
Dutch Trial register (trial number NTR3572).
Food allergy health related quality of life questionnaires (FAQLQ)
The FAQLQ used in this study is a disease specific instrument that evaluates the impact of 
food allergy on patients’ HRQL. For this study, the FAQLQ child form (FAQLQ-CF) for chil-
dren between 8 and 12 years of age, the teenager form (FAQLQ-TF) for children between 
13–17 years of age and the parent form (FAQLQ-PF) for parents of children between 0 
and 12 years of age were used. The FAQLQ-CF contains 24 items and 4 domains (allergen 
avoidance, risk of accidental exposure, emotional impact and dietary restrictions). The 
FAQLQ-TF contains 23 items and 3 domains (allergen avoidance and dietary restrictions, 
risk of accidental exposure and emotional impact). The FAQLQ-PF contains 14 items 
for children 0–3 years of age, 26 items for children 4–6 years of age and 30 items for 
children 7–12 years of age; and for all-ages, 3 domains (emotional impact, food anxiety 
and social and dietary limitations)(2,9,10). The questionnaire items are scored on a seven 
point scale ranging from 1 to 7. The answer options for children (8–12 years of age) 
are illustrated with smileys and are simple to use. The FAIM questionnaire is a disease 
specific instrument that measures self-perceived severity of food allergy (11). The FAIM 
consists of 4 expectations of outcome questions on the chance of accidental exposure, 
severe reactions, dying due to the food allergy and effectiveness of self-treatment and 
2 questions on extent of disease. The FAIM questionnaire items are also scored on a 
seven-point scale ranging from 1 to 7.
Statistical analysis
The total FAQLQ score was calculated by adding up the scores, and consequently dividing 
this score by the number of answered questions at each time point. The domain scores 
were calculated in the same manner. The FAQLQ mean total score and mean domain scores 
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were measured at baseline (before DBPCFC) and follow-up (6 months after DBPCFC). The 
FAIM mean total score was also measured at baseline and follow-up. The statistical signifi-
cance between the two measurement points (before and after DBPCFC) was calculated by 
using the paired t-test with 95 % confidence intervals and p-values (> 0.05). The changes in 
FAQLQ scores (follow-up score after the DBPCFC test minus baseline score before DBPCFC 
test) were calculated for the relevant FAQLQ (all domains) and for the FAIM. The statistical 
significance between the two groups (patients with a positive and a negative DBPCFC 
outcome) was calculated by using the Mann-Whitney U test. Multiple linear regressions, 
correcting for the possibly influencing factors on the change of FAQLQ overtime (depen-
dent variable), was also used to study possible improvement in HRQL. Possible influencing 
factors (independent variables) used in the multiple linear regression were: age, centre 
of inclusion (Erasmus Medical Centre Rotterdam, Reinier de Graaf Hospital, University 
Medical Centre Groningen), atopic features as hay fever, asthma and eczema, history of 
cashew nut allergy, multiple reported food allergies, anaphylaxis during DBPCFC, baseline 
score and outcome of the DBPCFC with cashew nut (positive (allergy confirmed)/ negative 
(allergy refuted) and the dose eliciting a reaction during the challenge with cashew nut. 
Pearson correlation coefficients were calculated for measuring validity between the base-
line, follow-up and change in FAQLQ (CF, TF and PF) scores and FAIM scores. All analyses 
were done with SPSS software, 20th edition.
RESULTS
Patients and clinical characteristics
In total 112 patients (67 boys, 60 %) with a median age of 9.0 years (range 2–17 years) 
were included. 6 children with an undetermined challenge test were excluded from the 
analysis. The questionnaires were completed before the challenge test and 6 months 
after the DBPCFC with cashew nut, and in total 143 pairs of questionnaires were 
completed from April 2012 to August 2015. Of these 143 pairs of questionnaires, 84 
parents’ forms 33 child forms and 26 teenager forms were obtained. Of all 112 children, 
74 children (66 %) had a history of cashew nut allergy and 39 children (34 %) had never 
eaten cashew nut before the challenge test. Positive challenge tests were observed in 
85 children (76 %), negative tests in 27 children (24 %). Most positively tested children 
had gastro-intestinal symptoms (nausea, vomiting, abdominal pain and diarrhoea) fol-
lowed by oral allergy symptoms, skin symptoms (redness and itch), angioedema and 
urticaria. In total 34 % (29/85) of the children with a positive DBPCFC to cashew nut had 
an anaphylactic reaction (8). The children with an anaphylactic reaction most commonly 
experienced a combination of skin and gastro-intestinal symptoms (n  =  22) followed 
by respiratory, gastro-intestinal and skin symptoms (N  =  5) and respiratory and skin 
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symptoms only (N = 2). Concerning atopic features, 34 (30 %) had asthma, 44 (39 %) had 
eczema and 55 (49 %) had hay fever. All children were sensitised in either SPT (median 
2.97 [0–15.16] HEP-index area) or specific IgE (sIgE) (median 3.42 [0-≥ 100] kU/L).
In order to exclude selection bias, we compared the patient characteristics and diag-
nostic results between the participating children (n  =  112) and the non-participating 
children from the IDEAL-study (n = 61) (Mann Whitney U test and chi square test). There 
was no significant difference in gender (p = 0.92), age (p = 0.74) symptoms according 
to asthma (p = 0.91), eczema (p = 0.68), and hay fever (p = 0.65), history of cashew nut 
allergy (p = 0.12), sIgE to cashew nut (p = 0.29), SPT cashew nut (p = 0.63) and DBPCFC 
outcome (p = 0.15).
Initial Health- Related Quality of Life
The mean baseline scores for the FAQLQ-CF, FAQLQ-TF and FAQLQ-PF of 3.32, 3.50 and 
2.37 respectively, were measured.
Change in Health-Related Quality of Life after a challenge test with cashew nut
The mean baseline scores for the FAQLQ-CF, FAQLQ-TF and FAQLQ-PF were 3.32, 3.50 
and 2.37, respectively. The mean baseline score and the mean follow-up score were 
compared for the FAQLQ-CF, FAQLQ-TF and FAQLQ-PF and its separate domains. There 
were no significant differences in baseline total and domain scores compared to the 
follow-up scores in the FAQLQ-CF and FAQLQ-TF and FAQLQ-PF. However, there was a 
small but, significant increase measured in FAIM score compared with the follow-up 
score for children as well as a significant decrease in FAIM score compared with the 
follow-up score for teenagers (p = 0.025 and p = 0.006 respectively) (Table 5.3).
Change in Health-Related Quality of Life after a challenge test with cashew nut 
in children with a positive and negative challenge outcome (delta scores)
The mean changes in scores (delta scores) were measured for the FAQLQ-CF, FAQLQ-
TF and FAQLQ-PF and the separate domains and the group of children with a positive 
challenge outcome were compared with the group of children with a negative chal-
lenge outcome. There were no significant differences in the changes in the scores of the 
FAQLQ-CF and FAQLQ-PF in the children with a positive challenge outcome compared to 
the children with a negative challenge result. However, there was a significant difference 
in the change in score in the domain ‘accidental exposure’ of the FAQLQ-TF (p = 0.049). 
The change in scores for the FAQLQ-TF in total and the other two domains showed no 
difference between the groups with a positive vs. a negative outcome. The same applies 
for the change in the FAIM scores of parents and teenagers. In children, the delta FAIM 
score in the negative DBPCFC tested group was significantly better than the delta score 
in the group with positive challenge outcomes (p = 0.026)(Table 5.4).
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Possibly influencing factors on Health Related Quality of Life changes
The association of factors that could have influenced the lack of improvement in HRQL 
were studied using multiple regression analysis in an associative model. Age, centre of 
recruitment, atopic features as hay fever, asthma and eczema, history of cashew nut 
allergy, number of reported food allergies, anaphylaxis during DBPCFC, outcome of 
the DBPCFC with cashew nut, the dose eliciting a reaction during the challenge, were 
not associated with impairment in HRQL. A higher FAQLQ baseline score (lower HRQL) 
significantly influenced improvement of HRQL for the child and the teenager group 
(p = 0.003 and p = 0.015, respectively) and a higher FAQLQ baseline score for parents of 
the children, was almost significantly associated with improvement of HRQL (p = 0.056).
The possible influence of symptoms caused by (accidental) cashew intake after the 
challenge in the 6 months before the FAQLQ’s were administered, were also evaluated. 
In the group of children with a positive challenge, there were no reported symptoms 
due to accidental exposure during this period of 6 months. In the group of children with 
a negative challenge, we measured introduction rate and reactions during introduction 
Table 5.3: Food quality of life before and after the DBPCFC test
FAQLQ Form Base-line Score
 (mean)
Follow-up score
(mean)
Delta Score
(mean)
Statistical 
Significance
(P- value)
Child Form FAQLQ
N = 33 Domain 1 3.06 3.57  0.51 0.102 
Domain 2 3.50 3.79  0.29 0.340 
Domain 3 3.93 3.75 -0.18 0.437 
Domain 4 3.44 3.43 -0.01 0.970 
Total 3.32 3.49  0.17 0.491 
FAIM 2.86 3.27  0.41 0.025 
Teenager 
Form
FAQLQ
N = 26 Domain 1 3.45 3.24 -0.21 0.392 
Domain 2 3.31 3.14 -0.17 0.591 
Domain 3 3.73 3.26 -0.47 0.086 
Total 3.50 3.22  0.28 0.286 
FAIM 3.26 2.89 -0.37 0.006 
Parents Form FAQLQ
N = 84 Domain 1 2.15 2.24  0.09 0.302 
Domain 2 2.79 2.80  0.01 0.961 
Domain 3 2.28 2.35  0.07 0.532 
Total 2.37 2.43  0.06 0.538 
FAIM 3.17 3.01 -0.16 0.113 
FAQLQ= Food Allergy Quality of Life Questionnaire, FAIM= Food Allergy Independent Measure
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(12). Only 3 children experienced mild symptoms during introduction, which did not 
allow analysis as a possible influencing factor on FAQLQ score.
Longitudinal and cross-sectional validity of Food Allergy of Life Questionnaires
We calculated a significant cross-sectional correlation between the baseline FAQLQ 
children, teenagers and parents of the children scores and the baseline FAIM scores. The 
Table 5.4: Food quality of life before and after DBPCFC test with cashew nut in children with a positive and 
negative challenge outcome
FAQLQ Form
Delta score *
Positive DBPCFC tested 
group
Delta score*
Negative DBPCFC 
tested group
Statistical 
significance (P- 
value)**
Child Form N = 24 N = 9
FAQLQ
Domain 1 0.53 0.44 0.777 
Domain 2 0.33 0.18 0.935 
Domain 3 0.14 -0.41 0.777 
Domain 4 -0.27 0.56 0.292 
Total 0.19 0.10 0.840 
FAIM 0.68 -0.32 0.026 
Teenager Form N = 21 N = 5
FAQLQ
Domain 1 -0.43 -0.90 0.215 
Domain 2 0.15 -1.49 0.049 
Domain 3 -0.26 -1.31 0.090 
Total -0.06 -1.18 0.085 
FAIM -0.32 -0.60 0.252 
Parents Form N = 62 N = 22
FAQLQ
Domain 1 0.16 -0.11 0.196 
Domain 2 0.08 -0.19 0.113 
Domain 3 0.08 0.03 0.541 
Total 0.11 -0.10 0.176 
FAIM -0.07 -0.41 0.066 
FAQLQ= Food Allergy Quality of Life Questionnaire, FAIM= Food Allergy Independent Measure, DBPCFC= 
Double-Blind Placebo-Controlled Food Challenge
* Follow-up score minus baseline score
** Statistical difference between the delta score of the positive and negative tested group
Child form: 1 domain: allergen avoidance, domain 2: risk accidental exposure, domain 3: emotional impact, 
domain 4: dietary restriction
Teenager form: domain 1: allergen avoidance, domain 2: risk accidental exposure, domain 3: emotional 
impact
Parents form: domain 1: emotional impact, domain 2: food anxiety, domain 3: social and dietary limita-
tions
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Pearson correlation coefficients thus obtained were 0.48 (p = 0.005) for the FAQLQ-CF, 
0.73 (p = 0.000) for the FAQLQ-TF, and 0.67 (p = 0.000) for the FAQLQ-PF. The follow-up 
score (after 6 months) also showed a significant correlation for the FAQLQ-CF, -TF and 
PF of 0.58 (p = 0.000), 0.74 (p = 0.000) and 0.73 (p = 0.000), respectively. The correlation 
between the change in the FAQLQ score (follow-up score minus baseline score) and the 
change in the FAIM score were correlated for the FAQLQ-TF (0.43, p = 0.025) and FAQLQ-
PF (0.54, p = 0.000), but not for the FAQLQ-CF (0.27, p = 0.124).
DISCUSSION
Previous studies with other allergenic foods showed that HRQL significantly improved 
after the food challenge, with greater improvements in HRQL after a negative outcome 
than a positive outcome (3, 13). Our study participants apparently did not experience 
substantial improvement of food allergy-related quality of life after a cashew nut chal-
lenge. However, there was a significant difference in delta score in the FAIM between 
the children in the group with a positive challenge outcome and those with a negative 
challenge outcome (p = 0.026). We could not find this difference in the teenagers or the 
parent group. Apparently, a negative challenge outcome improves the self-perceived 
severity of food allergy in young children. Perhaps young children are more focused 
on the tested foods than teens and adults, who may be more broadly concerned about 
their food allergies. This could result in a greater impact of a negative test outcome in 
younger children. This is also suggested by the observation that introduction of foods 
into the diet after a negative food challenge, is more successful in younger children than 
older children or adults (14). This may be cause and/or consequence of greater improve-
ment in perceived severity of food allergy in these patients seen in our results.
A possible cause for the lack of improvement in HRQL in this study is the relatively low 
baseline scores, which corresponded to the relatively benign perception of participants 
of the severity of their food allergy as measured with the FAIM. Although these were not 
as low as in the general population, baseline scores in the present study were lower than 
in several other HRQL studies where patients and not researchers initiated participant 
contact.
In a study also performed in Dutch children, van der Velde et al. found higher mean 
baseline scores for the child forms (3.80) and teenager forms (3.89) compared to our 
study with 3.32 for the child forms and 3.50 for the teenager forms (3). Thus there was 
less room for improvement of HRQL in our study compared to the above mentioned 
study This is also reflected in the fact that FAQLQ and FAIM scores changed very little in 
both the challenge positive and even in the challenge negative participants.
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Impairment of HRQL may also depend on the food causing the allergy. For example, 
it is demonstrated that parents of children with milk or egg allergy have a significantly 
poorer quality of life than parents of children with peanut or tree nut allergy (15). An 
explanation for this may be the ease to avoid cashew nut from the diet compared to 
avoidance of other allergens. The risk of accidental exposure is relatively low as it is 
seldom a hidden allergen. It is known that the numbers of allergic reactions caused by 
hidden allergens differ extremely per allergen (16). Consequently, the dietary impact of 
cashew nut allergy on the HRQL might be lower than that of, for example, peanut allergy.
Moreover, a previous study by our group demonstrated a low introduction rate of 
cashew nuts after a negative DBPCFC of 43.3 %, probably due to a low perceived need 
on the part of parents to do so. If the outcome of the DBPCFC does not change the diet 
of the children, and/or fear for accidental exposure does not drive the need for accurate 
diagnosis, then a part of the beneficial effect of the challenge test might be lacking (12).
Possibly, the long-time (6 months) between the challenge with cashew nut and ad-
ministration of the second questionnaire in our study might also be a reason for the 
unchanged HRQL in our children. A study by Soller et al. demonstrated an improvement 
of HRQL after a food challenge test for both allergic and non-allergic patients, however, 
this effect appeared to wane between 2 and 6 months after the challenge test (17).
The FAIM questionnaire was used to measure the validity of the FAQLQs. The Pearson 
correlations were significant for the baseline and follow-up scores and established the 
cross-sectional validity of the FAQLQs for children, teenagers and the parents of the 
children. The change in FAQLQ scores (follow-up minus baseline score) was significantly 
correlated with the change in FAIM scores for teenagers and parents of children, but not 
for children. The latter finding is in contrast to the previous study by Van der Velde et 
al. (3). However, their study showed a significant change (improvement) in HRQL after 
a DBPCFC. Therefore, it is likely that longitudinal validity could not be demonstrated 
because there was insufficient change in FAIM or FAQLQ scores in this study.
CONCLUSION
This study in participants of cashew nut allergy showed no difference in the change 
of HRQL after a positive vs. a negative DBPCFC test outcome. There was no significant 
change in HRQL after challenge testing, probably because participants did not experi-
ence a significant impairment (low baseline score) of their HRQL. Aside from the relative 
ease with which cashew nut may be avoided, this study was investigator initiated and 
not patient initiated. This may have contributed to the relatively good quality of life seen 
in the study subjects at the start of the study. Researchers in food allergy should thus be 
aware that participants recruited to a study may have relatively good initial HRQL and 
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that this may jeopardize efforts to demonstrate improvements in HRQL due to the study 
intervention.
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Chapter 5.3
Failure of introduction of cashew nuts 
after a negative food challenge test
In this letter, we describe the rate of introduction of cashew nuts after a negative food 
challenge test. This letter is published in Pediatric Allergy and Immunology in 2016.
Van der Valk JP, Gerth van Wijk R, Dubois AE, de Groot H, de Jong NW. Failure of introduc-
tion of cashew nut after a negative oral food challenge test in children. Pediatr Allergy 
Immunol. Sep;27(6):654–8 2016.
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To the editor,
Food challenge tests are helpful in assessing the clinical relevance of sensitisation, 
as determined by skin prick tests and/or specific IgE measurements. After a negative 
challenge, the patient is advised to introduce the negatively tested food into the diet. 
Previous studies with commonly challenged allergens demonstrated, however, that in 
spite of this advice the rate of introduction after a negative challenge is low (1–3).
We studied the introduction rate after a negative challenge in cashew nut sensitised 
children, ranging in age from 2 to 17 years. The patients were recruited from the study 
‘Improvement of Diagnostic mEthods for ALlergy assessment’ (IDEAL) with cashew nut 
allergy in children as a show case (trial number NTR3572). The inclusion and exclusion 
criteria and detailed study protocol were previously described (4). Briefly, all patients 
underwent a blood draw for sIgE determination, a skin prick test with cashew nut 
extract and a double-blind placebo-controlled food challenge (DBPCFC) test with 
cashew nut. The DBPCFC test consisted of an eight-step incremental dose regime of 
validated and standardised food challenge materials (5). The children consumed 3180 
mg cashew nut protein (22 cashew nuts) if all 8 dose-steps were passed. The challenge 
step was repeated if the child experienced subjective symptoms that disappeared in an 
hour (6). The DBPCFC test was discontinued and considered positive when 1) objective 
symptoms occurred, or when 2) subjective symptoms re-occurred twice after the same 
dose of challenge material had been administered, three times consecutively, or when 
3) subjective symptoms persisted for more than one hour (7). Repeating these portions 
was needed to find out whether the subjective symptoms reported by the child were 
reproducible and caused by the challenged food or coincidental symptoms due to other 
reasons.
The patient was contacted by telephone one week after the challenge test. The parent 
and/or the child was informed about the negative result of the challenge test (no cashew 
nut allergy). Then the physician explained that the cashew nut should be introduced into 
the diet and the importance of the introduction was explained. Furthermore, the patient 
was asked whether they thought they would be able to introduce the cashew into the 
diet, starting with small amounts of cashew nut, and if the response was affirmative, 
no further action was taken. When the patient and/or the family was not sure whether 
introduction would be successful, the physician explained the introduction method in 
more detail and an introduction schedule was recommended. In some cases the parents 
still felt that the introduction would give problems, then they were referred to a dieti-
cian, who again explained the introduction schedule (8, 9). The introduction schedules 
comprise instructions and photographs with information on the required amounts of 
specific food for home introduction.
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The patients were asked to complete a questionnaire 6 months after the finish of 
the IDEAL- study (inclusion May 2012-March 2015), with questions concerning the 
introduction of cashew nut in the diet of the child. The questionnaire was based on the 
questionnaire used in a study on the introduction rate of hens’ egg, cows’ milk, hazelnut 
and peanut, and slightly adjusted for the IDEAL study (2). The questionnaire contained 
14 questions on the successful or failed introduction, symptoms during introduction, 
the advice received and the understanding of the test result.
Children were divided in 3 groups: those with a successful introduction (starting as 
well as continuing eating cashew nut on a regular basis) those with a partly successful 
Table 5.5: Possible factors associated with a failed introduction after the DBPCFC test with cashew nut
Successful introduction
N (%)
Partial* introduction
N (%)
Failed 
introduction
N (%)
Total 13 (43.3) 6 (20.0) 11 (36.7)
Gender
Girl 2 (22.2) 2 (22.2) 5 (55.6) 
Boy 11 (52.4) 4 (19.0) 6 (28.6) 
Age
0-4 3 (75.0) 0 1 (25.0) 
4-8 5 (50.0) 3 (30.0) 2 (20.0) 
≥ 9 5 (31.2) 3 (18.8) 8 (50.0) 
Symptoms during FC 
according to the parents
No 13 (46.4) 5 (17.9) 10 (35.7) 
Yes 0 1 (50.0) 1 (50.0) 
Advice
Yes 11 (50.0) 5 (22.7) 6 (27.3) 
No 2 (28.6) 1 (14.3) 4 (57.1) 
Time to start eating the food
Never started 0 0 7 (100.0) 
A week 5 (83.3) 1 (16.7) 0 
A month 5 (62.5) 2 (25.0) 1 (12.5) 
A year 1 (50.0) 0 1 (50.0) 
Forgotten by patient 2 (33.3) 3 (50.0) 1 (16.7) 
Symptoms during 
introduction
Yes 0 0 3 (100.0) 
No 13 (61.9) 6 (28.6) 2 (9.5) 
Never started 0 0 6 (100.0) 
* Consumption of only traces or processed products
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introduction (consumption of only traces or processed products) and those with a failed 
introduction (never consumed or only once and never thereafter).
Possible factors influencing successful introduction, which were based on a previous 
study (i.e. gender, age, symptoms during the DBPCFC test according to the patient, 
time between the test result and the start of the introduction procedure advice and 
symptoms during introduction) were recorded (2).
A total of 179 children were included and underwent the DBPCFC of which 36 (20.1 %) 
tests were considered negative. Of these children (or their parents), 30 completed the 
questionnaire. The mean age of the children was 8.8 years (range 2–17 years), 21 boys 
(70 %) and 9 girls (30 %).
Successful introduction was reported in 13 children (43.3 %), partly successful in-
troduction in 6 children (20 %) and failed introduction in 11 children (36.7 %). Possible 
factors influencing the introduction rate are shown in Table 5.5. Statistical analysis could 
not be performed because of the small numbers. Other patients’ characteristics and di-
agnostic test results in the groups of children with a failed, partly- or successful cashew 
nut introduction are shown in Table 5.6. The results do not show obvious differences 
between the groups nor is there a trend visible.
The main reason for a failed introduction was difficulty in changing the habitual avoid-
ance of this food, followed by fear of the child and aversion to cashew nuts. Parents of 
one child said they were misinformed. Hence, this child did not introduce the cashew 
nut in the diet (Figure 5.1).
Table 5.6: Patients’ characteristics and diagnostic test results in the groups of children with a failed, partly 
- or successful cashew nut introduction.
Failed introduction
N = 11 (%)
Partly introduction
N = 6 (%)
Successful 
introduction
N = 13 (%)
Eczema 3 (27) 3 (50) 7 (54)
Asthma 3 (27) 2 (33) 1 (23)
Hay fever 4 (36) 4 (67) 7 (54)
Other nut allergies
Yes 5 (46) 4 (67) 8 (62) 
No 4 (36) 2 (33) 3 (23) 
Unknown 2 (18)  2 (15) 
History of cashew nut 
allergy
6 (55) 2 (33) 7 (54)
SPT cashew nut
(HEP-index area)
1.24 (range 0.39- 4.22) 0.30 (0- 1.82) 0.96 (0- 14.25)
sIgE cashew nut
( kU/l)
2.16 (range 0- 17.80) 0.77 (range 0.43 – 15.70 ) 1.30 ( range 0- 5.48)
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More boys (52.4 %) than girls (22.2 %) had a successful introduction. Younger children 
had higher rates of successful introduction than older children. These results are compa-
rable with an earlier study (2).
Symptoms from the perspective of the parents during the DBPCFC were rarely re-
ported. One child had skin symptoms and one child had respiratory symptoms.
Although all parents and children received advice to introduce the cashew nut into 
the diet after the negative DBPCFC, only 22/30 parents of the children (73 %) reported 
to have received the advice. Clearly, from the perspective of the patient, the advice as 
it was given was in some cases insufficient to result in retention by the patient and/or 
family.
A higher percentage of parents and/or children, who reported to have received ad-
vice to introduce cashew nut into their diet after the food challenge (FC) test, had a 
successful introduction (11/22 children), compared to the parents and/ or children that 
did not recall receiving such advice (2/7 children). Ten children introduced cashew nuts 
between one week and one month.
Three of the 30 children who completed the questionnaire, reported symptoms during 
the introduction of cashew nut at home. Two of them reported ‘oral allergy’ symptoms 
and one child had respiratory symptoms in combination with gastrointestinal symp-
toms.
Figure 5.1: Main reason for a failed introduction according to the questionnaires
Figure 5.1: Main reason for a failed introduction according to the questionnaires
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Our study showed a high failed introduction rate of 36.7 % after a DBPCFC test with 
cashew nut. For the purposes of discussion we might even add this to the 20 % of 
patients who had a partly successful introduction to yield an extremely high percent-
age of 56.7 %. Previous studies have reported rates of failed introduction with differ-
ent allergenic foods in 25 %, 28 % and 32 % of the patients, respectively (1–3). Studies 
performed by Flammarion et al., Dambacher et al. and Miceli Sopo et al. showed higher 
rates of successful introduction of 83 %, 81 % and 71 %, respectively (10–12). The first 
of these studies (10) included only children with cow’s milk allergy and in the second 
two studies the number of patients with a cow’s milk allergy and hen’s egg allergy was 
overrepresented (11,12). A previous study by our group demonstrated that hazelnut and 
peanut FC test were followed by higher rates of failed introduction (40.6 % and 39.5 %, 
respectively) than by hen’s egg and cow’s milk (13.2 % and 9.8 %, respectively)(2). The 
rate of successful introduction for cashew nut in our study was comparable with the 
rates of successful introduction for peanut and hazelnut. Awareness in patients and the 
fear of life-threatening reactions as may be caused by nut or peanut allergy, as com-
pared allergenic foods that elicit severe reactions less often, may be the reason for the 
differences between successful introduction rates of the different allergenic foods (13). 
Nuts and peanuts are not essential food products and a diet without nuts and peanuts 
will not lead to missing essential nutrients. It is easier to avoid nuts, in particular cashew 
nut, because these allergens are less often hidden in food products than hen’s egg and 
cow’s milk, although one should realise that cashew nuts are becoming increasingly 
common in processed food products (14). Recently, the LEAP study demonstrated that 
early introduction of peanut significantly decreased the development of peanut allergy 
in high risk children, which lead to new consensus guidelines regarding potential ben-
efits of early, rather than delayed, peanut introduction into the diet of this specific group 
of children (15,16). Introduction of cashew nut into the diet of the sensitised children in 
the present study might be of great importance. Moreover, the chance of developing an 
acute allergic reaction after long time elimination is demonstrated by Flinterman et al. 
(17).
A shortcoming in the study is that we did not define ‘continuing eating the cashew 
nut on a regular basis’. Currently, there are no published protocols with amount and 
frequency of exposure to the allergenic food, which may be considered adequate to 
prevent the occurrence of allergy. Often daily consumption is recommended, but more 
research is required to adequately define the minimum exposure parameters, which will 
maintain immunologic tolerance to the food in question.
A previous study by our group demonstrated that age, gender, symptoms during the 
challenge test, dietary advice and symptoms during introduction significantly influ-
enced introduction rates (2). This study confirms that boys and younger children have 
a higher successful introduction rate. Concerning advice and introduction rate, in our 
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study 73 % of the children received advice after the negative FC test according to the 
questionnaire compared to 52 % in the abovementioned study (2). Despite the higher 
rate of children who received advice to introduce the cashew nut in the diet, rates of 
successful introduction remain low. We speculate that the intention to introduce cashew 
nut into the diet after a negative challenge may be less than with other allergenic foods. 
The most frequently reported reason of the parents to consent to the DBPCFC with 
cashew nut was to determine the clinical relevance of sensitisation and not to be able to 
introduce the cashew nut in the event of a negative challenge test.
In our study, only 3 children experienced symptoms at home during the introduction 
of cashew nuts. This is lower than that found in a previous study by our group, where 
28 % of the children reported symptoms during home introduction of hen’s egg, cow’s 
milk, hazelnut and peanut (2). We used challenge material recipes with higher final dos-
ages than in the previous studies. A child consuming all doses would have eaten 3180 
mg cashew nut proteins compared to 350 mg of proteins in the recipes used in the 
previous studies. This higher final challenge dose may be more reassuring.
In this study, more than half of the children did not successfully introduce the cashew 
nut into their diet after a negative challenge. This emphasizes the need for introduction 
protocols and better coaching methods after a negative challenge. It also highlights the 
need for follow up and attention to this somewhat neglected group in comparison to 
children with a positive challenge test.
In conclusion, firstly, successful introduction is dependent on the type of the tested 
allergenic food, age, and gender. Secondly, clear and structured advisory protocols are 
indispensable, to provide the patient with clear-cut information and a follow-up proto-
col to measure insure successful introduction of the allergenic food. Finally, we advise 
physicians to discuss the goals of the DBPCFC with patients prior to the test, to perform 
the test at the youngest age possible, and to use adequate amounts of protein to reduce 
the chance of false negative testing which may consequently cause symptoms at home 
during introduction.
REFERENCES
 1. Eigenmann PA, Caubet JC, Zamora SA. Continuing food-avoidance diets after negative food 
challenges. Pediatric allergy and immunology : official publication of the European Society of 
Pediatric Allergy and Immunology. 2006 Dec;17(8):601-5.
 2. Van der Valk JP, Gerth van Wijk R, Vergouwe Y, de Jong NW. Failure of introduction of food al-
lergens after negative oral food challenge tests in children. European journal of pediatrics. 2015 
Aug;174(8):1093-9.
Failure of introduction of cashew nuts after a negative food challenge test 139
 3. Van Erp FC, Boot J, Knulst AC, Pasmans SG, van der Ent CK, Meijer Y. Reintroduction failure after 
negative peanut challenges in children. Pediatric allergy and immunology : official publication of 
the European Society of Pediatric Allergy and Immunology. 2014 Oct;25(6):580-5.
 4. Van der Valk JPM, Gerth van Wijk R, Dubois AEJ, De Groot H, Reitsma M, Vlieg-Boerstra BJ, Wichers 
HJ, de Jong NW. Multicentre double-blind placebo-controlled food challenge study in cashew 
sensitised children. PLoS One. 2016 Mar 11;11(3).
 5. Vlieg-Boerstra BJ, Herpertz I, Pasker L, van der Heide S, Kukler J, Jansink C, et al. Validation of novel 
recipes for double-blind, placebo-controlled food challenges in children and adults. Allergy. 2011 
Jul;66(7):948-54.
 6. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW et al. Stan-
dardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, 
Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL con-
sensus report. .J Allergy Clin Immunol. 2012 Dec;130(6):1260-74
 7. Niggemann B, Beyer K. Diagnosis of food allergy in children: toward a standardization of food 
challenge. Journal of pediatric gastroenterology and nutrition. 2007 Oct;45(4):399-404.
 8. http://www.martiniziekenhuis.nl/Kind—ziekenhuis/Introductietesten-/.
 9. Vlieg-Boerstra BJ, Dubois AE, van der Heide S, Bijleveld CM, Wolt-Plompen SA, Oude Elberink JN, 
et al. Ready-to-use introduction schedules for first exposure to allergenic foods in children at 
home. Allergy. 2008 Jul;63(7):903-9.
 10. Dambacher WM, de Kort EH, Blom WM, Houben GF, de Vries E. Double-blind placebo-controlled 
food challenges in children with alleged cow’s milk allergy: prevention of unnecessary elimina-
tion diets and determination of eliciting doses. Nutrition journal. 2013;12:22.
 11. Flammarion S, Santos C, Romero D, Thumerelle C, Deschildre A. Changes in diet and life of chil-
dren with food allergies after a negative food challenge. Allergy. 2010 Jun 1;65(6):797-8.
 12. Miceli Sopo S, Monaco S, Greco M, Onesimo R. Prevalence of adverse reactions following a passed 
oral food challenge and factors affecting successful re-introduction of foods. A retrospective 
study of a cohort of 199 children. Allergologia et immunopathologia. 2015 Aug 1.
 13. Skripak JM, Wood RA. Peanut and tree nut allergy in childhood. Pediatric allergy and immunol-
ogy : official publication of the European Society of Pediatric Allergy and Immunology. 2008 
Jun;19(4):368-73.
 14. Van der Valk JP, Dubois AE, Gerth van Wijk R, Wichers HJ, de Jong NW. Systematic review on 
cashew nut allergy. Allergy. 2014 Jun;69(6):692-8.
 15. Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF et al. LEAP Study Team. Ran-
domized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015 Feb 
26;372(9):803-13.
 16. Fleischer DM, Sicherer S, Greenhawt M, Campbell D, Chan E, Muraro A, Halken S et al. Consensus 
Communication on Early Peanut Introduction and Prevention of Peanut Allergy in High-Risk 
Infants. Pediatr Dermatol. 2016 Jan;33(1):103-6.

Chapter 6
General discussion and summary

Chapter 6.1
Discussion
Discussion 145
Clinical presentation of cashew nut allergy
The IDEAL-study is developed to improve the diagnostics for food allergy with cashew 
nut allergy as a show-case. We performed a prospective multi-centre study with a rela-
tively large number (n = 179) of cashew nut sensitised children (chapter 3.1). More than 
75 % of these children showed a clinical response in the DBPCFC test. This percentage 
is much higher than that observed in a previous other cashew nut study (1). Only in 
8/42 (19 %) children a cashew nut allergy could be confirmed with a positive challenge 
test in this study. The percentage of a clinically relevant sensitisation to cashew nut in 
our study was also higher compared to the results of studies with other food allergens 
such as hazelnut. A study by Flinterman et al. showed that of the 28 children sensitised 
to hazelnut, a DBPCFC test could only confirm a hazelnut allergy in half of the patients 
(2). During the challenge test in our study, most patients experienced gastro-intestinal 
symptoms, with skin manifestations as the second most prevalent symptom. This is in 
contrast to other studies on cashew-allergic patients in which skin symptoms were ob-
served more frequently than respiratory and gastro-intestinal symptoms (1). Sixty-three 
percent of the children tested reported a history of allergic reactions to cashew nuts in 
our study. However, a cashew nut allergy could not be confirmed with the DBPCFC test 
in almost 20 % of the children with a positive history. Half of these children experienced 
the last allergic symptoms to cashew nut between one month and two years before the 
challenge test. A negative oral food challenge test after positive testing and/or posi-
tive history is reported between 9 % and 38 % for peanut allergy (3–7). Children with a 
positive history and negative testing may have outgrown their allergy or may have an 
unreliable history. In addition personal co-factors or differences in exposure may ac-
count for this discrepancy.
We showed that cashew nuts allergens are highly potent and can cause relatively 
severe reactions. With the first dosage of only 1 mg of cashew protein, 46 % of the par-
ticipating, sensitised children experienced subjective and 11 % objective symptoms. In 
our study we demonstrated that the ED05, ED10 and ED50 for objective signs ranged from 
0.8 to 1.6 mg, 3.5 to 4.3 mg and 108.4 to 149.1 mg of cashew nut protein based upon 
the Log-Normal, Log-Logistic and Weibull models (chapter 3.2). The study by Blom et 
al. showed a much higher ED05 in 31 cashew nut allergic children at 7.4 mg cashew nut 
protein compared to the ED05 in our study (8). The authors indicate in the discussion 
that this is an unexpected high quantity, taking into account that cashew nut allergy 
is considered to be as severe as a peanut allergy. The study by Eller et al. demonstrated 
in 780 challenge tests with egg, hazelnut, peanut and milk an ED05 causing objective 
symptoms of 2.08, 8.7, 18.9 and 59.3 mg protein, respectively (9). In contrast to our 
study, most (89 %) of all 449 reactions during the positive challenge test were defined 
as mild in this study. The study by Taylor et al. showed in 286 peanut allergic patients 
an ED05 of objective symptoms of 7.3 mg whole peanut (equivalent to 1.8 mg of peanut 
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protein based on 25 % protein in a peanut kernel). In this study, almost all the symptoms 
during the peanut challenge test were assessed as mild (10). Our study demonstrated a 
low cashew nut ED05 for objective symptoms compared to the above mentioned studies 
on EDs for other allergens. However, comparing the potency of allergens by comparing 
the EDs expressed as milligram proteins in the allergenic food is debatable, because 
the allergic reaction occurs in practice to quantities of the allergenic food as a whole. 
With different percentages of allergenic proteins in these different foods, a comparison 
of EDs as milligrams of the allergenic food, rather than just the protein it contains, may 
be more correct. The ED05 in our LOAEL- study is based on one study population and to 
make predictions on the whole at-risk cashew allergic population, the individual data 
has to be representative of the entire population. Therefore, more studies are needed 
on cashew nut thresholds to make predictions at a population level. However, this study 
demonstrates the potency of cashew allergens.
Our Low-dose follow-up study was performed to determine threshold levels lower 
than 1 mg cashew nut protein (chapter 3.2). Therefore, a subgroup of children (N = 12) 
from the IDEAL-study who reacted to the lowest dose of cashew nut protein (1 mg) were 
asked to participate in this follow-up study with low dose challenge tests. The LOAELs 
for objective and subjective symptoms were 0.30 and 0.01 mg cashew nut protein, 
respectively. Minimal eliciting doses for different allergenic foods were previously inves-
tigated by an expert panel in a study on threshold dose by Taylor et al. (11). This study 
demonstrated that the eliciting dose on which 1 % (ED01) of the population reacted with 
objective symptoms were 0.1 mg (Log-Logistic) and 0.22 mg (Log-Normal) for peanut 
and 0.08 mg (Log-Logistic) and 0.21 (Log-Normal) for milk. The ED01 ranges between 0.05 
and 0.21 mg protein for egg and 0.02 mg and 0.25 mg protein for hazelnut based upon 
the Log-Normal, Log-Logistic and Weibull models. The 0.30 mg cashew nut protein as 
lowest eliciting dose of mild objective symptoms in our LOAEL follow-up study has the 
same order of magnitude.
The individual thresholds for LOAELs in our study were not reproducible in all children. 
Three children reacted to a higher dose of cashew nut protein and four patients did 
not react anymore in the low dose challenge test, suggesting that their thresholds had 
increased beyond 3 mg cashew nut protein. Previously, Glaumann et al. observed in 29 
peanut-allergic patients that only two of these children reacting to the same threshold 
dose and with the same severity score in two successive food challenge test with peanut 
(12).
Furthermore, approximately 40 % of the children in our IDEAL- study showed anaphy-
lactic reactions and 6 % of these children was treated with epinephrine. Anaphylaxis was 
observed in 17 % of the children with the start of the allergic reaction to dose 1 (1 mg 
cashew nut protein). This demonstrated that a minimal amount of cashew nut can cause 
(severe) allergic reactions.
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OPTIMISATION OF THE DIAGNOSTIC PROCEDURE FOR FOOD ALLERGY
History
The first step in the diagnostic procedure of food allergy is taking the history. The his-
tory is important to determine if the reaction type is according to an immediate Type-I 
allergic reaction. Allergy testing starts with demonstrating sensitisation by either sIgE 
or a SPT.
Specific IgE
sIgE is regularly used to establish sensitisation in patients suspected for a food allergy 
(13). The sensitivity and specificity of sIgE tests are dependent on the tested allergen, 
age of the patients, population, geographic region, test method and chosen cut-off 
values of sIgE.
We demonstrated that sIgE to total cashew nut was associated with a positive DBPCFC 
test with a concordance-index (c-index) of 0.76 (chapter 4.2). The c-index is equal to 
the Area Under the Receiver Operating Characteristic Curve (AUC) for a dichotomous 
outcome. This association has to our knowledge never been previously determined. 
Maloney et al. acquired sIgE levels with 99 % PPV for walnut (cut-off level of 19 kU/l) and 
Buyuktiryaki et al. acquired sIgE levels with 95 % PPV for hazelnut (10 kU/l) (14–15).
For the major allergenic foods as hen’s egg, cow’s milk and peanut, sIgE sensitivity 
and specificity were determined in several studies with patients suspected for a food al-
lergy (15–20). These studies included children and adults from different continents. The 
study groups vary between 100 and 324 patients. A PPV of > 95 % was determined in this 
studies for hen’s egg (sIgE cut-off value varying between 6 and 13 kU/l), for cow’s milk 
(sIgE cut-off value varying between 13 and 32 kU/l), peanut (sIgE cut-off values varying 
between 15 and 24 kU/l). The sIgE cut-off values are very high and only a few patients 
have these values. Furthermore, these data cannot be extrapolated to each patient, be-
cause this PPV are dependent on age of the patients, population and geographic region.
Skin prick test
The SPT is an easy to perform and cheap test, recommended in the diagnosis of food 
allergy (13). The same as for the sIgE applies for the SPT, the sensitivity and specificity 
of the SPT are dependent on the tested allergen, the age of the patients, population, 
geographic region, test method and the chosen cut-off values of the SPT.
Our data showed that the SPT with cashew nut extract was strongly associated with 
a positive DBPCFC test with a c-index of 0.83 (chapter 4.2). The study by Ho et al. dem-
onstrated in 86 cashew nut challenge tests in children and teenagers that a SPT weal 
diameters of ≥ 8 mm predicted a positive food challenge with 95 % accuracy (21). The 
same applies for other nuts as hazelnut and walnut. For almond, pistachio, pecan, and 
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Brazil nut it was not possible to determine the 95 % positive predictive value (PPV) in 
this study.
The SPT sensitivity, specificity, PPV at different cut-off values for the major allergenic 
foods as hen’s egg, peanut and hazelnut were determined in several studies with pa-
tients suspected for a food allergy (22–27). All these studies were performed in children 
from different continents with study populations varying between 47 and 820 children. 
A PPV of 95 % was determined in these studies for hen’s egg (SPT cut-off values vary-
ing between ≥ 5 and ≥ 10 mm wheal diameter), for peanut (SPT cut-off values varying 
between ≥ 4 and ≥ 13 mm wheal diameter) and for hazelnut (SPT cut-off value varying 
between 8 ≥ and ≥ 12 mm wheal diameter).
Our data (chapter 4.2) show that sIgE to total cashew nut and, to an even greater extent 
SPT with cashew nut extract, are associated with a positive DBPCFC test (c-index of 0.76 
versus 0.83, respectively). The stronger associations with SPT than with sIgE were previ-
ously shown for other food allergens in predicting clinical allergy (16, 23–25). A previous 
retrospective study on 983 children who underwent food challenge test with egg, milk 
and peanut also demonstrated that SPT results were more strongly associated with a 
positive food challenge test than sIgE (LR 1.23 and 1.04) (28). The study by DunnGalvin et 
al., who aimed to predict the challenge outcome for 429 patients with suspected peanut, 
milk and egg allergy also showed a greater predictive capacity of SPT than sIgE (29). We 
showed that this is obviously the case for cashew nut allergy. One may speculate that a 
positive SPT indicates not only the presence of sIgE in the sensitised individual, but also 
reflects the biological activity of sIgE.
Optimisation of the measurement and interpretation of the skin prick test
In clinical practice and in most academic research, it is common to characterise the 
wheal shape by the ‘average diameter’. To determine the average diameter, the mean 
value of the longest and the midpoint orthogonal diameter (mm) of the wheal were 
measured. However, we demonstrated in the paper ‘Measurement and interpretation of 
skin prick test results’ (chapter 4.1) that this method is prone to errors, because it is as-
sumed that the wheal size varies between a circle and an ellipse. In fact, the wheals have 
pseudopodia and interpretation based on two orthogonal diameters is not accurate. 
Our study showed that for a given average wheal diameter, the actual wheal area could 
vary quite significantly and this inaccuracy grows with wheal size. This inaccuracy is 
completely eliminated if one applies the scanning method. In the scanning method, 
the area of the wheal was determined by using a flatbed scanner (Hewlett Packard) in 
combination with software earlier developed by Erasmus MC: Precise Automated Area 
Measurement of Skin Test (PAAMOST). This more precise method for measuring the 
wheal size area is previously described by Pijnenborg et al. (30). The scanning method 
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is also fast, easy in use, has a high reproducibility and is very useful in scientific research 
(30–33). To even further increase the accuracy of SPT results, the HEP-index area can be 
calculated, to rule out differences in skin reactivity. The HEP-index can be calculated 
by dividing the allergen area by the mean area of two histamine-induced wheal sizes 
of the positive controls. There are several factors that contribute to this difference e.g. 
poly-sensitised patients and patients with mould sensitisation have significantly higher 
skin reactions (34) and the skin response varies in different ethnicities (35). Furthermore, 
differences in technique of performing SPTs (inter-observer variability) contribute to the 
variation in wheal size (36). To correct for these factors, the calculation of the HEP-index 
area is useful and also easy to determine with the scanning method. Notwithstanding 
all advances of the scanning method inclusive the HEP-index calculation, the ‘average 
diameter’ method is as accurate in diagnosing cashew nut allergy as the ‘HEP-index area’ 
method. Therefore, the ‘average diameter’ method can be used if there is no scanning 
device available.
Component resolved diagnosis
CRD is an advanced method to measure sIgE to specific components of the allergens. We 
investigated the predictive value of CRD in cashew nut allergy (chapter 4.2). A markedly 
greater risk of cashew nut allergy as ascertained by DBPCFC was observed for higher 
values of sIgE to Ana o 1, 2 and 3. At higher levels of sIgE to Ana o 1, 2 and 3 total risks 
of approximately 100 % were observed. The associations were extremely strong with 
c-indices of 0.87, 0.85 and 0.89 for sIgE to Ana o 1, 2 and 3, respectively. This is never 
previously demonstrated for all three cashew nut components.
The cashew nut component analysis could not distinguish between a mild and a 
severe cashew nut allergy during the DBPCFC test with cashew nut. Savvatianos et al. 
previously demonstrated an association between sIgE to Ana o 3 and a positive chal-
lenge test (37). This research group investigated sensitisation to Ana o 3 in 63 children 
in whom clinical reactivity to cashew nut was documented. Their study demonstrated 
a near-optimal AUC of 0.97 in the Receiver Operator Characteristics (ROC) curve. How-
ever, the clinical diagnosis of cashew nut allergy was based on clinical history in 95 % 
of the cases and only in 5 % of the cases on food challenge tests. Therefore, the strong 
association observed with Ana o 3 levels may have been with sensitisation rather than 
with clinical allergy to cashew nut resulting in a stronger association. However, the gold 
standard is the DBPCFC test that all children underwent in our study. For other allergies 
such as that to peanut and hazelnut, the added value of CDR in the diagnosis of clinical 
allergy to these foods has been proved. Peanut allergen Ara h 2 and hazelnut allergen 
Cor a 14, which are both 2S Albumins (as is Ana o 3), are of great importance to estimate 
the risk of a positive challenge test outcome with peanut and hazelnut, respectively 
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(38–40). 2S Albumins are resistant to proteolysis, heat denaturation and pH changes and 
are therefore considered to be clinically relevant allergens (41).
CRD for hen’s egg, cow’s milk and soya had no added value in predicting the challenge 
outcome (42–50). Several studies demonstrated that the diagnostic sensitivity improves 
by CRD for wheat, kiwi, cherry, celery, carrot and shrimp (51–58).
Prediction models
CRD can also be used in models to predict the outcome of the food challenge tests. We 
developed a prediction model for the outcome of the DBPCFC with cashew nut (chapter 
4.3). The prediction model based on gender and sIgE to Ana o 3 with and without SPT 
gives the strongest association with an excellent c-index of 0.90 and 0.89 (corrected 
for optimism), respectively. Gender had a significantly added value in the model with 
higher risk on a positive challenge for girls. Why sensitisation to cashew nut is more of-
ten clinically relevant in girls than boys is currently unknown. The SPT is recommended 
in diagnosing food allergy, however, not all medical settings have the opportunity to 
perform the SPT (37). Therefore, we developed a model with and without the SPT. The 
SPT had minimal added value in the model with gender and sIgE to Ana o 3, however, if 
Ana o components are not available, the SPT is the second best in the diagnostic method 
for cashew nut allergy (likelihood ratio test statistic χ2: Ana o 13.75 and SPT 6). sIgE to 
total cashew nut had no added value in predicting the outcome of the DBPCFC if sIgE 
to the Ana o components was determined. Zomer-Kooijker et al. previously developed a 
prediction model for food allergy (59). This study demonstrated that the outcome of 129 
challenge test with different allergens can be predicted accurately on the index food, 
time gab between ingestion and the development of symptoms and the sIgE levels 
with and AUC of 0.90 in the ROC curve. The study by DunnGalvin et al. also showed the 
importance of taking multiple predictors into account as gender, age, history of allergy, 
total IgE minus sIgE and SPT to develop very strong prediction models for peanut-, 
egg- and milk, respectively (29). However, only 90 % of the diagnoses were established 
with food challenge test what the correlation may overestimate. Klemans et al. validated 
the above-mentioned model and conclude that the validation was good, however, the 
calibration poor, probably caused by overfitting of the data (40). The model predictions 
support the selection of children requiring a challenge test to diagnose cashew nut al-
lergy and this can saves cost, time and burdensome for the patient. In situations where 
there is limited availability of double blind testing for suspected cashew allergy, the use 
of the model and scoring system may be useful for identifying children who have ≥ 95 % 
chance of having a positive challenge test result and in whom such testing is less likely 
to influence management. In our present series, this pertains to a substantial number of 
patients (58/173 children, 34 %).
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Although, our prediction model is very useful in clinical practice and the number of 
food challenge tests can be decreased, beside internal validation, external validation is 
needed to extrapolate our model to other populations. For clinical practice, we devel-
oped an easy-use score chart based on the models. The score chart was developed to 
calculate the chance on a positive DBPCFC test outcome for each cashew nut sensitised 
patient individually.
Food challenge test
Notwithstanding, CRD and predictive models are incorporated into clinical use; the 
DBPCFC test remains the gold standard in diagnosing food allergy.
However, the DBPCFC test is a costly and time-consuming test for the physician and 
patient. Further disadvantages of the test are e.g. that test is not appropriate for each 
patient, intrinsic and extrinsic factors are absent in the artificial test setting, certain 
medications should be stopped and not all medical care centres have the opportunity 
to perform the DBPCFC test (60). Placebo reactions during the challenge test (61–62) 
and reactions during the introduction of the allergen after a negative food challenge 
test (63) are not only described in exceptional cases.
In the IDEAL-study, placebo reactions were observed in 11 % (20/179) of the children 
and consisted of reported subjective reactions in 70 % (14/20) and both, subjective 
and objective in 35 % (6/20). Placebo reactions were in 5 children the reason for of an 
undecided challenge outcome. We observed placebo reactions in 4 of the 12 patients 
(33 %) in the Low-dose follow-up study (chapter 3.2). This is a relatively high percentage 
for DBPCFC as compared to placebo reactions in other studies (61–62). Because of all 
these disadvantages, the search for better, cheaper and simpler alternatives as CRD and 
predictive models is needed. We demonstrated that prediction models may reduce the 
need for food challenge test. Therefore, this should be developed for all (major) allergens.
CONSEQUENCES OF CASHEW NUT ALLERGY
Co-sensitisation
We studied the clinical relevance of co-sensitisation between cashew nut and pistachio 
nut and mango in the pistachio nut part of the IDEAL-study (N = 29) (chapter 5.1). Cashew 
nut, pistachio nut and mango belong to the Anacardiaceae family and are botanically 
related. In line with previous reports, we showed a high rate of co-sensitisation between 
cashew nuts and pistachio nuts in SPT and sIgE (respectively 92 % and 98 %). Mango is 
also botanically related to cashew nut, but our study shows only 19 % co-sensitisation 
with mango in cashew positive SPT children and 21 % in sIgE positive children. We dem-
onstrated that the pistachio nut sensitisation was only clinically relevant in 34 %. In ad-
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dition, co-sensitisation to mango did not result in clinical reactivity to mango. Previous 
studies reported high percentages of co-sensitisation and cross-sensitisation between 
cashew nut and pistachio nut (64–70). The clinical relevance of these sensitisations has 
only been reported in two studies (66–67).
Because of the high amount of positive food challenges with cashew nut compared to 
the pistachio nut, it is most likely that the primary sensitiser is the cashew nut. However, 
confirmation with inhibition tests is needed.
Health related quality of life
With the advent of clinical trials for the treatment of food allergy, Health-Related Quality 
of Life (HRQL) is becoming an increasingly important outcome measure to document 
benefit of treatment. Previous studies with other allergenic foods showed that HRQL 
significantly improved after the food challenge, with greater improvements in HRQL 
after a negative outcome than a positive outcome (71–72). In contrast, we showed a 
significantly different change in FAQLQ-TF only for the domain ‘risk accidental exposure’ 
in teenagers with a negative and a positive challenge outcome (p  =  0.049). All the 
other FAQLQ scores and the FAIM score showed no significant differences in patients 
with positive vs negative test outcomes (chapter 5.2). A possible cause for this lack of 
improvement is the relatively low baseline scores, which corresponded to the relatively 
benign perception of participants of the severity of their food allergy as measured with 
the FAIM.
Impairment of HRQL may depend on the food causing the allergy. For example, it is 
demonstrated that parents of children with milk or egg allergy have a significantly poorer 
quality of life than parents of children with peanut or tree nut allergy (73). An explana-
tion for this may be the ease to avoid cashew nut from the diet compared to avoidance 
of other allergens. Aside from the relative ease with which cashew nut may be avoided 
and the fact that many participants had not had previous exposure to cashew nut, this 
study was investigator initiated and not patient initiated. This may have contributed to 
the relatively good quality of life seen in the study subjects at the start of the study.
Failure of introduction of cashew nut after a negative challenge test
One of the main aims of the DBPCFC test in case of a negative test outcome is to in-
troduce the tested allergen into the diet. Our follow-up study ‘Failure of introduction of 
cashew nuts after a negative food challenge test’ (N = 30) (chapter 5.3) showed a high failed 
introduction rate of 36.7 % after a negative DBPCFC test with cashew nut. Previous stud-
ies have reported rates of failed introduction with different allergenic foods in 25 %, 28 % 
and 32 % of the patients, respectively (63, 74–75). Studies performed by Flammarion et 
al., Dambacher et al. and Miceli Sopo et al. showed higher rates of successful introduction 
of 83 %, 81 % and 71 %, respectively (76–78). The first of these studies (77) included only 
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children with cow’s milk allergy and in the second two studies; the number of patients 
with a cow’s milk allergy and hen’s egg allergy was overrepresented (77–78). A previous 
study by our group demonstrated that hazelnut and peanut FC test were followed by 
higher rates of failed introduction (40.6 % and 39.5 %, respectively) than by hen’s egg 
and cow’s milk (13.2 % and 9.8 %, respectively)(2). The rate of successful introduction for 
cashew nut in our study was comparable with the rates of successful introduction for 
peanut and hazelnut.
Successful introduction is dependent on the type of the tested allergenic food, age, 
advice and gender. Clear and structured advisory protocols are indispensable, to pro-
vide the patient with clear-cut information and a follow-up protocol to measure insure 
successful introduction of the allergenic food. We advise physicians to discuss the goals 
of the DBPCFC with patients prior to the test, to perform the test at the youngest age 
possible, and to use adequate amounts of protein to reduce the chance of false negative 
testing which may consequently cause symptoms at home during introduction.
RECOMMENDATIONS FOR FUTURE RESEARCH
With the increase of processing of cashew nuts and change in eating habits and as 
consequence the increase of exposure to cashew nuts in the population, we expect 
that the prevalence of cashew nut allergy will rise. Therefore, clinicians will have to deal 
with cashew nut allergy more often. It is important to diagnose cashew nut allergy in an 
efficient and save way. We improved the diagnostic process for cashew nut allergy with 
predictive models including gender and Ana o (with and without SPT). These models 
facilitate the selection of children who have ≥  95 % chance of having a positive chal-
lenge test result and in whom such testing is less necessary. This may save time and 
costs for a selected group of patients. However, more research is needed to investigate 
if we can extrapolate this model to other populations. Furthermore, it is important to 
keep this predictive model for cashew nut allergy up to date for our own population. 
The prevalence of cashew nut sensitisation and cashew nut allergy increases over time, 
which raises the a priori probability of a cashew nut allergy. This will require adjustments 
to our model to ensure the usability of the model for our own population in the future.
In this study, we used purified Ana o 1, 2 and 3. The strong association between sIgE 
to Ana o components with a positive challenge test asks for commercially available Ana 
o components.
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The content of the thesis contributes to the knowledge of the cashew nut and cashew 
nut allergy. Cashew nut allergy is an important healthcare problem, especially in chil-
dren. We performed a prospective multicentre study (IDEAL-study) with a 179 cashew 
nut sensitised children.
Chapter 1. General introduction
The cashew nut (Anacardium occidentale) belongs to the Ancardiaceae family and is 
botanically related to pistachio (Pistacia vera) nut and the mango (Mangifera indica). The 
major allergen components of the cashew nut are Ana o 1, Ana o 2 and Ana o 3.
Cashew nut consumption has increased and post aut propter sensitisation rates has 
also increased, especially in children. Accurate interpretation of sensitisation is manda-
tory.
Chapter 2. Literature overview
The paper ‘Systematic review on cashew nut allergy’ summarises the current knowledge 
on cashew nut allergy. The literature search yielded 255 articles of which 40 met our 
selection criteria and were considered to be relevant for this review.
In comparison with literature and research focussed on peanut, cashew allergy is 
clearly an underestimated but important healthcare problem, especially in children. 
Further research is urgently needed on this relatively new food allergen.
Chapter 3. Clinical results of the IDEAL-study
The first paper in this chapter ‘Multicentre double-blind placebo-controlled food challenge 
study in children sensitised to cashew nut’ shows the clinical results of the IDEAL-study.
In total 179 children with cashew nut sensitisation and a clinical history of reactions 
to cashew nuts or unknown exposure (median age 9.0 years; range 2–17 years) partici-
pated in the study. Of these sensitised children, 137 (76.5 %) had a positive DBPCFC test. 
46 % manifesting subjective symptoms to the lowest dose of 1 mg cashew nut protein 
and 11 % developing objective symptoms to the lowest dose. Children most frequently 
had gastro-intestinal symptoms, followed by oral allergy and skin symptoms. A total of 
36 % (49/137) of the children experienced an anaphylactic reaction and 6 % (8/137) of 
the children were treated with epinephrine.
The second paper in this chapter ‘Threshold distribution and lowest observed adverse ef-
fect levels in cashew nut allergic children’, shows the threshold distribution curve of the 
IDEAL-study and the lowest observed effect level. The eliciting dose on which 5 %, 10 % 
and 50 % of the population reacted with objective symptoms ranges between 0.8 and 
1.6 mg (ED05), 3.5 and 4.3 mg (ED10) and 108 and 149.1 mg (ED50) of cashew nut protein 
based upon the Log-Normal, Log-Logistic and Weibull models. This ED05 for cashew nut 
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(objective symptoms) is low compared to the ED05 of peanut, hazelnut, milk and egg in 
other studies. The lowest dose on which mild objective and subjective symptoms oc-
curred was 0.30 mg and 0.01 mg cashew nut protein, respectively.
Chapter 4. Improvement of diagnostic methods
The first paper in this chapter ‘Measurement and interpretation of skin prick test results’ 
shows that the scanning method for SPT measurement is more accurate to measure 
the wheal area in a Type-I allergy than the average diameter. It is possible to correct 
for skin-sensitivity and inter-observer variability by using the ‘HEP-index area’ method. 
Therefore, we divided the area of the allergen-induced wheal by the area of the positive 
histamine-induced wheal controls. This ratio is defined as the (HEP)-index area. The HEP-
index area value 0.4 can be considered as an equal cut-off value of 3 mm wheal average 
diameter. However, in clinical practice, the ‘average diameter method’ is also useful, 
because this method is equally accurate in predicting cashew nut allergic reactions in 
the DBPCFC tests.
The second paper in this chapter, ‘sIgE Ana o 1,2 and 3 accurately distinguish tolerant from 
allergic children sensitised to cashew nuts’ demonstrates a steep rise in the risk of a positive 
challenge for sIgE to each individual component Ana o 1, 2 and 3 with estimated risks up 
to approximately 100 %. sIgE to Ana o 1, 2 and 3 better distinguishes between cashew-
allergic and tolerant children (c-index = 0.87, 0.85 and 0.89 respectively), than sIgE to 
cashew nut or SPT with a c-index of 0.76 and 0.83 respectively (c-index is equal to the 
Area Under the Receiver Operating Characteristic Curve for a dichotomous outcome).
We describe in third paper ‘Predictive model for cashew nut allergy in children’ a multivari-
ate model to predict the outcome of the DBPCFC test with cashew nut and showed easy 
to -use format of the models to calculate the risk of cashew nut allergy in sensitised 
children. Gender and Ana o components (with and without SPT) showed the highest 
discriminative ability (c-index = 0.90 with SPT and 0.89 without SPT). The models facili-
tate the selection of children requiring a challenge test to diagnose cashew nut allergy 
and may save time and cost for a selected group of patients. In situations where there 
is limited availability of double blind testing for suspected cashew allergy, the use of 
the model and scoring system may be useful for identifying children who have ≥ 95 % 
chance of having a positive challenge test result and in whom such testing is less likely 
to influence management. In our present series, this pertains to a substantial number of 
patients (58/173 children, 34 %).
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Chapter 5. The clinical consequence of cashew nut allergy
In the first paper in this chapter ‘Low percentage of clinically relevant pistachio nut and 
mango co-sensitisation in cashew nut sensitised children’ we assessed the clinical rel-
evance of pistachio nut and mango co-sensitisation in cashew nut sensitised children. 
All children sensitised to cashew and pistachio nut and/or mango underwent a DBPCFC 
with cashew nut, with pistachio nut and an open food challenge with mango.
Although co-sensitisation in skin test between cashew nut and pistachio nut was 
observed in 98 %, the pistachio nut sensitisation was only clinically relevant in 34.5 % of 
the children. Therefore, in case of a co-sensitisation between cashew nut and pistachio 
nut, a DBPCFC is recommended. None of the children was mango-allergic.
The second paper in this chapter ‘No difference in health-related quality of life, after a food 
challenge with cashew nut in children participating in a clinical trial’ demonstrates the ef-
fect on quality of life in positive and negative challenged children using FAQLQ’s before 
and after the DBPCFC test. The cashew nut allergic patients, both with positive and 
negative challenge outcome, experienced no significant change of HRQL in this study.
Aside from the relative ease with which cashew nut may be avoided and the fact that 
many participants had not had previous exposure to cashew nut, this study was inves-
tigator initiated and not patient initiated. This may have contributed to the relatively 
good quality of life seen in the study subjects at the start of the study.
We describe in last paper in this chapter ‘Failure of introduction of cashew nuts after a 
negative food challenge test’ the introduction rate of cashew nut after a negative chal-
lenge test.
After a negative challenge, the patient is advised to introduce the negatively tested 
food into the diet. Previous studies with commonly challenged allergens demonstrated, 
however, that in spite of this advice the rate of introduction after a negative challenge is 
low. In this study, successful introduction (starting as well as continuing eating cashew 
nut on a regular basis) was reported in 13 children (43.3 %), partly successful introduc-
tion (consumption of only traces or processed products) in 6 children (20 %) and failed 
introduction (never consumed or only once and never thereafter) in 11 children (36.7 %). 
Successful introduction was dependent on the type of the tested allergenic food, age, 
and gender. Secondly, clear and structured advisory protocols are indispensable to pro-
vide the patient with clear-cut information and a follow-up protocol to measure insure 
successful introduction of the allergenic food.
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Samenvatting
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De inhoud van dit proefschrift draagt bij aan de kennis van de cashewnoot en cashew-
nootallergie. Cashewnootallergie is een belangrijk gezondheidsprobleem, voornamelijk 
bij kinderen. We hebben een prospectieve multicenter studie (IDEAL-studie) uitgevoerd 
met 179 cashewnoot gesensibiliseerde kinderen.
Hoofstuk 1. Algemene introductie
De cashewnoot (Anacardium occidentale) behoort tot de Ancardiaceae familie en is 
botanisch verwant aan de pistachenoot (Pistacia vera) en mango (Mangifera indica). De 
belangrijkste allergenen van de cashewnoot zijn Ana o 1, Ana o 2 en Ana o 3.
De consumptie van cashewnoten neemt toe en daardoor ook het aantal cashewnoot 
gesensibiliseerde mensen, waaronder voornamelijk kinderen.
Hoofdstuk 2. Literatuur overzicht
Het artikel ‘Systematic review on cashew nut allergy’ geeft een samenvatting van de 
literatuur over cashewnootallergie. Het literatuuronderzoek leverde 255 artikelen op, 
waarvan 40 voldeden aan onze selectiecriteria en relevant waren voor het review.
In vergelijking met literatuur over pinda-allergie is cashewnootallergie een onderschat, 
maar belangrijk gezondheidsprobleem, voornamelijk bij kinderen. Meer onderzoek is 
dringend noodzakelijk naar dit relatief nieuwe voedselallergeen.
Hoofdstuk 3. Klinische resultaten van de IDEAL-studie
Het eerste artikel in dit hoofdstuk ‘Multicentre double-blind placebo-controlled food 
challenge study in children sensitised to cashew nut’ toont de klinische resultaten van de 
IDEAL-studie.
In totaal deden er 179 kinderen mee aan de studie (mediane leeftijd 9.0 jaar; range 
2–17 jaar) met een cashewnootsensibilisatie en een allergische reactie in de voorge-
schiedenis na de consumptie van cashewnoten of nooit blootgesteld aan cashewnoten. 
Van deze gesensibiliseerde kinderen hadden 137 (76.%) een positieve DBPGVP test. 46 % 
van de kinderen rapporteerde subjectieve klachten na inname van de laagste provoca-
tiedosis van 1 mg cashewnooteiwit en 11 % ontwikkelde objectieve klachten na deze 
dosis. De kinderen hadden het meest frequent maag-darmklachten, gevolgd door ‘oral 
allergy’ en huidklachten. Totaal had 36 % (49/137) van de kinderen een anafylactische 
reactie en 6 % (8/137) van deze kinderen werd behandeld met adrenaline.
Het tweede artikel in dit hoofdstuk ‘Threshold distribution and lowest observed adverse 
effect levels in cashew nut allergic children’, toont de drempelwaarde distributiecurve van 
de IDEAL-studie en de laagste hoeveelheid allergeen waarop een reactie plaats vond.
De uitlokkende dosering waarop 5 %, 10 % en 50 % van de populatie reageerde met 
objectieve symptomen varieert tussen de 0.8 en 1.6 mg (ED05), 3.5 en 4.3 mg (ED10) en 
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108 en 149.1 mg (ED50) gebaseerd op de Log-Normal, Log-Logistic en Weibull modellen. 
Deze ED05 voor cashewnoot (objectieve symptomen) is laag vergeleken met de ED05 
voor pinda, hazelnoot, melk en ei in andere studies. De laagste doses waarop milde ob-
jectieve en subjectieve klachten ontstonden was 0.30 mg en 0.01 mg cashewnooteiwit, 
respectievelijk.
Hoofstuk 4. Verbetering van de diagnostische methoden
In het eerste artikel van dit hoofdstuk ‘Measurement and interpretation of skin prick test 
results’ tonen we aan dat de scanmethode voor het meten van de huidpriktestresultaten 
nauwkeuriger is in het schatten van de ‘wheal’-oppervlakte door gebruik te maken van 
de gemiddelde diameter. Het is mogelijk om te corrigeren voor de huidgevoeligheid en 
de observatievariabiliteit tussen de personen die de huidtesten aflezen, door gebruik te 
maken van de HEP-index oppervlakte-methode. Daarvoor deelden we de oppervlakte 
van het allergeen-geïnduceerde ‘wheal’- oppervlakte door het gemiddelde ‘wheal’-op-
pervlakte van de positieve histamine-geïnduceerde controles. De ratio is gedefinieerd 
als de HEP-index oppervlakte. De HEP-index oppervlakte waarde van 0.4 kan gelijk be-
schouwd worden aan een grenswaarde van 3 mm van de gemiddelde ‘wheal’- diameter. 
Echter, in de klinische praktijk is de gemiddelde diametermethode bruikbaar, omdat het 
even nauwkeurig de uitkomst kan voorspellen van de DBPGVP test.
Het tweede artikel in dit hoofdstuk ‘sIgE Ana o 1,2 and 3 accurately distinguish tolerant 
from allergic children sensitised to cashew nuts’ laat bij de kinderen die deelnamen aan de 
IDEAL-studie, een snelle risico toename zien op een positieve provocatie bij stijgende 
sIgE- waarden tegen elke individuele component Ana o 1, Ana o 2 en Ana o 3 met risico’s 
op een positieve provocatie tot 100 %. sIgE tegen Ana o 1, 2 en 3 kan beter onderscheid 
maken tussen cashewnoot allergische en tolerante patiënten (c-index  =  0.87, 0.85 en 
0.89 respectievelijk) dan sIgE tegen cashewnoot en de huidpriktest (c-index 0.76 en 
0.83, respectievelijk) (De c-index is gelijk aan de ‘Area Under the Receiver Operating 
Characteristic Curve’ voor dichotome uitkomsten).
In het derde artikel in dit hoofdstuk ‘Predictive model for cashew nut allergy in children’ 
beschrijven we een model om de uitkomst van de cashewnootprovocatie te voorspellen 
en tonen we een eenvoudig bruikbaar format van de modellen om het risico op een 
cashewnootallergie te berekenen voor gesensibiliseerde kinderen. De hoogste discri-
minerende vermogens werden gevonden met geslacht en Ana o componenten (met en 
zonder huidpriktest) (c-index 0.90 met huidpriktest en 0.89 zonder huidpriktest). De mo-
dellen maken een selectie mogelijk van kinderen die een voedselprovocatietest nodig 
hebben om de diagnose cashewnootallergie te stellen en zouden tijd en kosten kunnen 
besparen in de geselecteerde groep van patiënten. In situaties waar er gelimiteerde 
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mogelijkheden zijn in het dubbelblindtesten van een cashewnootallergie kunnen de 
modellen en scoringssysteem bruikbaar zijn om kinderen te identificeren met een kans 
op een positieve provocatie uitkomst van ≥ 95 % en waarbij de provocatietest minder 
waarschijnlijk het beleid veranderd. In onze studie betrof dat een substantieel aantal 
kinderen (58/173 kinderen, 34 %).
Hoofdstuk 5. De klinische consequenties van een cashewnootallergie
Het eerste artikel in dit hoofdstuk ‘Low percentage of clinically relevant pistachio nut and 
mango co-sensitisation in cashew nut sensitised children’ beoordeelt de klinische rele-
vantie van de cashewnoot en mango co-sensibilisatie in cashewnoot gesensibiliseerde 
kinderen.
Alle kinderen, gesensibiliseerd voor cashewnoot en pistachenoot en/of mango on-
dergingen een DBPGVP test met cashewnoot en pistachenoot en een open voedselpro-
vocatie met mango. Ondanks dat we een co-sensibilisatie in de huidpriktest zagen van 
98 % tussen cashewnoot en pistachenoot, is de pistachenootsensibilisatie maar klinisch 
relevant in 34.5 % Daarvoor adviseren een DBPGVP test in geval van een co-sensibilisatie 
tussen cashewnoot en pistachenoot. Geen van de kinderen had een mango-allergie.
Het tweede artikel in dit hoofdstuk ‘No difference in health-related quality of life, after a 
food challenge with cashew nut in children participating in a clinical trial’’ toont het ef-
fect op kwaliteit van leven in de positief en negatief geteste kinderen voor en na de 
voedselprovocatie.
De cashewnoot-allergische patiënten, zowel met een positieve als een negatieve 
provocatie-uitslag ervaarden geen significante verbetering in kwaliteit van leven in 
deze studie. Naast dat het relatief makkelijker is om cashewnoten te vermijden en dat 
een groot aantal kinderen nog nooit blootgesteld is aan de cashewnoot, is deze studie 
ook geïnitieerd door onderzoekers en niet door de patiënt zelf. Mogelijk heeft dit bijge-
dragen aan de relatieve goede kwaliteit van leven van de kinderen voor de start van de 
studie.
We beschrijven in het laatste artikel in dit hoofdstuk ‘Failure of introduction of cashew 
nuts after a negative food challenge test’ de introductie graad van cashewnoten na een 
negatieve provocatietest. Na een negatieve provocatietest worden de kinderen geadvi-
seerd om het negatief geteste voedingsmiddel te introduceren in het dieet. Eerdere stu-
dies toonden aan dat de graad van introductie laag is van algemeen geteste allergenen, 
ondanks het advies om te introduceren. In deze studie, werd succesvolle introductie 
(starten en blijven eten van cashewnoot op regelmatige basis) gerapporteerd door 13 
kinderen (43.3 %), gedeeltelijke introductie (het eten van sporen cashewnoot of cashew-
noot verwerkt in andere voedingsmiddelen) in 6 kinderen (20 %) en gefaalde introductie 
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(nooit cashewnoten gegeten of eenmalig en daarna nooit meer geprobeerd) door 11 
kinderen (36.7 %). Succesvolle introductie is afhankelijk van het type geteste allergeen, 
de leeftijd en geslacht. Verder zijn een duidelijke en gestructureerde protocollen 
noodzakelijk om de patienten van informatie te voorzien en is een vervolg protocol 
noodzakelijk om te meten of het voedingsmiddel daadwerkelijk geïntroduceerd is.
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